[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 4915
1. Chaibundit C, Ricardo NM, Ricardo NM, O'Driscoll BM, Hamley IW, Yeates SG, Booth C: Aqueous gels of mixtures of ionic surfactant SDS with pluronic copolymers P123 or F127. Langmuir; 2009 Dec 15;25(24):13776-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Total concentrations (c, SDS+copolymer) were as high as 50 wt % with mole ratios SDS/copolymer (mr) in the ranges 1-5 (F127) and 1-7 (P123).
  • Determination of the temperature dependences of the dynamic moduli served to confirm the gel boundaries from tube inversion and to reveal the high elastic moduli of the gels, e.g., compared at comparable positions in the gel phase, a 50 wt % SDS/P123 with mr = 7 had G' three times that of a corresponding gel of P123 alone.
  • Small-angle X-ray scattering (SAXS) was used to show that the structures of all the SDS/F127 gels were bcc and that the structures of the SDS/P123 gels with mr = 1 were either fcc (c = 30 wt %) or hex (c = 40 wt %).
  • Assignment of structures to SDS/P123 gels with values of mr in the range 3-7 was more difficult, as high-order scattering peaks could be very weak, and at the higher values of c and mr, the SAXS peaks included multiple reflections.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19572512.001).
  • [ISSN] 1520-5827
  • [Journal-full-title] Langmuir : the ACS journal of surfaces and colloids
  • [ISO-abbreviation] Langmuir
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Moarbess G, El-Hajj H, Kfoury Y, El-Sabban ME, Lepelletier Y, Hermine O, Deleuze-Masquéfa C, Bonnet PA, Bazarbachi A: EAPB0203, a member of the imidazoquinoxaline family, inhibits growth and induces caspase-dependent apoptosis in T-cell lymphomas and HTLV-I-associated adult T-cell leukemia/lymphoma. Blood; 2008 Apr 1;111(7):3770-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] EAPB0203, a member of the imidazoquinoxaline family, inhibits growth and induces caspase-dependent apoptosis in T-cell lymphomas and HTLV-I-associated adult T-cell leukemia/lymphoma.
  • Imiquimod is an immune response modifier currently used as a topical treatment of genital warts, basal cell carcinoma, cutaneous metastasis of malignant melanoma, and vascular tumors.
  • HTLV-I-associated adult T-cell leukemia (ATL) and HTLV-I-negative peripheral T-cell lymphomas are associated with poor prognosis.
  • Using potentially achievable concentrations of EAPB0203, we demonstrate inhibition of cell proliferation, G2/M cell- cycle arrest, and induction of apoptosis in HTLV-I-transformed and HTLV-I-negative malignant T cells and fresh ATL cells, whereas normal resting or activated T lymphocytes were resistant.
  • These results support a potential therapeutic role for EAPB0203 in ATL and HTLV-I-negative T-cell lymphomas, either as a systemic or topical therapy for skin lesions.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Caspases / metabolism. Cell Division / drug effects. G2 Phase / drug effects. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Lymphoma, T-Cell / drug therapy. Quinoxalines / pharmacology. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Imiquimod .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18218850.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / BCL2L1 protein, human; 0 / EAPB0203; 0 / Inhibitor of Apoptosis Proteins; 0 / NF-kappa B; 0 / Quinoxalines; 0 / Tumor Suppressor Protein p53; 0 / bcl-X Protein; 9007-43-6 / Cytochromes c; 99011-02-6 / imiquimod; EC 3.4.22.- / Caspases
  •  go-up   go-down


3. deSousa JL, Leibovitch I, Malhotra R, O'Donnell B, Sullivan T, Selva D: Techniques and outcomes of total upper and lower eyelid reconstruction. Arch Ophthalmol; 2007 Dec;125(12):1601-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Multicenter, retrospective, interventional case series of all of the patients requiring unilateral reconstruction of both the upper and lower eyelids.
  • RESULTS: Six cases were identified, 1 following trauma and 5 following tumor excision (4 with basal cell carcinoma and 1 with melanoma).
  • Primary repair using preserved tissue was carried out in the case of traumatic avulsion.
  • Following tumor excision, bilamellar repair was performed using composite grafts for the posterior lamella and skin-muscle flaps for the anterior lamella.
  • Graft necrosis occurred in 3 cases (50%).
  • In all of the cases, the reconstructed eyelids were stiff and immobile.
  • Lagophthalmos (6 cases [100%]), ptosis (3 cases [50%]), lower eyelid retraction (3 cases [50%]), and ectropion (2 cases [33%]) were common.
  • Useful vision was retained in all of the cases.

  • MedlinePlus Health Information. consumer health - Eyelid Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18071107.001).
  • [ISSN] 0003-9950
  • [Journal-full-title] Archives of ophthalmology (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch. Ophthalmol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Vaz FS, Ferreira AM, Kulkarni MS, Motghare DD: Sexual risk behaviors and HIV/AIDS awareness among males in a rural community in Goa. J Commun Dis; 2006 Mar;38(1):74-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The study highlights the need for more effective behaviour change communication (BCC) strategies in the community as well as innovative methods like village level peer education.


5. McKenna JK, Florell SR: Cost-effective dynamic telepathology in the Mohs surgery laboratory utilizing iChat AV videoconferencing software. Dermatol Surg; 2007 Jan;33(1):62-8; discussion 68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the second part of the study, the Mohs surgeon consulted the dermatopathologist on 20 Mohs frozen section slides in which the surgeon had a particular question (e.g., "Is this part of a pilosebaceous unit or is this basal cell carcinoma?
  • There was agreement between conventional light microscopy and dynamic telepathology diagnosis in 19 of 20 tumors.
  • [MeSH-major] Remote Consultation / instrumentation. Skin Diseases / pathology. Telepathology / instrumentation. User-Computer Interface. Videoconferencing / instrumentation

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17214680.001).
  • [ISSN] 1076-0512
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / K23 RR17525-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


6. Semenov AN: Micelle formation in statistical copolymers. Phys Rev E Stat Nonlin Soft Matter Phys; 2006 Apr;73(4 Pt 1):041803
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The study is focused on the weak segregation regime for infinitely long copolymer chains near the disorder-to-order transition.
  • It is shown that the transition occurs below the spinodal (at chi(0)< chi*) and that it results in the formation of micelles rather than in a superposition pattern of a few harmonic composition waves.
  • A first-order transition from spherical-wave micelles to micelles with internal bcc structure is predicted at chi/chi*-1 proportional to epsilon(2).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16711829.001).
  • [ISSN] 1539-3755
  • [Journal-full-title] Physical review. E, Statistical, nonlinear, and soft matter physics
  • [ISO-abbreviation] Phys Rev E Stat Nonlin Soft Matter Phys
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Younis LK, El Sakka H, Haque I: The Prognostic Value of E-cadherin Expression in Breast Cancer. Int J Health Sci (Qassim); 2007 Jan;1(1):43-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Prognostic Value of E-cadherin Expression in Breast Cancer.
  • BACKGROUND: Breast cancer continues to be a major cause of morbidity and mortality throughout the world.
  • The behavior of breast cancer varies widely.
  • Several parameters have been investigated to predict the prognosis in breast cancer.
  • Among the novel prognostic markers is E-cadherin; a calcium-dependent epithelial cell adhesion molecule.
  • The objective of the present study was to assess the prognostic value of E-cadherin expression in breast cancer cases, and its correlations with the other studied prognostic parameters.
  • METHODS: The study comprised 54 breast cancer patients admitted at King Fahd Specialist Hospital, Qassim during the period 2001-2006.
  • Fifty cases (92.6%) had invasive ductal carcinoma, four cases had lobular carcinomas, and most were grade II (82%), stage II (48%), and the majority of cases had positive axillary lymph nodes (70.3%).
  • Representative sections from formalin-fixed paraffin embedded tissue blocks were taken from the 54 cases of breast cancer, and were stained for E-cadherin expression by immunohistochemical technique (monoclonal E-cadherin (NCL-E-cad), Novocastra).
  • All the lobular carcinoma cases were negative for membranous expression of E-cadherin while 72% of invasive ductal carcinomas were positive for the marker.
  • RESULTS: A significant correlation was found between strong E-cadherin expression and node negative cases.
  • Node negative cases were found to be an independent predictor of strong E-cadherin expression while node positive cases predicted negative expression of E-cadherin (P = 0 .026).
  • Also loss of E-cadherin was noted in advanced stages of breast cancer supporting the view that loss of E-cadherin expression is a marker of aggressiveness.
  • CONCLUSION: A significant correlation was found between strong E-cadherin expression and node negative cases.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 1993 Dec;143(6):1731-42 [8256859.001]
  • [Cites] Mod Pathol. 2003 Nov;16(11):1067-75 [14614045.001]
  • [Cites] Surg Oncol. 2000 Dec;9(4):151-71 [11476987.001]
  • [Cites] EMBO J. 1995 Dec 15;14(24):6107-15 [8557030.001]
  • [Cites] J Pathol. 2001 Apr;193(4):433-41 [11276001.001]
  • [Cites] Saudi Med J. 2001 Feb;22(2):110-3 [11299401.001]
  • [Cites] Saudi Med J. 2000 Sep;21(9):869-72 [11376366.001]
  • [Cites] J Pak Med Assoc. 2001 Jul;51(7):243-7 [11558215.001]
  • [Cites] Br J Cancer. 2001 Dec 14;85(12):1958-63 [11747340.001]
  • [Cites] Ann Surg. 2002 Jan;235(1):10-26 [11753038.001]
  • [Cites] Saudi Med J. 2002 Oct;23(10):1210-3 [12436125.001]
  • [Cites] Saudi Med J. 2003 Jun;24(6):623-7 [12847591.001]
  • [Cites] J Cancer Res Clin Oncol. 2005 Jan;131(1):14-8 [15459769.001]
  • [Cites] Curr Opin Cell Biol. 2005 Oct;17(5):499-508 [16107313.001]
  • [Cites] Indian J Med Sci. 1991 Apr;45(4):85-7 [1660447.001]
  • [Cites] Curr Opin Cell Biol. 1993 Oct;5(5):806-11 [8240824.001]
  • [Cites] Int J Cancer. 1992 Aug 19;52(1):48-51 [1500227.001]
  • [Cites] Am J Pathol. 1993 Apr;142(4):987-93 [7682767.001]
  • [Cites] Anticancer Res. 1997 Jan-Feb;17(1B):561-7 [9066580.001]
  • (PMID = 21475451.001).
  • [ISSN] 1658-3639
  • [Journal-full-title] International journal of health sciences
  • [ISO-abbreviation] Int J Health Sci (Qassim)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  • [Other-IDs] NLM/ PMC3068666
  • [Keywords] NOTNLM ; E-cadherin / breast cancer / immunohistochemistry / immunostaining / prognostic factors
  •  go-up   go-down


8. Puizina-Ivić N, Sapunar D, Marasović D, Mirić L: An overview of Bcl-2 expression in histopathological variants of basal cell carcinoma, squamous cell carcinoma, actinic keratosis and seborrheic keratosis. Coll Antropol; 2008 Oct;32 Suppl 2:61-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An overview of Bcl-2 expression in histopathological variants of basal cell carcinoma, squamous cell carcinoma, actinic keratosis and seborrheic keratosis.
  • The Bcl-2 protein has been shown to suppress cell death and protects cell against apoptosis induced by different death-inducing signals.
  • In this study the authors have analyzed imunohistochemically the expression of Bcl-2 protein in the histopathological variants of the most common malignant tumors of the skin--basal cell carcinoma (BCC) and squamous cell tumor (SCC), as well as in the precancerous lesion actinic keratosis (AK) and in benign tumor seborrheic keratosis (SK).
  • Bcl-2 expression in solid, adenoid and cystic variants of BCC exhibited immunoreactivity of tumor stroma with more intense staining among peripheral palisading cells.
  • In cases of hypertrophic and atrophic variants of AK, Bcl-2 expression was confined to basal cell layer, as well as in one case of hypertrophic variant in suprabasal cells.
  • In clonal variant immunostaining was positive among cells in characteristic "nests" Distribution of Bcl-2 protein expression in solid, adenoid and cystic variant of BCC showed that peripheral proliferating cells are protected against apoptosis what permits tumor growth.
  • In morpheaform variant reduced amount of Bcl-2 expression indicated that this variant of BCC has increased cell proliferation, and in practice shows tendency for recurrence and difficulties to eradicate.
  • Bcl-2 expression supports the observation that tumor cells are derived from basal keratinocytes.
  • [MeSH-major] Carcinoma, Basal Cell / metabolism. Carcinoma, Squamous Cell / metabolism. Keratosis, Actinic / metabolism. Keratosis, Seborrheic / metabolism. Proto-Oncogene Proteins c-bcl-2 / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Apoptosis. Case-Control Studies. Humans. Immunohistochemistry


9. Wang SQ, Goldberg LH: Multiple polypoid basal cell carcinomas on the perineum of a patient with basal cell nevus syndrome. J Am Acad Dermatol; 2007 Aug;57(2 Suppl):S36-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple polypoid basal cell carcinomas on the perineum of a patient with basal cell nevus syndrome.
  • We present a case report of a patient with basal cell nevus syndrome (BCNS) who developed multiple polypoid basal cell carcinomas (PBCC) in the perineum.
  • PBCC is a rare variant of nodular BCCs.
  • [MeSH-major] Basal Cell Nevus Syndrome / pathology. Carcinoma, Basal Cell / pathology. Genital Neoplasms, Male / pathology. Skin Neoplasms / pathology


10. de Giorgi V, Massi D, Sestini S, Alfaioli B, Carelli G, Carli P: Cutaneous collision tumour (melanocytic naevus, basal cell carcinoma, seborrhoeic keratosis): a clinical, dermoscopic and pathological case report. Br J Dermatol; 2005 Apr;152(4):787-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous collision tumour (melanocytic naevus, basal cell carcinoma, seborrhoeic keratosis): a clinical, dermoscopic and pathological case report.
  • The most common association, basal cell carcinoma (BCC) and naevus, is very difficult to diagnose clinically.
  • Histologically, the lesion was a melanocytic compound naevus and a BCC with a seborrhoeic keratosis.
  • The case was investigated clinically and by focusing on the dermoscopic features and their pathological correlates.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Keratosis, Seborrheic / pathology. Neoplasms, Multiple Primary / pathology. Nevus, Pigmented / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Dermoscopy / methods. Diagnosis, Differential. Female. Hip. Humans. Melanoma / diagnosis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15840116.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


11. Limtong S, Imanishi Y, Jindamorakot S, Ninomiya S, Yongmanitchai W, Nakase T: Torulaspora maleeae sp. nov., a novel ascomycetous yeast species from Japan and Thailand. FEMS Yeast Res; 2008 Mar;8(2):337-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Nine strains of a new Torulaspora species were isolated from natural samples collected in Japan and Thailand including one strain obtained from a leaf of Rhizophora stylosa (NBRC 11061T), one strain from soil (NBRC 11062), six strains from mosses (ST-14, ST-266, ST-510, ST-511, ST-513 and ST-581) and one strain from sediment in mangrove forest (RV-51).
  • The type strain is NBRC 11061T (BCC 25515T=CBS 10694T).

  • SILVA. SILVA LSU Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17986255.001).
  • [ISSN] 1567-1356
  • [Journal-full-title] FEMS yeast research
  • [ISO-abbreviation] FEMS Yeast Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Fungal; 0 / DNA, Intergenic; 0 / DNA, Ribosomal
  •  go-up   go-down


12. Karaçal N, Ambarcioglu O, Topal U, Sapan LA, Kutlu N: Reverse-flow submental artery flap for periorbital soft tissue and socket reconstruction. Head Neck; 2006 Jan;28(1):40-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The reverse-flow manner of the flap has been used in limited cases because of possible drawbacks such as venous congestion.
  • The diagnosis of three patients was basal cell carcinoma of the eyelids, which required orbital exenteration, and the other patient had traumatic periorbital defects.
  • RESULTS: No major complications were noted other than one case of temporary palsy of the marginal mandibular branch of the facial nerve and one other of venous congestion, which subsided spontaneously.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Eyelid Neoplasms / surgery. Orbit / surgery. Reconstructive Surgical Procedures / methods. Surgical Flaps

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley Periodicals, Inc. Head Neck 28: XXX-XXX, 2005.
  • (PMID = 16331691.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Avgeri SG, Matthaiou DK, Dimopoulos G, Grammatikos AP, Falagas ME: Therapeutic options for Burkholderia cepacia infections beyond co-trimoxazole: a systematic review of the clinical evidence. Int J Antimicrob Agents; 2009 May;33(5):394-404
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic options for Burkholderia cepacia infections beyond co-trimoxazole: a systematic review of the clinical evidence.
  • Burkholderia cepacia complex (BCC) is an important group of pathogens affecting patients with cystic fibrosis and chronic granulomatous disease as well as immunocompromised and hospitalised patients.
  • However, in some cases it cannot be administered because of allergic or hypersensitivity reactions, intolerance or resistance.
  • The search identified 48 relevant case reports (57 cases) and 8 cohort studies or trials.
  • Nineteen (33.3%) of 57 patients included in the case reports received ceftazidime-based regimens, 14 (73.7%) of whom were cured.
  • Seven (12.3%) of 57 cases were treated with penicillins, four of which were piperacillin (all had a favourable outcome).
  • Based on the data reported in the eight relevant cohort studies or trials identified, favourable outcomes were observed in 68.4% (26/38) to 100% (16/16) of cases treated with ceftazidime and 66.7% (6/9) of cases treated with meropenem.
  • Thus, Ceftazidime, meropenem and penicillins, mainly piperacillin, either alone or in combination with other antimicrobial agents, may be considered as alternative options for BCC infections, according to the in vitro antimicrobial susceptibility patterns and clinical results.
  • However, the available clinical data are not sufficient and further clinical experience is required to clarify the appropriateness of these antibiotics for BCC infections.
  • [MeSH-major] Anti-Bacterial Agents / therapeutic use. Burkholderia Infections / drug therapy. Burkholderia cepacia complex / drug effects. Trimethoprim, Sulfamethoxazole Drug Combination / therapeutic use

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. TRIMETHOPRIM/SULFAMETHOXAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19097867.001).
  • [ISSN] 1872-7913
  • [Journal-full-title] International journal of antimicrobial agents
  • [ISO-abbreviation] Int. J. Antimicrob. Agents
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 8064-90-2 / Trimethoprim, Sulfamethoxazole Drug Combination
  • [Number-of-references] 110
  •  go-up   go-down


14. Behrendt U, Schumann P, Stieglmeier M, Pukall R, Augustin J, Spröer C, Schwendner P, Moissl-Eichinger C, Ulrich A: Characterization of heterotrophic nitrifying bacteria with respiratory ammonification and denitrification activity--description of Paenibacillus uliginis sp. nov., an inhabitant of fen peat soil and Paenibacillus purispatii sp. nov., isolated from a spacecraft assembly clean room. Syst Appl Microbiol; 2010 Oct;33(6):328-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the course of studying the influence of N-fertilization on N(2) and N(2)O flux rates in relation to soil bacterial community composition of a long-term fertilization experiment in fen peat grassland, a strain group was isolated that was related to a strain isolated from a spacecraft assembly clean room during diversity studies of microorganisms, which withstood cleaning and bioburden reduction strategies.

  • SILVA. SILVA SSU Database .
  • StrainInfo. culture/stock collections - online strain list (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier GmbH. All rights reserved.
  • (PMID = 20813476.001).
  • [ISSN] 1618-0984
  • [Journal-full-title] Systematic and applied microbiology
  • [ISO-abbreviation] Syst. Appl. Microbiol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ EU888513/ FN556467
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / DNA, Bacterial; 0 / DNA, Ribosomal; 0 / RNA, Ribosomal, 16S; 0 / Soil
  •  go-up   go-down


15. Ma Y, Hu C, Riegel AT, Fan S, Rosen EM: Growth factor signaling pathways modulate BRCA1 repression of estrogen receptor-alpha activity. Mol Endocrinol; 2007 Aug;21(8):1905-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The breast cancer susceptibility gene BRCA1 is mutated in about one half of all hereditary breast cancer cases, and its expression is frequently decreased in sporadic cancers.
  • [MeSH-minor] Cell Line, Tumor. Female. Humans. Male. Phosphatidylinositol 3-Kinases / metabolism. Proto-Oncogene Proteins c-akt / metabolism


16. Wakai K, Tamakoshi K, Date C, Fukui M, Suzuki S, Lin Y, Niwa Y, Nishio K, Yatsuya H, Kondo T, Tokudome S, Yamamoto A, Toyoshima H, Tamakoshi A, JACC Study Group: Dietary intakes of fat and fatty acids and risk of breast cancer: a prospective study in Japan. Cancer Sci; 2005 Sep;96(9):590-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dietary intakes of fat and fatty acids and risk of breast cancer: a prospective study in Japan.
  • To examine the possible association of dietary fat and fatty acids with breast cancer risk in a population with a low total fat intake and a high consumption of fish, we analyzed data from the Japan Collaborative Cohort (JACC) Study.
  • During the mean follow-up of 7.6 years, 129 breast cancer cases were documented.
  • We found no clear association of total fat intake with breast cancer risk; the multivariate-adjusted RR across quartiles were 1.00, 1.29, 0.95, and 0.80 (95% confidence interval [CI] 0.46-1.38).
  • This prospective study did not support any increase in the risk of breast cancer associated with total or saturated fat intake, but it suggested the protective effects of the long-chain n-3 fatty acids that are abundant in fish.
  • [MeSH-major] Breast Neoplasms / epidemiology. Dietary Fats. Fatty Acids / physiology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Dietary Fats.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (Cancer Sci 2005; 96: 590 - 599).
  • (PMID = 16128744.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dietary Fats; 0 / Fatty Acids
  •  go-up   go-down


17. Zhou Y, Eppenberger-Castori S, Eppenberger U, Benz CC: The NFkappaB pathway and endocrine-resistant breast cancer. Endocr Relat Cancer; 2005 Jul;12 Suppl 1:S37-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The NFkappaB pathway and endocrine-resistant breast cancer.
  • Endocrine therapy with an estrogen receptor (ER)-targeted antiestrogen, such as tamoxifen, or estrogen ablation by aromatase inhibitors is clinically indicated for the management of all forms of ER-positive breast cancer.
  • However, 30-50% of ER-positive breast cancer cases fail to benefit clinically from endocrine therapy alone, and recent molecular evidence suggests that 'crosstalk' pathways originating from activated receptor tyrosine kinases and/or other proliferative and survival signals may be contributing to this endocrine resistance.
  • With the demonstration that activation of NFkappaB is absolutely required for normal mammary gland development, NFkappaB involvment in human breast cancers was initially explored and linked to the development of hormone-independent (ER-negative) breast cancer.
  • Newer clinical evidence now implicates NFkappaB activation, particularly DNA-binding by the p50 subunit of NFkappaB, as a potential prognostic marker capable of identifying a high-risk subset of ER-positive, primary breast cancers destined for early relapse despite adjuvant endocrine therapy with tamoxifen.
  • Furthermore, initial preclinical studies suggest that treatment strategies designed to prevent or interrupt activation of NFkappaB in cell-line models of these more aggressive, ER-positive breast cancers can restore their sensitivity to such standard endocrine agents as tamoxifen.
  • [MeSH-major] Antineoplastic Agents, Hormonal / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / metabolism. NF-kappa B / antagonists & inhibitors
  • [MeSH-minor] Drug Resistance, Neoplasm / drug effects. Female. Humans. Neoplasms, Hormone-Dependent / drug therapy. Neoplasms, Hormone-Dependent / metabolism. Receptors, Estrogen / antagonists & inhibitors. Receptors, Estrogen / metabolism. Signal Transduction / drug effects

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16113098.001).
  • [ISSN] 1351-0088
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50-CA58207; United States / NIA NIH HHS / AG / R01-AG20521; United States / NCI NIH HHS / CA / R01-CA36773; United States / NCI NIH HHS / CA / R01-CA71468
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / NF-kappa B; 0 / Receptors, Estrogen
  • [Number-of-references] 59
  •  go-up   go-down


18. Ishikawa T, Momiyama N, Hamaguchi Y, Tanabe M, Tomita S, Ichikawa Y, Nakatani Y, Sasaki T, Nozawa A, Inayama Y, Inui K, Shimada H: Blue-dye technique complements four-node sampling for early breast cancer. Eur J Surg Oncol; 2005 Dec;31(10):1119-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Blue-dye technique complements four-node sampling for early breast cancer.
  • AIMS: To examine four-node axillary sampling assisted by a blue dye (4NAS/dye) technique as a sentinel node biopsy (SNB) for breast cancer.
  • METHODS: Lymphatic mapping was performed by injection of patent blue for 33 consecutive cases with breast cancer.
  • The same study with 30 cases was conducted at an independent hospital to confirm the feasibility of this method.
  • This method was then applied to 101 consecutive clinically node-negative patients to avoid axillary-node dissection, with intraoperative diagnosis made by frozen section examination.
  • Pathological examination revealed that the nodal status was correctly predicted by the dye alone in 62.5% of cases with metastasis, whereas in 100% by 4NAS/dye.
  • The dye alone was not sufficient to identify SNs, especially in cases with prior excisional biopsy.
  • The identification rate of SNs and the accuracy rate in another feasibility study were 100% and 92.5% in 30 consecutive cases, respectively.
  • 4NAS/dye successfully detected SNs in 100 of 101 cases of the subsequent observational study with an acceptable post-operative axillary morbidity and thus succeeded as an SNB.
  • [MeSH-major] Breast Neoplasms / pathology. Coloring Agents. Lymph Nodes / pathology. Sentinel Lymph Node Biopsy / methods
  • [MeSH-minor] Adult. Aged. Axilla. Feasibility Studies. Female. Humans. Lymphatic Metastasis. Middle Aged. Neoplasm Staging. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Surg Oncol. 2007 Jun;33(5):670 [17344016.001]
  • (PMID = 16005597.001).
  • [ISSN] 0748-7983
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Coloring Agents
  •  go-up   go-down


19. Anim JT, John B, Abdulsathar S SA, Prasad A, Saji T, Akhtar N, Ali V, Al-Saleh M: Relationship between the expression of various markers and prognostic factors in breast cancer. Acta Histochem; 2005;107(2):87-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between the expression of various markers and prognostic factors in breast cancer.
  • The immunohistochemical detection of six markers of breast cancer has been compared in the present study with known prognostic factors of the disease to establish locally a standard panel of markers for the management of breast cancer.
  • Sections of tissue of 114 consecutive breast cancer cases were studied immunohistochemically, using antibodies against oestrogen receptor (ER), progesterone receptor (PR), androgen receptor, c-erbB2, cathepsin D, and cyclin D.
  • Using the chi(2)-test, relationships were determined between marker labelling and histological type of cancer, tumour grade, tumour size, axillary lymph node status and age of patient.
  • A p value below 0.05 was considered significant.
  • A positive relationship was found between ER and PR and lower grades of cancer, and a negative relationship was found with medullary and atypical medullary carcinoma.
  • The four other markers showed no relationship with grade or type of cancer.
  • Our study confirms the association between ER and PR and histological type and grade of breast cancer, both known parameters of good prognosis.
  • We found no consistent relationship between the other four markers and prognostic factors studied, other than the suggestion that c-erbB2 and cathepsin D may be useful markers for poor prognosis and can be usefully applied locally, especially in the light of the current availability of trastuzumab (Herceptin) for management of c-erbB2-positive cases.
  • [MeSH-major] Biomarkers, Tumor / analysis. Breast Neoplasms / metabolism. Breast Neoplasms / pathology
  • [MeSH-minor] Adult. Humans. Immunohistochemistry. Lymphatic Metastasis / pathology. Middle Aged. Neoplasm Staging. Prognosis


20. Lipozencić J, Celić D, Strnad M, Toncić RJ, Pasić A, Rados J, Znaor A: Skin cancers in Croatia, 2003-2005: epidemiological study. Coll Antropol; 2010 Sep;34(3):865-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Skin cancers in Croatia, 2003-2005: epidemiological study.
  • This study presents the incidence of major nonmelanoma skin cancers (major NMSCs), other nonmelanoma skin cancers (other NMSCs) and malignant melanoma (MM) in Croatia.
  • The skin cancers recorded between 1 January 2003 and 31 December 2005 were retrospectively analyzed.
  • Incident cases of NMSCs were identified by the use of a questionnaire distributed to dermatology departments in Croatia and then collected at the University Department of Dermatology and Venereology, Zagreb University Hospital Center, and from the records kept at the National Cancer Registry.
  • Incident cases of MM were extracted from the National Cancer Registry.
  • During the 3-year period, 9,479 cases of major NMSCs are recorded, 4,622 (49%) in male and 4,857 (51%) in female patients.
  • Basal cell carcinoma (BCC) was the most common major NMSC in both sexes.
  • In the total number of major NMSCs, there were 7,244 cases of BCC.
  • Squamous cell carcinoma (SCC) was the second most common major NMSC.
  • There were 1,860 SCC cases.
  • The crude incidence rate was 54.9/100,000 for BCC in males, 53.9/100,000 in females, and 14.6/100,000 for SCC in male and 13.4/100,000 in female patients.
  • Other NMSCs were registered in 119 cases (53% male and 47% female).
  • MM was registered in 1,427 cases (48% male and 52% female.
  • [MeSH-major] Skin Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Aged. Carcinoma, Basal Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Child. Child, Preschool. Croatia / epidemiology. Female. Humans. Incidence. Infant. Infant, Newborn. Male. Melanoma / epidemiology. Middle Aged. Time Factors

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20977074.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


21. Gorey KM, Luginaah IN, Schwartz KL, Fung KY, Balagurusamy M, Bartfay E, Wright FC, Anucha U, Parsons RR: Increased racial differences on breast cancer care and survival in America: historical evidence consistent with a health insurance hypothesis, 1975-2001. Breast Cancer Res Treat; 2009 Feb;113(3):595-600
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased racial differences on breast cancer care and survival in America: historical evidence consistent with a health insurance hypothesis, 1975-2001.
  • PURPOSE: This study examined whether race/ethnicity had differential effects on breast cancer care and survival across age strata and cohorts within stages of disease.
  • METHODS: The Detroit Cancer Registry provided 25,997 breast cancer cases.
  • Within node positive disease all treatment disadvantages among younger African American women disappeared with socioeconomic adjustment.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Health Disparities.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2007 Jun 1;109(11):2161-70 [17455219.001]
  • [Cites] Breast Cancer Res Treat. 2006 May;97(2):149-55 [16322888.001]
  • [Cites] J Clin Oncol. 2007 Jun 20;25(18):2516-21 [17577028.001]
  • [Cites] J Clin Oncol. 2007 Jun 20;25(18):2522-7 [17577029.001]
  • [Cites] Breast Cancer Res Treat. 2008 Jun;109(3):545-57 [17659438.001]
  • [Cites] Arch Fam Med. 1999 Nov-Dec;8(6):521-8 [10575392.001]
  • [Cites] Med Care. 2000 Jul;38(7):705-18 [10901354.001]
  • [Cites] Am J Public Health. 2000 Dec;90(12):1866-72 [11111258.001]
  • [Cites] Cancer. 2000 Dec 1;89(11):2202-13 [11147590.001]
  • [Cites] J Gen Intern Med. 2001 Mar;16(3):189-99 [11318915.001]
  • [Cites] Am J Public Health. 2002 Jan;92(1):64-70 [11772763.001]
  • [Cites] Am J Epidemiol. 2002 Mar 15;155(6):534-45 [11882527.001]
  • [Cites] J Natl Cancer Inst. 2002 Apr 3;94(7):490-6 [11929949.001]
  • [Cites] JAMA. 2002 Apr 24;287(16):2106-13 [11966385.001]
  • [Cites] Cancer. 2002 Jun 1;94(11):2844-54 [12115371.001]
  • [Cites] Am J Epidemiol. 2002 Sep 1;156(5):471-82 [12196317.001]
  • [Cites] Milbank Q. 2002;80(4):677-707, iv [12532644.001]
  • [Cites] Ann Epidemiol. 2003 Jan;13(1):32-41 [12547483.001]
  • [Cites] Med Care. 2003 Jun;41(6):722-8 [12773838.001]
  • [Cites] J Clin Epidemiol. 2003 Jul;56(7):678-85 [12921937.001]
  • [Cites] Am J Public Health. 2003 Oct;93(10):1655-71 [14534218.001]
  • [Cites] Arch Intern Med. 2003 Oct 13;163(18):2135-44 [14557210.001]
  • [Cites] J Health Care Poor Underserved. 2003 Nov;14(4):503-15 [14619552.001]
  • [Cites] Cancer Causes Control. 2003 Oct;14(8):761-6 [14674740.001]
  • [Cites] Am J Public Health. 2004 Oct;94(10):1795-9 [15451752.001]
  • [Cites] Am J Public Health. 2004 Nov;94(11):1992-7 [15514242.001]
  • [Cites] Med Care Rev. 1989 Winter;46(4):349-85 [10304178.001]
  • [Cites] Cancer. 1990 Sep 15;66(6):1297-301 [2400978.001]
  • [Cites] Health Policy. 1991;19(2-3):91-118 [10115996.001]
  • [Cites] Am J Epidemiol. 1992 Mar 15;135(6):609-18 [1580237.001]
  • [Cites] J Natl Cancer Inst. 1993 Jun 16;85(12):979-87 [8496983.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):788-98 [8334632.001]
  • [Cites] Am J Public Health. 1994 Jun;84(6):1003-6 [8203664.001]
  • [Cites] JAMA. 1994 Sep 28;272(12):947-54 [8084062.001]
  • [Cites] Med Care Res Rev. 1995 Sep;52(3):389-408 [10144870.001]
  • [Cites] Cancer. 1997 Jul 1;80(1):80-90 [9210712.001]
  • [Cites] Am J Obstet Gynecol. 1997 Jun;176(6):S233-9 [9215214.001]
  • [Cites] Am J Public Health. 1997 Jul;87(7):1156-63 [9240106.001]
  • [Cites] Ann Epidemiol. 2006 Oct;16(10):789-91; author reply 792-3 [16882472.001]
  • [Cites] Breast Cancer Res Treat. 2007 Jan;101(2):207-14 [16838114.001]
  • [Cites] Ethn Dis. 1997 Spring-Summer;7(2):137-49 [9386954.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1310-8 [9529023.001]
  • [Cites] Am J Public Health. 1999 Jan;89(1):36-42 [9987462.001]
  • [Cites] Health Serv Res. 1999 Apr;34(1 Pt 2):271-9 [10199674.001]
  • [Cites] Surgery. 1999 Apr;125(4):375-9 [10216527.001]
  • [Cites] JAMA. 1999 Jul 14;282(2):159-63 [10411197.001]
  • [Cites] Am J Clin Oncol. 1999 Oct;22(5):436-40 [10521053.001]
  • [Cites] Milbank Q. 1999;77(3):401-7 [10526551.001]
  • [Cites] Breast J. 2005 Mar-Apr;11(2):124-8 [15730458.001]
  • [Cites] Breast Cancer Res Treat. 2005 Jun;91(3):243-8 [15952057.001]
  • [Cites] Am J Public Health. 2006 Jan;96(1):160-6 [16317209.001]
  • [Cites] Breast Cancer Res Treat. 2006 Jan;95(1):89-95 [16244785.001]
  • [Cites] Am J Epidemiol. 2007 Jul 1;166(1):71-8 [17426038.001]
  • (PMID = 18330694.001).
  • [ISSN] 1573-7217
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] ENG
  • [Grant] Canada / Canadian Institutes of Health Research / / 42633-1; Canada / Canadian Institutes of Health Research / / 67161; Canada / Canadian Institutes of Health Research / / 67161-1; Canada / Canadian Institutes of Health Research / / 42633; None / None / / 42633-1; None / None / / 42633; None / None / / N01 PC065064; None / None / / 67161-1; None / None / / 67161; United States / NCI NIH HHS / PC / N01-PC 65064
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ CAMS1396; NLM/ PMC2909273
  •  go-up   go-down


22. Ayhan M, Aytug Z, Karatas-Silistreli O, Yakut M, Gorgu M: The use of nail enfolded flaps for reconstruction of full-thickness ala nasi defects: an early report of experience. Acta Chir Plast; 2006;48(3):79-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common etiology of nasal defects that require reconstruction is basal cell carcinoma, as well as squamous cell carcinoma and melanoma.
  • In reconstructing full-thickness ala nasi defects following excision of basal cell carcinomas, we present our technique of the nail enfolded local flaps which involves the harvesting of the nail plate and placing it to serve as a supporting component.
  • Lining deficiencies of the alar lobule were resurfaced with skin grafts.
  • None of the cases experienced skin graft loss or nail plate exposure.
  • [MeSH-major] Nose / surgery. Reconstructive Surgical Procedures / methods. Skin Neoplasms / surgery. Surgical Flaps

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17165594.001).
  • [ISSN] 0001-5423
  • [Journal-full-title] Acta chirurgiae plasticae
  • [ISO-abbreviation] Acta Chir Plast
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


23. Merritt BG, Snow SN, Longley BJ: Desmoplastic trichoepithelioma, infiltrative/morpheaform BCC, and microcystic adnexal carcinoma: differentiation by immunohistochemistry and determining the need for Mohs micrographic surgery. Cutis; 2010 May;85(5):254-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Desmoplastic trichoepithelioma, infiltrative/morpheaform BCC, and microcystic adnexal carcinoma: differentiation by immunohistochemistry and determining the need for Mohs micrographic surgery.
  • Desmoplastic trichoepithelioma (DTE), infiltrative/morpheaform basal cell carcinoma (BCC), and microcystic adnexal carcinoma (MAC) are tumors in this category that may be difficult to differentiate, especially when evaluating thin biopsy specimens.
  • An accurate diagnosis has important clinical implications.
  • While DTE is a benign neoplasm with indolent behavior, infiltrative/morpheaform BCC and MAC can be highly aggressive, leading to substantial local destruction and potential metastasis.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Skin Appendage / pathology. Mohs Surgery. Skin Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Immunohistochemistry. Keratin-20. Male. Middle Aged. Staining and Labeling

  • Genetic Alliance. consumer health - Microcystic adnexal carcinoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20540416.001).
  • [ISSN] 0011-4162
  • [Journal-full-title] Cutis
  • [ISO-abbreviation] Cutis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Keratin-20
  •  go-up   go-down


24. Pant K, Dutta U: Understanding and management of male breast cancer: a critical review. Med Oncol; 2008;25(3):294-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Understanding and management of male breast cancer: a critical review.
  • Breast cancer is a rare disease in men representing nearly 1% of the total breast cancer cases worldwide.
  • While treatments developed for women with breast cancer are often applied to treat men with breast cancer, however, lack of awareness of this disease leads to its detection at a later stage in men.
  • This review discusses male breast cancer and draws comparisons with female breast cancer and discusses current treatments available to treat this disease.
  • It is believed that this review shall provide concise and relevant information increasing the awareness of issues revolving around male breast cancer (MBC).
  • [MeSH-major] Breast Neoplasms / therapy. Breast Neoplasms, Male / epidemiology. Breast Neoplasms, Male / therapy
  • [MeSH-minor] Antineoplastic Agents, Hormonal / therapeutic use. Aromatase Inhibitors / therapeutic use. Chemotherapy, Adjuvant. Estrogens / metabolism. Female. Humans. Male. Neoplasm Staging. Sex Characteristics. Tamoxifen / therapeutic use

  • Genetic Alliance. consumer health - Breast Cancer.
  • Genetic Alliance. consumer health - Breast Cancer, Male.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Male Breast Cancer.
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 1997 Jan;82(1):70-4 [8989235.001]
  • [Cites] Eur J Cancer. 1995 Nov;31A(12):1960-4 [8562148.001]
  • [Cites] Cancer. 1999 Feb 1;85(3):629-39 [10091736.001]
  • [Cites] J Clin Endocrinol Metab. 1974 Mar;38(3):476-9 [4815174.001]
  • [Cites] Int J Oncol. 2004 Mar;24(3):663-70 [14767551.001]
  • [Cites] Nat Genet. 1994 May;7(1):103-7 [8075631.001]
  • [Cites] Endocrinology. 1996 Dec;137(12):5739-42 [8940410.001]
  • [Cites] Br J Cancer. 1985 Jan;51(1):115-9 [3966965.001]
  • [Cites] Am J Hum Genet. 2001 Feb;68(2):410-9 [11170890.001]
  • [Cites] Cancer. 1989 Oct 15;64(8):1583-5 [2676137.001]
  • [Cites] Cancer. 1996 Feb 1;77(3):490-8 [8630956.001]
  • [Cites] Endocrinology. 1985 Jan;116(1):38-46 [2981072.001]
  • [Cites] Endocr Relat Cancer. 1999 Jun;6(2):131-7 [10731101.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2750-6 [16782915.001]
  • [Cites] Endocrinology. 1997 Dec;138(12):5125-35 [9389492.001]
  • [Cites] Bull Cancer. 2005 Mar;92(3):281-5 [15820923.001]
  • [Cites] Am J Clin Oncol. 1987 Feb;10(1):55-60 [3825994.001]
  • [Cites] J Steroid Biochem Mol Biol. 2003 Sep;86(3-5):225-30 [14623515.001]
  • [Cites] Eur J Cancer. 1998 Aug;34(9):1341-7 [9849414.001]
  • [Cites] Expert Opin Pharmacother. 2007 Feb;8(2):193-202 [17257089.001]
  • [Cites] J Health Psychol. 2002 May;7(3):209-17 [22114245.001]
  • [Cites] Med Oncol. 2008;25(2):113-24 [17973095.001]
  • [Cites] Ann Intern Med. 2002 Oct 15;137(8):678-87 [12379069.001]
  • [Cites] Mol Cell Endocrinol. 1998 Apr 30;139(1-2):117-29 [9705080.001]
  • [Cites] Int J Cancer. 1996 Feb 8;65(4):446-9 [8621225.001]
  • [Cites] BMJ. 2001 Nov 3;323(7320):1055-8 [11691767.001]
  • [Cites] Eur J Cancer. 2006 Feb;42(3):334-41 [16377181.001]
  • [Cites] Cancer Treat Rev. 2006 Apr;32(2):101-5 [16472925.001]
  • [Cites] Cancer Detect Prev. 2006;30(6):530-4 [17113724.001]
  • [Cites] Recent Prog Horm Res. 1997;52:185-213; discussion 213-4 [9238853.001]
  • [Cites] Gynecol Obstet Fertil. 2006 May;34(5):413-9 [16630739.001]
  • [Cites] BMJ. 1998 Oct 17;317(7165):1072-5 [9774301.001]
  • [Cites] Endocrinology. 1993 Mar;132(3):1396-401 [8440194.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Jan;15(1):39-44 [16434584.001]
  • [Cites] Cancer. 2004 Jul 1;101(1):51-7 [15221988.001]
  • [Cites] Oncologist. 2005 Aug;10(7):471-9 [16079314.001]
  • [Cites] Cancer. 2005 Dec 1;104(11):2359-64 [16270318.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1687-717 [15894097.001]
  • [Cites] Breast Cancer Res Treat. 2007 May;103(1):11-21 [17033919.001]
  • [Cites] J Endocrinol. 2000 Feb;164(2):225-38 [10657858.001]
  • [Cites] Lancet. 2006 Feb 18;367(9510):595-604 [16488803.001]
  • [Cites] Cancer Res. 1997 Jun 1;57(11):2109-11 [9187104.001]
  • (PMID = 18074245.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Aromatase Inhibitors; 0 / Estrogens; 094ZI81Y45 / Tamoxifen
  • [Number-of-references] 43
  •  go-up   go-down


25. Sneddon JB: The contribution of niche-derived factors to the regulation of cancer cells. Methods Mol Biol; 2009;568:217-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The contribution of niche-derived factors to the regulation of cancer cells.
  • In normal adult tissues, paracrine signals that derive from the stem cell niche, or microenvironment, play an important role in regulating the critical balance between activity and quiescence of stem cells.
  • Similarly, evidence has emerged to support the hypothesis that signals derived from the microenvironment regulate cancer cells in an analogous manner.
  • We recently reported that in basal cell carcinoma of the skin and in diverse other solid tumors, fibroblasts that comprise the tumor cell niche are, indeed, molecularly distinct from those that comprise the normal stroma.
  • [MeSH-major] Biological Factors / metabolism. Cell Culture Techniques / methods. Neoplastic Stem Cells / pathology. Stem Cell Niche / pathology
  • [MeSH-minor] Cell Separation. Colonic Neoplasms / genetics. Colonic Neoplasms / pathology. Fibroblasts / cytology. Gene Expression Regulation, Neoplastic. Humans. In Situ Hybridization. Intercellular Signaling Peptides and Proteins / genetics. Intercellular Signaling Peptides and Proteins / metabolism. RNA / genetics. RNA / metabolism. Skin Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19582430.001).
  • [ISSN] 1064-3745
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] eng
  • [Grant] United States / Howard Hughes Medical Institute / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biological Factors; 0 / GREM1 protein, human; 0 / Intercellular Signaling Peptides and Proteins; 63231-63-0 / RNA
  •  go-up   go-down


26. Matsuda J, Shao H, Nakamura Y, Akiba E: The nanostructure and hydrogenation reaction of Mg50Co50 BCC alloy prepared by ball-milling. Nanotechnology; 2009 May 20;20(20):204015
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The nanostructure and hydrogenation reaction of Mg50Co50 BCC alloy prepared by ball-milling.
  • Selected-area electron diffraction patterns (SAEDPs) revealed that these nanocrystals have a body-centered cubic (BCC) structure with a lattice parameter of about 0.3 nm.
  • The SAEDPs showed polycrystalline rings corresponding to the BCC phase and the Co metal phase.

  • Hazardous Substances Data Bank. MAGNESIUM COMPOUNDS .
  • Hazardous Substances Data Bank. HYDROGEN .
  • Hazardous Substances Data Bank. COBALT, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19420663.001).
  • [ISSN] 1361-6528
  • [Journal-full-title] Nanotechnology
  • [ISO-abbreviation] Nanotechnology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Alloys; 0 / Macromolecular Substances; 0 / Magnesium Compounds; 3G0H8C9362 / Cobalt; 7YNJ3PO35Z / Hydrogen
  •  go-up   go-down


27. Skaria AM: Electrocoagulation and hazardous damage to a dental prosthesis. J Am Acad Dermatol; 2006 Mar;54(3):543-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report the case of 50-year-old patient who experienced minor damage to a dental prosthesis after undergoing bipolar electrocoagualtion during micrographic surgery for scirrhous basal cell carcinoma of the cheek.
  • [MeSH-minor] Carcinoma, Basal Cell / surgery. Facial Neoplasms / surgery. Humans. Male. Middle Aged


28. Micali G, Lacarrubba F, Dinotta F, Massimino D, Nasca MR: Treating skin cancer with topical cream. Expert Opin Pharmacother; 2010 Jun;11(9):1515-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treating skin cancer with topical cream.
  • IMPORTANCE OF THE FIELD: Topical pharmacotherapy is an approach to consider in selected skin cancers.
  • This paper reviews and discusses the use of topical pharmacotherapy in the treatment of skin cancer.
  • AREAS COVERED IN THIS REVIEW: This paper examines the existing literature and updates current knowledge of topical pharmacotherapy for skin cancer using fluorouracil, imiquimod, diclofenac and retinoids.
  • WHAT THE READER WILL GAIN: There is a gap between current and best practice in that the use of pharmacotherapy in the treatment of skin cancer is only partially known.
  • TAKE HOME MESSAGE: Topical pharmacotherapy represents an option for treatment of actinic keratoses and selected basal cell carcinomas.
  • Moreover, preliminary reports indicate imiquimod to be effective for skin or mucosal cancers such as Bowen's disease, erythroplasia of Queyrat and lentigo maligna.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Basal Cell / drug therapy. Keratosis, Actinic / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. DICLOFENAC .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20408746.001).
  • [ISSN] 1744-7666
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Retinoids; 144O8QL0L1 / Diclofenac; 99011-02-6 / imiquimod; U3P01618RT / Fluorouracil
  • [Number-of-references] 112
  •  go-up   go-down


29. Zemelman V, Silva P, Sazunic I: Basal cell carcinoma: analysis of regression after incomplete excision. Clin Exp Dermatol; 2009 Oct;34(7):e425
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basal cell carcinoma: analysis of regression after incomplete excision.
  • [MeSH-major] Carcinoma, Basal Cell / surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Female. Humans. Male. Neoplasm Regression, Spontaneous. Neoplasm, Residual. Reoperation

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19686288.001).
  • [ISSN] 1365-2230
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] England
  •  go-up   go-down


30. Kump E, Ji J, Wernli M, Häusermann P, Erb P: Gli2 upregulates cFlip and renders basal cell carcinoma cells resistant to death ligand-mediated apoptosis. Oncogene; 2008 Jun 19;27(27):3856-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gli2 upregulates cFlip and renders basal cell carcinoma cells resistant to death ligand-mediated apoptosis.
  • Mutations in the Hedgehog signaling pathway is responsible for the formation of various cancers, including some forms of basal cell carcinoma (BCC).
  • The direct functional connection between Gli2 and cFlip was not only demonstrated in a keratinocytic cell line but also in BCC tissue.
  • As cFlip and Bcl-2 are highly expressed in BCCs, as a consequence of high Gli2 expression, this may explain the marked resistance of the tumor to the extrinsic and intrinsic apoptotic pathway.
  • We could now demonstrate that Gli2 gene silencing in BCC tissues made the tumor sensitive to TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-mediated cell death by downregulating cFlip.
  • [MeSH-major] Apoptosis / physiology. Carcinoma, Basal Cell / pathology. Gene Expression Regulation, Neoplastic. Kruppel-Like Transcription Factors / genetics. Nuclear Proteins / genetics. Receptors, TNF-Related Apoptosis-Inducing Ligand / physiology
  • [MeSH-minor] Carboxylic Ester Hydrolases / physiology. Cell Death. Cell Line. Cell Line, Tumor. Down-Regulation. Drug Resistance, Neoplasm. Gene Silencing. Humans. Intracellular Signaling Peptides and Proteins. Keratinocytes / physiology. Mitochondrial Proteins / physiology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18264131.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / GLI2 protein, human; 0 / Intracellular Signaling Peptides and Proteins; 0 / Kruppel-Like Transcription Factors; 0 / Mitochondrial Proteins; 0 / Nuclear Proteins; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; EC 3.1.1.- / Carboxylic Ester Hydrolases; EC 3.1.1.29 / PTH2 protein, human
  •  go-up   go-down


31. Mariolis-Sapsakos T, Theodoropoulos G, Flessas II, Orfanos F, Orfanos N, Konstantinou EA, Zagouri F, Vlachodimitropoulos D, Zografos GC: Lobular breast cancer in men: case report and review of the literature. Onkologie; 2010;33(12):698-700
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lobular breast cancer in men: case report and review of the literature.
  • BACKGROUND: Lobular breast cancer in men is an extremely infrequent occurrence due to the lack of lobules and acini in the male breast.
  • Such a rare case is described here.
  • CASE REPORT: A 74-year-old patient presented with a sizeable lesion in the right breast, which proved to be a lobular carcinoma.
  • This case represented a lobular carcinoma in a genotypically male patient under no exogenous or endogenous estrogenic influence.
  • CONCLUSIONS: The increasing number of male lobular breast cancer cases should be explored more extensively with particular emphasis placed on causally related genetic and hormonal factors.
  • [MeSH-major] Breast Neoplasms, Male / diagnosis. Carcinoma, Lobular / diagnosis
  • [MeSH-minor] Aged. Biopsy, Fine-Needle. Breast / pathology. Chemotherapy, Adjuvant. Combined Modality Therapy. Humans. Karyotyping. Male. Mastectomy, Modified Radical. Neoplasm Invasiveness. Neoplasm Staging


32. Della Puppa A, Dal Pos S, Zovato S, Orvieto E, Ciccarino P, Manara R, Zustovich F, Berti F, Gardiman MP, Scienza R: Solitary intra-ventricular brain metastasis from a breast carcinoma. J Neurooncol; 2010 Mar;97(1):123-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary intra-ventricular brain metastasis from a breast carcinoma.
  • Prevalence of symptomatic central nervous system (CNS) metastases among patients with breast cancer ranges from 5% to 16%, although autoptic studies have reported prevalence rates of up to 30%.
  • Descriptions of solitary intra-ventricular metastasis are very rare; to date no cases from breast cancer have been reported in the literature.
  • We present the unusual case of a breast cancer patient who developed a solitary choroid plexus metastasis in the left lateral ventricle.
  • [MeSH-major] Brain Neoplasms / secondary. Breast Neoplasms / pathology. Carcinoma / pathology. Lateral Ventricles / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] No Shinkei Geka. 1999 Apr;27(4):359-63 [10347852.001]
  • [Cites] J Neurooncol. 1999;45(3):237-40 [10845394.001]
  • [Cites] South Med J. 1998 Dec;91(12 ):1159-62 [9853731.001]
  • [Cites] AJNR Am J Neuroradiol. 2005 Jun-Jul;26(6):1475-8 [15956518.001]
  • [Cites] Neurol Med Chir (Tokyo). 1997 Dec;37(12 ):916-9 [9465591.001]
  • [Cites] Neurol India. 2008 Apr-Jun;56(2):179-81 [18688144.001]
  • [Cites] Magn Reson Med Sci. 2003 Oct 1;2(3):155-8 [16222108.001]
  • [Cites] J Clin Neurosci. 2004 Jun;11(5):521-3 [15177398.001]
  • [Cites] J Neurosurg. 2000 Mar;92(3):506 [10701550.001]
  • [Cites] J Neurooncol. 2005 Jan;71(2):157-60 [15690132.001]
  • [Cites] J Neurooncol. 1996 Jan;27(1):47-52 [8699225.001]
  • [Cites] J Clin Neurosci. 2008 May;15(5):594-7 [18313927.001]
  • (PMID = 19727563.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Cheng NX, Liu LG, Hui L, Chen YL, Xu SL: Breast cancer following augmentation mammaplasty with polyacrylamide hydrogel (PAAG) injection. Aesthetic Plast Surg; 2009 Jul;33(4):563-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer following augmentation mammaplasty with polyacrylamide hydrogel (PAAG) injection.
  • This report presents two cases of breast cancer occurring after injection of PAAG in augmented breasts.
  • The delayed diagnosis and more aggressive disease due to PAAG injection should be cause for concern.
  • It is very important to detect breast cancer early when it is covered by the induration of the injected gel and inflammation reaction after PAAG injection.
  • PAAG injection for augmentation mammaplasty may affect the outcome of breast cancer diagnosis and prognosis.
  • [MeSH-major] Acrylic Resins / administration & dosage. Acrylic Resins / adverse effects. Breast Neoplasms / chemically induced. Gels / administration & dosage. Gels / adverse effects. Mammaplasty / methods

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Reconstruction.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19156460.001).
  • [ISSN] 1432-5241
  • [Journal-full-title] Aesthetic plastic surgery
  • [ISO-abbreviation] Aesthetic Plast Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acrylic Resins; 0 / Gels; 0 / polyacrylamide gels
  •  go-up   go-down


34. Mazzucchelli R, Lopez-Beltran A, Cheng L, Scarpelli M, Kirkali Z, Montironi R: Rare and unusual histological variants of prostatic carcinoma: clinical significance. BJU Int; 2008 Nov;102(10):1369-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare and unusual histological variants of prostatic carcinoma: clinical significance.
  • We review the clinicopathological features of the following unusual histological variants of prostatic carcinoma: small cell carcinoma, ductal adenocarcinoma, sarcomatoid (carcinosarcoma), basal cell, squamous cell and adenosquamous, and urothelial carcinoma.
  • These variants are rare and account for 5-10% of carcinomas that originate in the prostate.
  • Only basal cell carcinoma is seen as a low-grade carcinoma.
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Carcinoma, Acinar Cell / pathology. Carcinoma, Small Cell / pathology. Carcinoma, Squamous Cell / pathology. Carcinoma, Transitional Cell / pathology. Carcinosarcoma / pathology. Humans. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18793296.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 56
  •  go-up   go-down


35. Kwon S, Kim TS, Yu GH, Jung JH, Park HD: Bacterial community composition and diversity of a full-scale integrated fixed-film activated sludge system as investigated by pyrosequencing. J Microbiol Biotechnol; 2010 Dec;20(12):1717-23
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bacterial community composition and diversity of a full-scale integrated fixed-film activated sludge system as investigated by pyrosequencing.

  • SILVA. SILVA SSU Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21193829.001).
  • [ISSN] 1738-8872
  • [Journal-full-title] Journal of microbiology and biotechnology
  • [ISO-abbreviation] J. Microbiol. Biotechnol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ GU539392/ GU539393/ GU539394/ GU539395/ GU539396/ GU539397/ GU539398/ GU539399/ GU539400/ GU539401/ GU539402/ GU539403/ GU539404/ GU539405/ GU539406/ GU539407/ GU539408/ GU539409/ GU539410/ GU539411/ GU539412/ GU539413/ GU539414/ GU539415/ GU539416/ GU539417/ GU539418/ GU539419/ GU539420/ GU539421/ GU539422/ GU539423/ GU539424/ GU539425/ GU539426/ GU539427/ GU539428/ GU539429/ GU539430/ GU539431/ GU539432/ GU539433/ GU539434/ GU539435/ GU539436/ GU539437/ GU539438/ GU539439/ GU539440/ GU539441/ GU539442/ GU539443/ GU539444/ GU539445/ GU539446/ GU539447/ GU539448/ GU539449/ GU539450/ GU539451/ GU539452/ GU539453/ GU539454/ GU539455/ GU539456/ GU539457/ GU539458/ GU539459/ GU539460/ GU539461/ GU539462/ GU539463/ GU539464/ GU539465/ GU539466/ GU539467/ GU539468/ GU539469/ GU539470/ GU539471/ GU539472/ GU539473/ GU539474/ GU539475/ GU539476/ GU539477/ GU539478/ GU539479/ GU539480/ GU539481/ GU539482/ GU539483/ GU539484/ GU539485/ GU539486/ GU539487/ GU539488/ GU539489/ GU539490/ GU539491/ GU539492/ GU539493/ GU539494/ GU539495/ GU539496/ GU539497/ GU539498/ GU539499/ GU539500/ GU539501/ GU539502/ GU539503/ GU539504/ GU539505/ GU539506/ GU539507/ GU539508/ GU539509/ GU539510/ GU539511/ GU539512/ GU539513/ GU539514/ GU539515/ GU539516/ GU539517/ GU539518/ GU539519/ GU539520/ GU539521/ GU539522/ GU539523/ GU539524/ GU539525/ GU539526/ GU539527/ GU539528/ GU539529/ GU539530/ GU539531/ GU539532/ GU539533/ GU539534/ GU539535/ GU539536/ GU539537/ GU539538/ GU539539/ GU539540/ GU539541/ GU539542/ GU539543/ GU539544/ GU539545/ GU539546/ GU539547/ GU539548/ GU539549/ GU539550/ GU539551/ GU539552/ GU539553/ GU539554/ GU539555/ GU539556/ GU539557/ GU539558/ GU539559/ GU539560/ GU539561/ GU539562/ GU539563/ GU539564/ GU539565/ GU539566/ GU539567/ GU539568/ GU539569/ GU539570/ GU539571/ GU539572/ GU539573/ GU539574/ GU539575/ GU539576/ GU539577/ GU539578/ GU539579/ GU539580/ GU539581/ GU539582/ GU539583/ GU539584/ GU539585/ GU539586/ GU539587/ GU539588/ GU539589/ GU539590/ GU539591/ GU539592/ GU539593/ GU539594/ GU539595/ GU539596/ GU539597/ GU539598/ GU539599/ GU539600/ GU539601/ GU539602/ GU539603/ GU539604/ GU539605/ GU539606/ GU539607/ GU539608/ GU539609/ GU539610/ GU539611/ GU539612/ GU539613/ GU539614/ GU539615/ GU539616/ GU539617/ GU539618/ GU539619/ GU539620/ GU539621/ GU539622/ GU539623/ GU539624/ GU539625/ GU539626/ GU539627/ GU539628/ GU539629/ GU539630/ GU539631/ GU539632/ GU539633/ GU539634/ GU539635/ GU539636/ GU539637/ GU539638/ GU539639/ GU539640/ GU539641/ GU539642/ GU539643/ GU539644/ GU539645/ GU539646/ GU539647/ GU539648/ GU539649/ GU539650/ GU539651/ GU539652/ GU539653/ GU539654/ GU539655/ GU539656/ GU539657/ GU539658/ GU539659/ GU539660/ GU539661/ GU539662/ GU539663/ GU539664/ GU539665/ GU539666/ GU539667/ GU539668/ GU539669/ GU539670/ GU539671/ GU539672/ GU539673/ GU539674/ GU539675/ GU539676/ GU539677/ GU539678/ GU539679/ GU539680/ GU539681/ GU539682/ GU539683/ GU539684/ GU539685/ GU539686/ GU539687/ GU539688/ GU539689/ GU539690/ GU539691/ GU539692/ GU539693/ GU539694/ GU539695/ GU539696/ GU539697/ GU539698/ GU539699/ GU539700/ GU539701/ GU539702/ GU539703/ GU539704/ GU539705/ GU539706/ GU539707/ GU539708/ GU539709/ GU539710/ GU539711/ GU539712/ GU539713/ GU539714/ GU539715/ GU539716/ GU539717/ GU539718/ GU539719/ GU539720/ GU539721/ GU539722/ GU539723/ GU539724/ GU539725/ GU539726/ GU539727/ GU539728/ GU539729/ GU539730/ GU539731/ GU539732/ GU539733/ GU539734/ GU539735/ GU539736/ GU539737/ GU539738/ GU539739/ GU539740/ GU539741/ GU539742/ GU539743/ GU539744/ GU539745/ GU539746/ GU539747/ GU539748/ GU539749/ GU539750/ GU539751/ GU539752/ GU539753/ GU539754/ GU539755/ GU539756/ GU539757/ GU539758/ GU539759/ GU539760/ GU539761/ GU539762/ GU539763/ GU539764/ GU539765/ GU539766/ GU539767/ GU539768/ GU539769/ GU539770/ GU539771/ GU539772/ GU539773/ GU539774/ GU539775/ GU539776/ GU539777/ GU539778/ GU539779/ GU539780/ GU539781/ GU539782/ GU539783/ GU539784/ GU539785/ GU539786/ GU539787/ GU539788/ GU539789/ GU539790/ GU539791/ GU539792/ GU539793/ GU539794/ GU539795/ GU539796/ GU539797/ GU539798/ GU539799/ GU539800/ GU539801/ GU539802/ GU539803/ GU539804/ GU539805/ GU539806/ GU539807/ GU539808/ GU539809/ GU539810/ GU539811/ GU539812/ GU539813/ GU539814/ GU539815/ GU539816/ GU539817/ GU539818/ GU539819/ GU539820/ GU539821/ GU539822/ GU539823/ GU539824/ GU539825/ GU539826/ GU539827/ GU539828/ GU539829/ GU539830/ GU539831/ GU539832/ GU539833/ GU539834/ GU539835/ GU539836/ GU539837/ GU539838/ GU539839/ GU539840/ GU539841/ GU539842/ GU539843/ GU539844/ GU539845/ GU539846/ GU539847/ GU539848/ GU539849/ GU539850/ GU539851/ GU539852/ GU539853/ GU539854/ GU539855/ GU539856/ GU539857/ GU539858/ GU539859/ GU539860/ GU539861/ GU539862/ GU539863/ GU539864/ GU539865/ GU539866/ GU539867/ GU539868/ GU539869/ GU539870/ GU539871/ GU539872/ GU539873/ GU539874/ GU539875/ GU539876/ GU539877/ GU539878/ GU539879/ GU539880/ GU539881/ GU539882/ GU539883/ GU539884/ GU539885/ GU539886/ GU539887/ GU539888/ GU539889/ GU539890/ GU539891/ GU539892/ GU539893/ GU539894/ GU539895/ GU539896/ GU539897/ GU539898/ GU539899/ GU539900/ GU539901/ GU539902/ GU539903/ GU539904/ GU539905/ GU539906/ GU539907/ GU539908/ GU539909/ GU539910/ GU539911/ GU539912/ GU539913/ GU539914/ GU539915/ GU539916/ GU539917/ GU539918/ GU539919/ GU539920/ GU539921/ GU539922/ GU539923/ GU539924/ GU539925/ GU539926/ GU539927/ GU539928/ GU539929/ GU539930/ GU539931/ GU539932/ GU539933/ GU539934/ GU539935/ GU539936/ GU539937/ GU539938/ GU539939/ GU539940/ GU539941/ GU539942/ GU539943/ GU539944/ GU539945/ GU539946/ GU539947/ GU539948/ GU539949/ GU539950/ GU539951/ GU539952/ GU539953/ GU539954/ GU539955/ GU539956/ GU539957/ GU539958/ GU539959/ GU539960/ GU539961/ GU539962/ GU539963/ GU539964/ GU539965/ GU539966/ GU539967/ GU539968/ GU539969/ GU539970/ GU539971/ GU539972/ GU539973/ GU539974/ GU539975/ GU539976/ GU539977/ GU539978/ GU539979/ GU539980/ GU539981/ GU539982/ GU539983/ GU539984/ GU539985/ GU539986/ GU539987/ GU539988/ GU539989/ GU539990/ GU539991/ GU539992/ GU539993/ GU539994/ GU539995/ GU539996/ GU539997/ GU539998/ GU539999/ GU540000/ GU540001/ GU540002/ GU540003/ GU540004/ GU540005/ GU540006/ GU540007/ GU540008/ GU540009/ GU540010/ GU540011/ GU540012/ GU540013/ GU540014/ GU540015/ GU540016/ GU540017/ GU540018/ GU540019/ GU540020/ GU540021/ GU540022/ GU540023/ GU540024/ GU540025/ GU540026/ GU540027/ GU540028/ GU540029/ GU540030/ GU540031/ GU540032/ GU540033/ GU540034/ GU540035/ GU540036/ GU540037/ GU540038/ GU540039/ GU540040/ GU540041/ GU540042/ GU540043/ GU540044/ GU540045/ GU540046/ GU540047/ GU540048/ GU540049/ GU540050/ GU540051/ GU540052/ GU540053/ GU540054/ GU540055/ GU540056/ GU540057/ GU540058/ GU540059/ GU540060/ GU540061/ GU540062/ GU540063/ GU540064/ GU540065/ GU540066/ GU540067/ GU540068/ GU540069/ GU540070/ GU540071/ GU540072/ GU540073/ GU540074/ GU540075/ GU540076/ GU540077/ GU540078/ GU540079/ GU540080/ GU540081/ GU540082/ GU540083/ GU540084/ GU540085/ GU540086/ GU540087/ GU540088/ GU540089/ GU540090/ GU540091/ GU540092/ GU540093/ GU540094/ GU540095/ GU540096/ GU540097/ GU540098/ GU540099/ GU540100/ GU540101/ GU540102/ GU540103/ GU540104/ GU540105/ GU540106/ GU540107/ GU540108/ GU540109/ GU540110/ GU540111/ GU540112/ GU540113/ GU540114/ GU540115/ GU540116/ GU540117/ GU540118/ GU540119/ GU540120/ GU540121/ GU540122/ GU540123/ GU540124/ GU540125/ GU540126/ GU540127/ GU540128/ GU540129/ GU540130/ GU540131/ GU540132/ GU540133/ GU540134/ GU540135/ GU540136/ GU540137/ GU540138/ GU540139/ GU540140/ GU540141/ GU540142/ GU540143/ GU540144/ GU540145/ GU540146/ GU540147/ GU540148/ GU540149/ GU540150/ GU540151/ GU540152/ GU540153/ GU540154/ GU540155/ GU540156/ GU540157/ GU540158/ GU540159/ GU540160/ GU540161/ GU540162/ GU540163/ GU540164/ GU540165/ GU540166/ GU540167/ GU540168/ GU540169/ GU540170/ GU540171/ GU540172/ GU540173/ GU540174/ GU540175/ GU540176/ GU540177/ GU540178/ GU540179/ GU540180/ GU540181/ GU540182/ GU540183/ GU540184/ GU540185/ GU540186/ GU540187/ GU540188/ GU540189/ GU540190/ GU540191/ GU540192/ GU540193/ GU540194/ GU540195/ GU540196/ GU540197/ GU540198/ GU540199/ GU540200/ GU540201/ GU540202/ GU540203/ GU540204/ GU540205/ GU540206/ GU540207/ GU540208/ GU540209/ GU540210/ GU540211/ GU540212/ GU540213/ GU540214/ GU540215/ GU540216/ GU540217/ GU540218/ GU540219/ GU540220/ GU540221/ GU540222/ GU540223/ GU540224/ GU540225/ GU540226/ GU540227/ GU540228/ GU540229/ GU540230/ GU540231/ GU540232/ GU540233/ GU540234/ GU540235/ GU540236/ GU540237/ GU540238/ GU540239/ GU540240/ GU540241/ GU540242/ GU540243/ GU540244/ GU540245/ GU540246/ GU540247/ GU540248/ GU540249/ GU540250/ GU540251/ GU540252/ GU540253/ GU540254/ GU540255/ GU540256/ GU540257/ GU540258/ GU540259/ GU540260/ GU540261/ GU540262/ GU540263/ GU540264/ GU540265/ GU540266/ GU540267/ GU540268/ GU540269/ GU540270/ GU540271/ GU540272/ GU540273/ GU540274/ GU540275/ GU540276/ GU540277/ GU540278/ GU540279/ GU540280/ GU540281/ GU540282/ GU540283/ GU540284/ GU540285/ GU540286/ GU540287/ GU540288/ GU540289/ GU540290/ GU540291/ GU540292/ GU540293/ GU540294/ GU540295/ GU540296/ GU540297/ GU540298/ GU540299/ GU540300/ GU540301/ GU540302/ GU540303/ GU540304/ GU540305/ GU540306/ GU540307/ GU540308/ GU540309/ GU540310/ GU540311/ GU540312/ GU540313/ GU540314/ GU540315/ GU540316/ GU540317/ GU540318/ GU540319/ GU540320/ GU540321/ GU540322/ GU540323/ GU540324/ GU540325/ GU540326/ GU540327/ GU540328/ GU540329/ GU540330/ GU540331/ GU540332/ GU540333/ GU540334/ GU540335/ GU540336/ GU540337/ GU540338/ GU540339/ GU540340/ GU540341/ GU540342/ GU540343/ GU540344/ GU540345/ GU540346/ GU540347/ GU540348/ GU540349/ GU540350/ GU540351/ GU540352/ GU540353/ GU540354/ GU540355/ GU540356/ GU540357/ GU540358/ GU540359/ GU540360/ GU540361/ GU540362/ GU540363/ GU540364/ GU540365/ GU540366/ GU540367/ GU540368/ GU540369/ GU540370/ GU540371/ GU540372/ GU540373/ GU540374/ GU540375/ GU540376/ GU540377/ GU540378/ GU540379/ GU540380/ GU540381/ GU540382/ GU540383/ GU540384/ GU540385/ GU540386/ GU540387/ GU540388/ GU540389/ GU540390/ GU540391
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / DNA, Bacterial; 0 / DNA, Ribosomal; 0 / RNA, Ribosomal, 16S; 0 / Sewage
  •  go-up   go-down


36. Aram S, Moghaddam NA: Bilateral ovarian fibroma associated with Gorlin syndrome. J Res Med Sci; 2009 Jan;14(1):57-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gorlin syndrome (GS), also known as nevoid basal cell carcinoma syndrome (NBCCS), is a rare inherited multisystem disorder.
  • Accurate diagnosis is only possible with close attention to the familial and past medical history and physical examination.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am Fam Physician. 2002 Jun 15;65(12):2501-4 [12086239.001]
  • [Cites] Am J Med Genet. 2002 Sep 15;112(1):61-4 [12239722.001]
  • [Cites] Arch Pathol Lab Med. 2004 Mar;128(3):313-7 [14987156.001]
  • [Cites] Prenat Diagn. 2005 Nov;25(11):997-9 [16231297.001]
  • [Cites] Am J Surg Pathol. 1984 Mar;8(3):231-6 [6703200.001]
  • [Cites] Am J Hum Genet. 1997 Jan;60(1):10-2 [8981940.001]
  • [Cites] J Pediatr Surg. 1986 Oct;21(10):908-10 [3783383.001]
  • [Cites] J Med Genet. 1993 Jun;30(6):460-4 [8326488.001]
  • [Cites] J BUON. 2004 Apr-Jun;9(2):209-13 [17415818.001]
  • [Cites] Rofo. 2007 Jun;179(6):618-26 [17492539.001]
  • [Cites] West Indian Med J. 2007 Jan;56(1):90-5 [17621852.001]
  • [Cites] J Pediatr Surg. 1990 Jun;25(6):690-1 [2359009.001]
  • [Cites] Am J Med Genet. 1997 Mar 31;69(3):299-308 [9096761.001]
  • (PMID = 21772861.001).
  • [ISSN] 1735-1995
  • [Journal-full-title] Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences
  • [ISO-abbreviation] J Res Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Iran
  • [Other-IDs] NLM/ PMC3129069
  • [Keywords] NOTNLM ; Gorlin syndrome / multiple keratocysts / ovarian fibroma
  •  go-up   go-down


37. Soysal HG: Orbital exenteration: a 10-year experience of a general oncology hospital. Orbit; 2010 Jun;29(3):135-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orbital exenteration: a 10-year experience of a general oncology hospital.
  • The age, sex, the location of tumour, the duration of symptoms, histopathological diagnosis, and previous recurrences were noted.
  • Seven different types of histopathology were encountered: squamous cell carcinoma (31 cases), basal cell carcinoma (26 cases), malignant melanoma (5 cases), sebaceous cell carcinoma (2 cases), rhabdomyosarcoma (2 cases), mucoepidermoid carcinoma (1 case) and adenoid cystic carcinoma (1 case).
  • CONCLUSIONS: Large proportion of the patients that underwent exenteration had a history of previous unsuccessful treatment and a long duration of disease.
  • [MeSH-major] Neoplasm Invasiveness / pathology. Orbit Evisceration / methods
  • [MeSH-minor] Adult. Aged. Biopsy, Needle. Cohort Studies. Conjunctival Neoplasms / pathology. Conjunctival Neoplasms / surgery. Eye Neoplasms / pathology. Eye Neoplasms / surgery. Eyelid Neoplasms / pathology. Eyelid Neoplasms / surgery. Female. Hospitals, General. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. Oncology Service, Hospital. Orbital Neoplasms / pathology. Orbital Neoplasms / surgery. Prognosis. Retrospective Studies. Risk Assessment. Survival Analysis. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20497078.001).
  • [ISSN] 1744-5108
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


38. Thomson P, Palamaras I, Hill V, Robles W, Stevens H: Patients are happy to be informed of their final non-melanoma skin cancer results by post. Dermatol Online J; 2010;16(1):5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patients are happy to be informed of their final non-melanoma skin cancer results by post.
  • During the past year, because of increasing pressure to see more patients, we have started to write to our patients informing them in a letter of their final skin cancer histology results following surgery for non-melanoma skin cancers: basal cell carcinoma and squamous cell carcinoma only.
  • A questionnaire-based study was carried out to assess whether patients were happy to receive information concerning their non-melanoma skin cancer diagnosis in a carefully worded letter.
  • One-hundred fifty patients were involved with a diagnosis of "completely excised non-melanoma skin cancer (NMSC)" that had previously received their final diagnosis by post.
  • Eighty-seven percent felt that they had been given the cancer diagnosis in an appropriate manner; 90 percent reported that they had understood the explanation about their skin cancer.
  • In addition, 81 percent stated that they had been sufficiently involved in the discussion about their skin cancer and its treatment.
  • [MeSH-major] Carcinoma, Basal Cell / psychology. Carcinoma, Squamous Cell / psychology. Communication. Patient Acceptance of Health Care. Patient Satisfaction. Patients / psychology. Postal Service. Skin Neoplasms / psychology. Truth Disclosure

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20137747.001).
  • [ISSN] 1087-2108
  • [Journal-full-title] Dermatology online journal
  • [ISO-abbreviation] Dermatol. Online J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Fantini F, Gualdi G, Cimitan A, Giannetti A: Metastatic basal cell carcinoma with squamous differentiation: report of a case with response of cutaneous metastases to electrochemotherapy. Arch Dermatol; 2008 Sep;144(9):1186-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic basal cell carcinoma with squamous differentiation: report of a case with response of cutaneous metastases to electrochemotherapy.
  • BACKGROUND: Metastatic basal cell carcinoma is a rare disease with poor prognosis.
  • Electrochemotherapy is a recently described therapy that relies on the permeation of cancer cell membranes by electrical pulses to enhance cytotoxic drug penetration.
  • It has been successfully used in the treatment of primary and metastatic skin cancers.
  • We report a case of metastatic basal cell carcinoma in which electrochemotherapy was effective in inducing local regression of skin metastases.
  • OBSERVATIONS: A 75-year-old man presented with a pigmented, deeply infiltrating nodule in the right axilla manifesting as basal cell carcinoma with squamous differentiation at histopathologic examination.
  • Three successive sessions of electrochemotherapy with bleomycin sulfate were then performed on isolated skin metastases.
  • Conclusion Electrochemotherapy is an effective and well-tolerated adjunct to the therapeutic options in metastatic basal cell carcinoma, characterized by an advantageous risk-benefit ratio and minimal downtime.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / secondary. Electrochemotherapy. Skin Neoplasms / pathology. Skin Neoplasms / secondary
  • [MeSH-minor] Aged. Antibiotics, Antineoplastic / therapeutic use. Bleomycin / therapeutic use. Cell Differentiation. Humans. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18794464.001).
  • [ISSN] 1538-3652
  • [Journal-full-title] Archives of dermatology
  • [ISO-abbreviation] Arch Dermatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 11056-06-7 / Bleomycin
  •  go-up   go-down


40. Bhoumik A, Fichtman B, Derossi C, Breitwieser W, Kluger HM, Davis S, Subtil A, Meltzer P, Krajewski S, Jones N, Ronai Z: Suppressor role of activating transcription factor 2 (ATF2) in skin cancer. Proc Natl Acad Sci U S A; 2008 Feb 5;105(5):1674-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suppressor role of activating transcription factor 2 (ATF2) in skin cancer.
  • Crossing the conditionally expressed ATF2 mutant with K14-Cre mice (K14.ATF2(f/f)) resulted in selective expression of mutant ATF2 within the basal layer of the epidermis.
  • When subjected to a two-stage skin carcinogenesis protocol [7,12-dimethylbenz[a]anthracene/phorbol 12-tetradecanoate 13-acetate (DMBA/TPA)], K14.ATF2(f/f) mice showed significant increases in both the incidence and prevalence of papilloma development compared with the WT ATF2 mice.
  • Significantly, a reduction of nuclear ATF2 and increased beta-catenin expression were seen in samples of squamous and basal cell carcinoma, as opposed to normal skin.
  • Our data reveal that loss of ATF2 transcriptional activity serves to promote skin tumor formation, thereby indicating a suppressor activity of ATF2 in skin tumor formation.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. 12-O-TETRADECANOYLPHORBOL-13-ACETATE .
  • Hazardous Substances Data Bank. 7,12-DIMETHYLBENZ(A)ANTHRACENE .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2004 Nov 15;64(22):8222-30 [15548688.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 17;96(17):9827-32 [10449779.001]
  • [Cites] Mol Cell Biol. 2007 Mar;27(5):1730-44 [17189429.001]
  • [Cites] Genes Dev. 2007 Mar 1;21(5):562-77 [17344417.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2430-8 [17363560.001]
  • [Cites] Mol Cell Biol. 2000 Jul;20(13):4814-25 [10848607.001]
  • [Cites] Oncogene. 2000 Aug 17;19(35):4011-21 [10962557.001]
  • [Cites] Clin Cancer Res. 2001 Feb;7(2):331-42 [11234888.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):3908-12 [11358804.001]
  • [Cites] Oncogene. 2001 Apr 30;20(19):2453-64 [11402340.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10863-8 [11517342.001]
  • [Cites] Oncogene. 2002 Jul 18;21(31):4728-38 [12101411.001]
  • [Cites] J Clin Invest. 2002 Sep;110(5):643-50 [12208865.001]
  • [Cites] Cell. 2002 Sep 20;110(6):751-62 [12297048.001]
  • [Cites] Nat Genet. 2003 Mar;33(3):416-21 [12590261.001]
  • [Cites] Dev Cell. 2003 Jun;4(6):879-89 [12791272.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8103-7 [14678960.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4222-7 [15010535.001]
  • [Cites] Nature. 1986 Oct 30-Nov 5;323(6091):822-4 [2430189.001]
  • [Cites] Oncogene. 1990 Mar;5(3):295-302 [2138276.001]
  • [Cites] Carcinogenesis. 1993 Feb;14(2):319-21 [8435875.001]
  • [Cites] Oncogene. 1993 May;8(5):1127-33 [8479737.001]
  • [Cites] Mol Cell Biol. 1993 Sep;13(9):5479-89 [8355695.001]
  • [Cites] J Biol Chem. 1993 Oct 5;268(28):21225-31 [8407959.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jan 18;91(2):609-13 [8290571.001]
  • [Cites] Cancer Res. 1994 Mar 1;54(5):1178-89 [8118803.001]
  • [Cites] Cancer Res. 1994 Apr 1;54(7 Suppl):1882s-1885s [8137304.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10613-8 [17556541.001]
  • [Cites] J Biol Chem. 2007 Oct 26;282(43):31504-16 [17716970.001]
  • [Cites] Science. 1995 Jan 20;267(5196):389-93 [7824938.001]
  • [Cites] Exp Cell Res. 1995 Feb;216(2):422-30 [7843287.001]
  • [Cites] Carcinogenesis. 1995 Apr;16(4):749-56 [7728951.001]
  • [Cites] EMBO J. 1995 Apr 18;14(8):1798-811 [7737130.001]
  • [Cites] Cancer Res. 1996 Feb 1;56(3):483-9 [8564958.001]
  • [Cites] Mol Cell Biol. 1996 Oct;16(10):5232-44 [8816436.001]
  • [Cites] Carcinogenesis. 1996 Dec;17(12):2551-7 [9006088.001]
  • [Cites] Genes Dev. 1998 Jan 15;12(2):233-45 [9436983.001]
  • [Cites] Genes Dev. 1998 Aug 15;12(16):2469-74 [9716400.001]
  • [Cites] Science. 1998 Sep 4;281(5382):1509-12 [9727977.001]
  • [Cites] Mol Cell Biol. 1998 Dec;18(12):7020-9 [9819389.001]
  • [Cites] Nature. 1999 Apr 8;398(6727):518-22 [10206645.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 May 11;96(10):5522-7 [10318916.001]
  • [Cites] J Biol Chem. 1999 Jun 18;274(25):17813-9 [10364225.001]
  • [Cites] Mol Cell. 2005 May 27;18(5):577-87 [15916964.001]
  • (PMID = 18227516.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Databank-accession-numbers] GEO/ GSE9328
  • [Grant] United States / NCI NIH HHS / CA / R01 CA099961; United States / NCI NIH HHS / CA / CA099961
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Activating Transcription Factor 2; 0 / Carcinogens; 0 / Notch1 protein, mouse; 0 / Presenilin-1; 0 / Proto-Oncogene Proteins c-myb; 0 / Receptor, Notch1; 0 / Tumor Suppressor Proteins; 0 / beta Catenin; 136601-57-5 / Cyclin D1; 57-97-6 / 9,10-Dimethyl-1,2-benzanthracene; 9007-49-2 / DNA; NI40JAQ945 / Tetradecanoylphorbol Acetate
  • [Other-IDs] NLM/ PMC2234203
  •  go-up   go-down


41. Zinkernagel MS, Catalano E, Ammann-Rauch D: Free tarsal graft combined with skin transposition flap for full-thickness lower eyelid reconstruction. Ophthal Plast Reconstr Surg; 2007 May-Jun;23(3):228-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Free tarsal graft combined with skin transposition flap for full-thickness lower eyelid reconstruction.
  • We present the surgical outcome in a series of 4 patients with large full-thickness eyelid defects after basal cell carcinoma excision.
  • The patients underwent reconstructive eyelid surgery using autogenous free tarsal grafts combined with a skin transposition flap from the upper eyelid.
  • In all 4 cases, posterior lamellae were reconstructed using a free tarsal graft, and the outer lamella was developed with a transposition skin flap from the upper eyelid.
  • The skin flap provided adequate vascular support in all cases.
  • Autogenous tarsus as a free graft proves to be a simple procedure for posterior lamella substitution in lower eyelid surgery, especially in combination with a skin transposition flap from the upper eyelid.
  • [MeSH-major] Eyelids / transplantation. Ophthalmologic Surgical Procedures. Reconstructive Surgical Procedures. Skin Transplantation / methods. Surgical Flaps
  • [MeSH-minor] Adult. Aged, 80 and over. Carcinoma, Basal Cell / pathology. Carcinoma, Basal Cell / surgery. Eyelid Neoplasms / pathology. Eyelid Neoplasms / surgery. Female. Humans. Male

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17519664.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Park MJ, Char K, Bang J, Lodge TP: Interplay between cubic and hexagonal phases in block copolymer solutions. Langmuir; 2005 Feb 15;21(4):1403-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The phase behavior of a symmetric styrene-isoprene (SI) diblock copolymer in a styrene-selective solvent, diethylphthalate, was investigated by in situ small-angle X-ray scattering on isotropic and shear-oriented solutions and by rheology and birefringence.
  • A remarkable new feature in this phase diagram is the coexistence of both body-centered cubic (bcc) and hexagonally close-packed (hcp) sphere phases, in a region between close-packed spheres (cps) and hexagonally packed cylinders (hex) over the concentration range phi approximately 0.33-0.45.
  • The stability of these supercooled cylinders is quite dependent on concentration, and for phi > or = 0.40, the supercooled cylinders do not revert to spheres even after quiescent annealing for 1 month.
  • The spontaneous formation of spheres due to the dissociation of cylinders is kinetically hindered in this case, and the system is apparently not amenable to any pretransitional fluctuations of cylinders prior to the cylinder-to-sphere transition.
  • This contrasts with the case of cylinders transforming to spheres upon heating in the melt.


43. Meachery G, De Soyza A, Nicholson A, Parry G, Hasan A, Tocewicz K, Pillay T, Clark S, Lordan JL, Schueler S, Fisher AJ, Dark JH, Gould FK, Corris PA: Outcomes of lung transplantation for cystic fibrosis in a large UK cohort. Thorax; 2008 Aug;63(8):725-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Lung transplantation is an important option to treat patients with advanced cystic fibrosis (CF) lung disease.
  • The outcomes of a large UK cohort of CF lung transplantation recipients is reported.
  • METHODS: Retrospective review of case notes and transplantation databases.
  • A diverse range of pathogens were encountered, including the Burkholderia cepacia complex (BCC).
  • Patients with BCC infection had poorer outcomes and represented the majority of those who had a septic death.
  • CONCLUSION: Lung transplantation is an important therapeutic option in patients with CF even in those with more complex microbiology.


44. Perrem K, Lynch A, Conneely M, Wahlberg H, Murphy G, Leader M, Kay E: The higher incidence of squamous cell carcinoma in renal transplant recipients is associated with increased telomere lengths. Hum Pathol; 2007 Feb;38(2):351-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The higher incidence of squamous cell carcinoma in renal transplant recipients is associated with increased telomere lengths.
  • The incidence and aggressiveness of nonmelanoma skin cancers, including basal cell carcinoma and squamous cell carcinoma (SCC), in immunocompromised renal transplant recipients (RTRs) is dramatically higher (up to 100-fold) compared with the normal population.
  • SCC lesions are also predominant in RTRs, in contrast to the normal population where basal cell carcinoma is more common.
  • The mechanisms underlying this phenomenon are unknown, but effective treatments for these skin tumors would have a significant impact upon morbidity in this group of patients.
  • The fundamental role of telomeres and telomerase in the development of most human cancers, including melanoma, is well established, but very few reports have assessed their function during the onset of nonmelanoma skin cancer.
  • To assess whether telomere maintenance plays any role in the increased incidence of SCC in renal transplant patients, we analyzed both the telomere lengths and telomerase expression levels in 44 SCCs and 22 Bowen's disease (BD) samples (carcinoma in situ) from RTRs and nontransplant patients.
  • [MeSH-major] Bowen's Disease / etiology. Carcinoma, Squamous Cell / etiology. Kidney Transplantation / adverse effects. Skin Neoplasms / etiology. Telomere / genetics
  • [MeSH-minor] Base Sequence. Cell Line. HeLa Cells. Humans. Immunocompromised Host. Immunohistochemistry. In Situ Hybridization, Fluorescence / methods. Telomerase / biosynthesis


45. Stoebner PE, Le Gallic L, Berthe ML, Boulle N, Lallemant B, Marque M, Gaspard C, Delfour C, Lavabre-Bertrand T, Martinez J, Meunier L: Decreased expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor in basal cell carcinomas. Exp Dermatol; 2008 Nov;17(11):908-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Decreased expression of thymidine phosphorylase/platelet-derived endothelial cell growth factor in basal cell carcinomas.
  • Thymidine phosphorylase (TP)/platelet-derived endothelial cell growth factor is associated with tumor angiogenesis.
  • We evaluated the TP mRNA and protein expression in basal cell carcinomas (BCC) and in various skin tumors including numerous BCC histological simulants.
  • Immunohistochemistry was performed on 99 paraffin sections of formalin-fixed skin tumors using monoclonal antibodies (mAb) against TP.
  • TP mRNA levels were measured by real time RT-PCR in whole BCCs (wBCC) and laser capture microdissected (LCM) BCC tumor cells.
  • TP immunostaining was negative in all BCC variants and in most of the benign trichogeneic tumors studied.
  • By contrast, TP was constantly immunodetected in actinic keratosis (AK), squamous cell carcinomas (SCC), syringomatous carcinomas (SC), basosquamous carcinomas (BSC) and melanomas.
  • TP mRNA levels were low and statistically not different in wBCC and normal skin but were strongly downregulated in LCM-BCC as compared with LCM-normal epidermis.
  • We concluded that (i) anti-TP mAb is an useful marker to differentiate BCC from AK, SCC, BSC and SC but not from trichoblastic tumors, (ii) the lack of TP protein expression in BCC tumoral cells is linked to transcriptional regulatory mechanisms, (iii) the low TP mRNA levels in whole BCC may be related to the low intra-tumoral microvessel density, the slow growth and the very low metastatic potential of these tumors.
  • [MeSH-major] Carcinoma, Basal Cell / pathology. Skin Neoplasms / pathology. Thymidine Phosphorylase / genetics
  • [MeSH-minor] Carcinoma, Basosquamous / genetics. Carcinoma, Basosquamous / metabolism. Carcinoma, Basosquamous / pathology. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Down-Regulation. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Keratosis, Actinic / genetics. Keratosis, Actinic / metabolism. Keratosis, Actinic / pathology. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18341568.001).
  • [ISSN] 1600-0625
  • [Journal-full-title] Experimental dermatology
  • [ISO-abbreviation] Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 2.4.2.4 / Thymidine Phosphorylase
  •  go-up   go-down


46. Hanrahan EO, Gonzalez-Angulo AM, Giordano SH, Rouzier R, Broglio KR, Hortobagyi GN, Valero V: Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. J Clin Oncol; 2007 Nov 1;25(31):4952-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma.
  • PURPOSE: With mammographic screening, the frequency of diagnosis of stage T1a,bN0M0 breast cancer has increased.
  • We reviewed T1a,bN0M0 breast cancer cases registered in the Surveillance, Epidemiology, and End Results (SEER) Program to investigate the impact of prognostic factors on breast cancer-specific (BCSM) and non-breast cancer-related mortality.
  • METHODS: We identified T1a,bN0M0 breast cancer cases registered in the SEER Program from 1988 to 2001, and used the Kaplan-Meier product limit method to describe overall survival (OS).
  • We estimated the probabilities of death resulting from breast cancer and from other causes, and analyzed associations of patient and tumor characteristics with OS, BCSM, and non-breast cancer-related mortality using the log-rank test, Cox proportional hazards models, and a competing-risk model.
  • RESULTS: We identified 51,246 T1a,bN0M0 cases.
  • Median age at diagnosis was 65 years (range, 20 to 101 years).
  • Characteristics associated with increased probability of BCSM included age younger than 50 years at diagnosis, high tumor grade, estrogen receptor-negative status, progesterone receptor-negative status, and fewer than six nodes removed at axillary dissection.
  • The constructed nomograms allow a comparison of predicted breast cancer-specific survival and non-breast cancer-specific survival in individual patients.
  • CONCLUSION: Overall, the prognosis of patients with T1a,bN0M0 breast cancer is excellent.
  • [MeSH-major] Breast Neoplasms / mortality. Breast Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Neoplasm Staging. Prognosis. Proportional Hazards Models. SEER Program. Survival Analysis. United States

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17971593.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


47. Ohson K, DesGroseilliers JP, Weatherhead S, Weatherhead L: Imiquimod 5% cream use for the treatment of basal cell carcinomas in elderly patients, in long-term care facilities, not amenable to surgical or radiation therapy. J Cutan Med Surg; 2006 Jul-Aug;10(4):201-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imiquimod 5% cream use for the treatment of basal cell carcinomas in elderly patients, in long-term care facilities, not amenable to surgical or radiation therapy.
  • [MeSH-major] Aminoquinolines / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Basal Cell / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17234120.001).
  • [ISSN] 1203-4754
  • [Journal-full-title] Journal of cutaneous medicine and surgery
  • [ISO-abbreviation] J Cutan Med Surg
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; P1QW714R7M / imiquimod
  •  go-up   go-down


48. Lin HY, Cheng CY, Hsu WM, Kao WH, Chou P: Incidence of eyelid cancers in Taiwan: a 21-year review. Ophthalmology; 2006 Nov;113(11):2101-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESIGN: Retrospective population-based cancer registry data review.
  • PARTICIPANTS: A total of 1166 primary eyelid cancers coded to International Classification of Diseases 8 or 9, site 172.1 (malignant melanoma of eyelid) and 173.1 (other malignant neoplasm of eyelid) were retrieved from the Taiwan National Cancer Registry between January 1979 and December 1999.
  • We further examined the effects of age, period of diagnosis, and birth cohort on incidence trends using age-period-cohort analysis.
  • RESULTS: The mean age at diagnosis of eyelid cancers was 62.6+/-14.1 years.
  • The most common eyelid malignancy was basal cell carcinoma (BCC; 65.1%), followed by squamous cell carcinoma (12.6%), and sebaceous cell carcinoma (7.9%).
  • The increasing rates were mainly driven by an increase in the incidence of BCC.
  • Cohort effects were found to play a major role in terms of model fit for the incidence trends of BCC.
  • Basal cell carcinoma dominates the incidence trends, and the significant cohort effects give a warning of increasing risk of BCC in younger birth cohorts.
  • [MeSH-major] Carcinoma, Basal Cell / epidemiology. Eyelid Neoplasms / epidemiology
  • [MeSH-minor] Adenocarcinoma, Sebaceous / epidemiology. Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / epidemiology. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Registries. Retrospective Studies. Sebaceous Gland Neoplasms / epidemiology. Taiwan / epidemiology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16962174.001).
  • [ISSN] 1549-4713
  • [Journal-full-title] Ophthalmology
  • [ISO-abbreviation] Ophthalmology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


49. Thompson DJ, Healey CS, Baynes C, Kalmyrzaev B, Ahmed S, Dowsett M, Folkerd E, Luben RN, Cox D, Ballinger D, Pharoah PD, Ponder BA, Dunning AM, Easton DF, Studies in Epidemiology and Risks of Cancer Heredity Team: Identification of common variants in the SHBG gene affecting sex hormone-binding globulin levels and breast cancer risk in postmenopausal women. Cancer Epidemiol Biomarkers Prev; 2008 Dec;17(12):3490-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of common variants in the SHBG gene affecting sex hormone-binding globulin levels and breast cancer risk in postmenopausal women.
  • BACKGROUND: Circulating levels of sex hormone-binding globulin (SHBG) are inversely associated with breast cancer risk in postmenopausal women.
  • Associations between SHBG SNPs and breast cancer were tested in up to 6,622 postmenopausal breast cancer cases and 6,784 controls.
  • One further SHBG SNP was significantly associated with breast cancer (rs6257, per-allele odds ratio, 0.88; 95% confidence interval, 0.82-0.95; P = 0.002).
  • CONCLUSION: At least 3 SNPs showed associations with SHBG levels that were highly significant but relatively small in magnitude. rs6257 is a potential breast cancer susceptibility variant, but relationships between the genetic determinants of SHBG levels and breast cancer are complex.
  • [MeSH-major] Breast Neoplasms / genetics. Genetic Variation. Polymorphism, Single Nucleotide. Postmenopause. Sex Hormone-Binding Globulin / genetics
  • [MeSH-minor] Aged. Case-Control Studies. Female. Genotype. Haplotypes. Humans. Linear Models. Middle Aged. Risk

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast Cancer Res. 2008;10(3):R47 [18507837.001]
  • [Cites] Clin Endocrinol (Oxf). 2008 Jul;69(1):129-35 [18598274.001]
  • [Cites] J Steroid Biochem Mol Biol. 1999 Sep-Oct;70(4-6):115-21 [10622399.001]
  • [Cites] N Engl J Med. 2000 Jul 13;343(2):78-85 [10891514.001]
  • [Cites] Breast Cancer Res. 1999;1(1):14-7 [11250676.001]
  • [Cites] J Biol Chem. 2001 Sep 28;276(39):36383-90 [11473114.001]
  • [Cites] Am J Hum Genet. 2002 Feb;70(2):425-34 [11791212.001]
  • [Cites] J Natl Cancer Inst. 2002 Apr 17;94(8):606-16 [11959894.001]
  • [Cites] Carcinogenesis. 2002 Aug;23(8):1315-20 [12151349.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Dec;88(12):5976-80 [14671199.001]
  • [Cites] Br J Cancer. 2004 Jan 12;90(1):153-9 [14710223.001]
  • [Cites] J Natl Cancer Inst. 2004 Jun 16;96(12):936-45 [15199113.001]
  • [Cites] Metabolism. 1997 Sep;46(9):988-91 [9284884.001]
  • [Cites] J Biol Chem. 1998 Dec 18;273(51):34105-14 [9852068.001]
  • [Cites] Br J Cancer. 1999 Jul;80 Suppl 1:95-103 [10466767.001]
  • [Cites] Bioinformatics. 2005 Jan 15;21(2):263-5 [15297300.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Apr;90(4):2198-204 [15634719.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 May;14(5):1096-101 [15894658.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jun;90(6):3653-8 [15755867.001]
  • [Cites] Nat Genet. 2005 Nov;37(11):1217-23 [16244653.001]
  • [Cites] Endocr Relat Cancer. 2005 Dec;12(4):1071-82 [16322344.001]
  • [Cites] Nat Rev Cancer. 2005 Dec;5(12):977-85 [16341085.001]
  • [Cites] JAMA. 2006 Mar 15;295(11):1288-99 [16537739.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Apr;15(4):675-82 [16614108.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Dec;91(12):5029-37 [16926255.001]
  • [Cites] Nat Genet. 2007 Feb;39(2):165-7 [17200668.001]
  • [Cites] BMC Cancer. 2007;7:60 [17411440.001]
  • [Cites] PLoS Genet. 2007 Mar 16;3(3):e42 [17367212.001]
  • [Cites] Nature. 2007 Jun 28;447(7148):1087-93 [17529967.001]
  • [Cites] PLoS Genet. 2008 May;4(5):e1000072 [18464913.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Feb;89(2):917-24 [14764814.001]
  • (PMID = 19064566.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / 10118; United Kingdom / Cancer Research UK / / A10118; United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Sex Hormone-Binding Globulin
  • [Other-IDs] NLM/ PMC2660245; NLM/ UKMS4231
  • [Investigator] Abraham J; Ahmed S; Antoniou A; Baynes C; Benusiglio P; Blows F; Cebrian A; Conroy D; Curzon B; Dew G; Driver K; Field H; Ghoussaini M; Harrington P; Healey C; Irvine S; Kalmyrzaev B; Jordan C; Lesueur F; Luccarini C; Mayes R; Maranian M; Morrison J; Munday H; Perkins B; Pooley K; Redman K; Scollen S; Shadforth D; Shah M; Simpson A; Stafford A; Thompson D; Tyrer J; Smith P; West J
  •  go-up   go-down


50. Laitman Y, Kaufman B, Lahad EL, Papa MZ, Friedman E: Germline CHEK2 mutations in Jewish Ashkenazi women at high risk for breast cancer. Isr Med Assoc J; 2007 Nov;9(11):791-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Germline CHEK2 mutations in Jewish Ashkenazi women at high risk for breast cancer.
  • BACKGROUND: Germline mutations in BRCA1 and BRCA2 genes account for only 20-40% of familial breast cancer cases.
  • The CHEK2 gene encodes a checkpoint kinase, involved in response to DNA damage, and hence is a candidate gene for breast cancer susceptibility.
  • Indeed, the CHEK2*1100delC truncating mutation was reported in a subset of mostly North European breast cancer families.
  • OBJECTIVES: To evaluate whether CHEK2 germline mutations contribute to a breast cancer predisposition in Ashkenazi** Jewish high risk families.
  • RESULTS: Overall, 172 high risk women were genotyped: 75 (43.6%) with breast cancer (average age at diagnosis 49.6 +/- 9.6 years, mean +/- SD) and 97 asymptomatic individuals (age at counseling 48.3 +/- 8.2 years).
  • Segregation analysis of the 1157T and S428F mutations (shown to affect protein function) with the cancer phenotype showed concordance for the CHK2*1157T mutation, as did two of three families with the CHK2*S428F mutation.
  • CONCLUSIONS: CHEK2 missense mutations may contribute to breast cancer susceptibility in Ashkenazi Jews.
  • [MeSH-major] Breast Neoplasms / genetics. Genetic Predisposition to Disease / ethnology. Germ-Line Mutation / genetics. Jews / genetics. Mutation, Missense / genetics. Protein-Serine-Threonine Kinases / genetics

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18085035.001).
  • [ISSN] 1565-1088
  • [Journal-full-title] The Israel Medical Association journal : IMAJ
  • [ISO-abbreviation] Isr. Med. Assoc. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Israel
  • [Chemical-registry-number] EC 2.7.1.11 / Checkpoint Kinase 2; EC 2.7.11.1 / CHEK2 protein, human; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


51. Malone KE, Daling JR, Doody DR, Hsu L, Bernstein L, Coates RJ, Marchbanks PA, Simon MS, McDonald JA, Norman SA, Strom BL, Burkman RT, Ursin G, Deapen D, Weiss LK, Folger S, Madeoy JJ, Friedrichsen DM, Suter NM, Humphrey MC, Spirtas R, Ostrander EA: Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years. Cancer Res; 2006 Aug 15;66(16):8297-308
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years.
  • Although well studied in families at high-risk, the roles of mutations in the BRCA1 and BRCA2 genes are poorly understood in breast cancers in the general population, particularly in Black women and in age groups outside of the very young.
  • We examined the prevalence and predictors of BRCA1 and BRCA2 mutations in 1,628 women with breast cancer and 674 women without breast cancer who participated in a multicenter population-based case-control study of Black and White women, 35 to 64 years of age.
  • Among cases, 2.4% and 2.3% carried deleterious mutations in BRCA1 and BRCA2, respectively.
  • BRCA1 mutations were significantly more common in White (2.9%) versus Black (1.4%) cases and in Jewish (10.2%) versus non-Jewish (2.0%) cases; BRCA2 mutations were slightly more frequent in Black (2.6%) versus White (2.1%) cases.
  • In models considering all predictors together, early onset ages in cases and in relatives, family history of ovarian cancer, and Jewish ancestry remained strongly and significantly predictive of BRCA1 carrier status, whereas BRCA2 predictors were fewer and more modest in magnitude.
  • These results provide first-time prevalence estimates for BRCA1/BRCA2 in breast cancer cases among understudied racial and age groups and show key predictors of mutation carrier status for both White and Black women and women of a wide age spectrum with breast cancer in the general population.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Res. 2007 May 15;67(10):5057; author reply 5057-8 [17510441.001]
  • (PMID = 16912212.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / N01 HD 3-3175; United States / NICHD NIH HHS / HD / N01 HD 2-3166; United States / NICHD NIH HHS / HD / N01 HD 3-3176; United States / NCI NIH HHS / CN / N01-CN-0532; United States / NCI NIH HHS / PC / N01-PC-67006; United States / Intramural NIH HHS / / ; United States / NICHD NIH HHS / HD / Y01 HD 7022; United States / NICHD NIH HHS / HD / N01 HD 3-3174; United States / NCI NIH HHS / CN / N01-CN-67010; United States / NICHD NIH HHS / HD / N01 HD 3-3168; United States / NCI NIH HHS / CN / N01-CN-65064; United States / NCI NIH HHS / CA / T32 CA080416
  • [Publication-type] Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BRCA1 Protein; 0 / BRCA2 Protein
  •  go-up   go-down


52. Hu MB, Xie W, Xiong B, Han DF, Li Y, Feng MH, Zhou YF: [Study on the relationship between polymorphisms of genes (CYP17, CYP19 and SULT1A1) and susceptibility to breast cancer in Chinese women]. Zhonghua Liu Xing Bing Xue Za Zhi; 2006 Apr;27(4):351-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Study on the relationship between polymorphisms of genes (CYP17, CYP19 and SULT1A1) and susceptibility to breast cancer in Chinese women].
  • OBJECTIVE: To investigate the relationship between polymorphisms of genes (CYP17, CYP19 and SULT1A1) involved in estrogen metabolism and susceptibility to breast cancer in Chinese women.
  • METHODS: A case-control study was performed.
  • PCR-base restriction fragment length polymorphism (PCR-RFLP) and short tandem repeat polymorphism (STRP) assays were used to detect the polymorphism distribution of CYP17, CYP19 and SULT1A1 in 213 breast cancer cases and 430 matched controls.
  • Logistic regression analyses were used to determine the OR, multivariate adjusted OR and 95% CI of each and all three genes and estrogen exposure factors on the risk of breast cancer.
  • RESULTS: The frequency of A2 allele of CYP17 was 49.8% in cases and 49.1% in controls (P > 0.05).
  • The frequency His allele of SULT1A1 in cases (13.6%) was significant higher than that of controls (9.5%) (P = 0.03).
  • There was also significant difference in the frequencies of (TTTA)10 allele CYP19 which was 12.4% in cases and 8.2% in controls (P = 0.02).
  • Multigenic model indicated that there was an increased risk of breast cancer with more numbers of high-risk genotypes in a dose-response effect (trend P = 0.05).
  • Data from multivariate analysis showed that the allele of SULT1A1 His and CYP19 (TTTA)10 was positively associated with the risk of breast cancer.
  • CONCLUSION: This study indicated that the polymorphisms of estrogen-metabolizing genes were related to breast cancer.
  • [MeSH-major] Aromatase / genetics. Arylsulfotransferase / genetics. Breast Neoplasms / genetics. Genetic Predisposition to Disease. Steroid 17-alpha-Hydroxylase / genetics
  • [MeSH-minor] Case-Control Studies. China. Female. Humans. Polymerase Chain Reaction. Polymorphism, Restriction Fragment Length

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16875543.001).
  • [ISSN] 0254-6450
  • [Journal-full-title] Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi
  • [ISO-abbreviation] Zhonghua Liu Xing Bing Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] EC 1.14.14.1 / Aromatase; EC 1.14.99.9 / Steroid 17-alpha-Hydroxylase; EC 2.8.2.1 / Arylsulfotransferase; EC 2.8.2.1 / SULT1A1 protein, human
  •  go-up   go-down


53. Karppinen SM, Barkardottir RB, Backenhorn K, Sydenham T, Syrjäkoski K, Schleutker J, Ikonen T, Pylkäs K, Rapakko K, Erkko H, Johannesdottir G, Gerdes AM, Thomassen M, Agnarsson BA, Grip M, Kallioniemi A, Kere J, Aaltonen LA, Arason A, Møller P, Kruse TA, Borg A, Winqvist R: Nordic collaborative study of the BARD1 Cys557Ser allele in 3956 patients with cancer: enrichment in familial BRCA1/BRCA2 mutation-negative breast cancer but not in other malignancies. J Med Genet; 2006 Nov;43(11):856-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nordic collaborative study of the BARD1 Cys557Ser allele in 3956 patients with cancer: enrichment in familial BRCA1/BRCA2 mutation-negative breast cancer but not in other malignancies.
  • Several studies have indicated that the BARD1 gene is a potential target for germline changes predisposing to breast and ovarian cancer.
  • The C-terminal Cys557Ser change has previously been uncovered to associate with an increased risk of breast cancer and was recently shown to result in defective apoptotic activities.
  • AIM AND METHODS: Conformation-sensitive gel electrophoresis, minisequencing, TaqMan assays, denaturing high-performance liquid chromatography analysis and DNA sequencing were used to investigate the prevalence of the Cys557Ser allele in a large Nordic case-control study cohort consisting of 2906 patients with breast or ovarian cancer, 734 with prostate cancer, 188 with colorectal cancer, 128 men with breast cancer, and 3591 controls from Finland, Iceland, Denmark, Sweden and Norway.
  • RESULTS: The frequency of the BARD1 Cys557Ser variant seemed to increase among patients from families with breast or ovarian cancer lacking BRCA1 or BRCA2 mutations: a significant difference was obtained compared with controls (6.8% v 2.7%; p<0.001; odds ratio (OR) 2.6; 95% confidence interval (CI) 1.7 to 4.0) and with patients from BRCA1/BRCA2 mutation-positive families (6.8% v 2.2%; p = 0.01; OR 3.2; 95% CI 1.2 to 8.3).
  • In contrast, no major association with male breast, ovarian, colorectal or prostate cancer was observed.
  • Additionally, a novel BARD1 allele resulting in Ser558Pro was identified in familial breast cancer cases.
  • CONCLUSION: These results provide further evidence that BARD1 Cys557Ser confers a slightly increased risk of breast cancer in women.
  • [MeSH-major] Alleles. Breast Neoplasms / genetics. Mutation, Missense. Tumor Suppressor Proteins / genetics. Ubiquitin-Protein Ligases / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Breast Neoplasms, Male / genetics. Case-Control Studies. Cohort Studies. Colorectal Neoplasms / genetics. DNA Mutational Analysis. Female. Genes, BRCA1. Genes, BRCA2. Genetic Predisposition to Disease. Genetic Testing. Humans. Male. Middle Aged. Ovarian Neoplasms / genetics. Prostatic Neoplasms / genetics


54. Upjohn E, Braue A, Ryan A: Primary cutaneous carcinosarcoma: dermoscopic and immunohistochemical features. Australas J Dermatol; 2010 Feb;51(1):26-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An excisional biopsy was carried out and histology showed a biphasic tumour with a basal cell carcinoma like epithelial component and a dermal undifferentiated sarcoma, with pleomorphic spindle cells and numerous osteoclast-like giant cells.
  • Based on immunohistochemistry findings, a diagnosis of primary cutaneous carcinosarcoma was made and the patient underwent wide local excision.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Carcinosarcoma / diagnosis. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20148837.001).
  • [ISSN] 1440-0960
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


55. Xiong H, van der Lelie D, Gang O: Phase behavior of nanoparticles assembled by DNA linkers. Phys Rev Lett; 2009 Jan 9;102(1):015504
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The formation of a crystalline bcc phase was observed for a limited range of linker lengths, while the number of linkers per particle controlled the onset of system crystallization.

  • Hazardous Substances Data Bank. GOLD, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19257208.001).
  • [ISSN] 0031-9007
  • [Journal-full-title] Physical review letters
  • [ISO-abbreviation] Phys. Rev. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Single-Stranded; 7440-57-5 / Gold
  •  go-up   go-down


56. Jaatinen A, Achim CV, Elder KR, Ala-Nissila T: Thermodynamics of bcc metals in phase-field-crystal models. Phys Rev E Stat Nonlin Soft Matter Phys; 2009 Sep;80(3 Pt 1):031602
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thermodynamics of bcc metals in phase-field-crystal models.
  • We examine the influence of different forms of the free-energy functionals used in the phase-field-crystal (PFC) model, and compare them with the second-order density-functional theory (DFT) of freezing, by using bcc iron as an example case.
  • We show that this functional reproduces reasonable values for both bulk and surface properties of bcc iron, and therefore it should be useful in modeling bcc materials.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19905118.001).
  • [ISSN] 1550-2376
  • [Journal-full-title] Physical review. E, Statistical, nonlinear, and soft matter physics
  • [ISO-abbreviation] Phys Rev E Stat Nonlin Soft Matter Phys
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


57. Wang X, Wu X, Liang Z, Huang Y, Fenech M, Xue J: A comparison of folic acid deficiency-induced genomic instability in lymphocytes of breast cancer patients and normal non-cancer controls from a Chinese population in Yunnan. Mutagenesis; 2006 Jan;21(1):41-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A comparison of folic acid deficiency-induced genomic instability in lymphocytes of breast cancer patients and normal non-cancer controls from a Chinese population in Yunnan.
  • We hypothesized that the genomic response to folate deficiency might be different between breast cancer cases and healthy subjects.
  • To test this hypothesis, we performed a comprehensive study on the genotoxic and cytotoxic effects of in vitro folic acid (FA) deficiency on primary human lymphocytes from 19 breast cancer patients and 20 age-matched healthy females from Yunnan, China using the cytokinesis-block micronucleus assay.
  • The results showed that 30 nM FA was associated with increased frequencies of micronucleated binucleated cell (MNed BNC), nucleoplasmic bridges (NPB), nuclear buds (BUD), apoptosis (APO) and necrosis (NEC) relative to 120 and 240 nM FA (P<0.001) in lymphocytes of case and control groups in vitro, however there were no significant differences between the 120 and 240 nM FA within each sampling group.
  • The case group showed significantly higher frequencies of MNed BNC than control at 120 and 240 nM FA (P<0.05-0.001) but not at 30 nM FA (P=0.052).
  • NEC was significantly higher in breast cancer group than control at all concentrations of FA (P<0.005).
  • FA concentration explained 60, 39, 39, 52 and 71% of the variance of MNed BNC, NPB, BUD, APO and NEC, respectively compared with breast cancer status which only explained 6 and 7% of the variance of MNed BNC and NEC(Two way ANOVA, P<0.0001).
  • Difference of difference analysis showed that breast cancer cases were not abnormally sensitive to the genome-damaging effect of folate deficiency.
  • We concluded that (i) increased concentrations of FA abolished the genome-damaging effect of FA deficiency in lymphocytes of both breast cancer patients and controls to a similar extent and (ii) FA concentration is much more important than breast cancer status in determining genomic instability and cell death.
  • [MeSH-major] Breast Neoplasms. Folic Acid Deficiency / metabolism. Genomic Instability. Lymphocytes / drug effects
  • [MeSH-minor] Adult. Aged. Apoptosis / drug effects. Breast / metabolism. Breast / pathology. Case-Control Studies. China / epidemiology. Cytokinesis / drug effects. Female. Folic Acid / pharmacology. Humans. Micronuclei, Chromosome-Defective. Micronucleus Tests. Middle Aged. Necrosis. Population Groups

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Folic Acid.
  • Hazardous Substances Data Bank. FOLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16339195.001).
  • [ISSN] 0267-8357
  • [Journal-full-title] Mutagenesis
  • [ISO-abbreviation] Mutagenesis
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 935E97BOY8 / Folic Acid
  •  go-up   go-down


58. Lin SJ, Jee SH, Kuo CJ, Wu RJ, Lin WC, Chen JS, Liao YH, Hsu CJ, Tsai TF, Chen YF, Dong CY: Discrimination of basal cell carcinoma from normal dermal stroma by quantitative multiphoton imaging. Opt Lett; 2006 Sep 15;31(18):2756-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discrimination of basal cell carcinoma from normal dermal stroma by quantitative multiphoton imaging.
  • We performed multiphoton fluorescence (MF) and second-harmonic generation (SHG) imaging on human basal cell carcinoma samples.
  • In the dermis, basal cell carcinomas can be identified by masses of autofluorescent cells with relatively large nuclei and marked peripheral palisading.
  • However, within the cancer stroma, SHG signals diminish and are replaced by autofluorescent signals, indicating that normal collagen structures responsible for SHG have been altered.
  • To better delineate the cancer cells and cancer stroma from the normal dermis, a quantitative MF to SHG index is developed.
  • We demonstrate that this index can be used to differentiate cancer cells and adjacent cancer stroma from the normal dermis.
  • Our work shows that MF and SHG imaging can be an alternative for Mohs' surgery in the real-time guidance of the secure removal of basal cell carcinoma.
  • [MeSH-major] Carcinoma, Basal Cell / diagnosis. Dermis / pathology. Skin Neoplasms / diagnosis. Stromal Cells / ultrastructure
  • [MeSH-minor] Cell Nucleus / ultrastructure. Humans. Microscopy, Fluorescence, Multiphoton

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16936882.001).
  • [ISSN] 0146-9592
  • [Journal-full-title] Optics letters
  • [ISO-abbreviation] Opt Lett
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Bianchini G, Iwamoto T, Qi Y, Coutant C, Shiang CY, Wang B, Santarpia L, Valero V, Hortobagyi GN, Symmans WF, Gianni L, Pusztai L: Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer. Cancer Res; 2010 Nov 1;70(21):8852-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer.
  • Different kinases are expressed in different clinical subsets of breast cancer.
  • In this study, we assessed kinase expression patterns in different clinical subtypes of breast cancer, evaluated the prognostic and predictive values of kinase metagenes, and investigated their functions in vitro.
  • Four hundred twenty-eight protein kinases in gene expression data were examined from 684 cases of breast cancer and 51 breast cancer cell lines to identify kinase expression patterns.
  • Downregulation of these kinases caused significant subtype-specific inhibition of cell growth in vitro.
  • [MeSH-major] Breast Neoplasms / classification. Breast Neoplasms / metabolism. Protein Kinases / chemistry. Protein Kinases / metabolism. Receptor, ErbB-2 / metabolism. Receptors, Estrogen / metabolism. Receptors, Progesterone / metabolism


60. Moore AB, Shannon J, Chen C, Lampe JW, Ray RM, Lewis SK, Lin M, Stalsberg H, Thomas DB: Dietary and stored iron as predictors of breast cancer risk: A nested case-control study in Shanghai. Int J Cancer; 2009 Sep 1;125(5):1110-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dietary and stored iron as predictors of breast cancer risk: A nested case-control study in Shanghai.
  • Increases in risk of breast cancer in successive generations of migrants to the United States from China and rapid temporal changes in incidence rates in China following social and economic changes clearly implicate environmental factors in the etiology of this disease.
  • Case-control and cohort studies have provided evidence that at least some of these factors may be dietary.
  • Iron, an essential element necessary for cell function, has also been demonstrated to have potential carcinogenic and co-carcinogenic activities.
  • A case-control study nested in a cohort of women in Shanghai, China, was conducted to evaluate possible associations between risk of proliferative and nonproliferative fibrocystic changes as well as breast cancer and dietary iron intake and plasma ferritin levels.
  • Plasma ferritin levels and reported dietary iron intake were compared in 346 women with fibrocystic changes, 248 breast cancer cases and 1,040 controls.
  • Similar, but weaker, trends were observed for proliferative changes and for breast cancer.
  • Risk of breast cancer relative to the risk of fibrocystic changes was associated with dietary iron intake in women with nonproliferative fibrocystic changes (OR: 2.63, 95% CI: 1.04-6.68, p = 0.02).
  • In conclusion, this study finds significant associations between iron (stored and dietary) and fibrocystic disease and breast cancer.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IRON COMPOUNDS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 UICC.
  • [Cites] Free Radic Biol Med. 1996;20(4):553-66 [8904296.001]
  • [Cites] Cancer Res. 1990 Jun 1;50(11):3176-81 [2334913.001]
  • [Cites] Exp Cell Res. 1985 Dec;161(2):277-84 [2998833.001]
  • [Cites] Int J Vitam Nutr Res. 1986;56(3):281-6 [3781753.001]
  • [Cites] Cancer Res. 1987 Nov 1;47(21):5771-6 [3664480.001]
  • [Cites] Cancer Lett. 1988 Aug 30;41(3):251-6 [3409203.001]
  • [Cites] Anticancer Res. 1989 Nov-Dec;9(6):1477-82 [2560618.001]
  • [Cites] J Natl Cancer Inst. 1997 Mar 5;89(5):355-65 [9060957.001]
  • [Cites] Int J Cancer. 1997 May 2;71(3):333-9 [9139863.001]
  • [Cites] Br J Radiol. 1997 Apr;70(832):375-82 [9166074.001]
  • [Cites] Carcinogenesis. 1997 Sep;18(9):1757-62 [9328172.001]
  • [Cites] Arch Biochem Biophys. 1997 Oct 15;346(2):180-6 [9343364.001]
  • [Cites] Cancer Causes Control. 1998 Jan;9(1):19-27 [9486460.001]
  • [Cites] J Epidemiol Community Health. 1998 Feb;52(2):105-10 [9578857.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):81-90 [15668480.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):243-50 [15668501.001]
  • [Cites] Int J Cancer. 2005 Jul 20;115(6):981-93 [15723298.001]
  • [Cites] Am J Epidemiol. 2005 Jun 15;161(12):1115-22 [15937020.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):2889-97 [16365006.001]
  • [Cites] Phys Med Biol. 2007 Jul 7;52(13):3895-911 [17664584.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Aug;16(8):1682-5 [17684146.001]
  • [Cites] Lancet Oncol. 2008 Aug;9(8):803-7 [18672216.001]
  • [Cites] Int J Cancer. 2003 Sep 20;106(5):771-83 [12866039.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Nov;12(11 Pt 1):1159-67 [14652275.001]
  • [Cites] J Nutr. 2003 Nov;133(11 Suppl 2):3898S-3906S [14672288.001]
  • [Cites] Nutr Cancer. 2003;46(2):131-7 [14690788.001]
  • [Cites] Phys Med Biol. 2004 Jan 7;49(1):99-110 [14971775.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Feb;13(2):205-12 [14973098.001]
  • [Cites] Ann Epidemiol. 2004 Mar;14(3):195-201 [15036223.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Jul;13(7):1106-13 [15247120.001]
  • [Cites] Blood. 2004 Sep 1;104(5):1450-8 [15150082.001]
  • [Cites] N Engl J Med. 1974 May 30;290(22):1213-6 [4825851.001]
  • [Cites] N Engl J Med. 1975 May 1;292(18):951-6 [1090831.001]
  • [Cites] Scand J Haematol Suppl. 1977;32:87-98 [272039.001]
  • [Cites] Clin Chem. 1981 Jan;27(1):78-82 [7449126.001]
  • [Cites] IARC Sci Publ. 1980;(32):5-338 [7216345.001]
  • [Cites] Public Health Nutr. 1998 Sep;1(3):139-45 [10933411.001]
  • [Cites] Int J Cancer. 2001 Jan 15;91(2):260-3 [11146455.001]
  • [Cites] Curr Med Chem. 2001 Jun;8(7):839-49 [11375754.001]
  • [Cites] J Natl Cancer Inst. 2002 Oct 2;94(19):1445-57 [12359854.001]
  • [Cites] Anticancer Res. 2002 Sep-Oct;22(5):2685-92 [12529982.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6B):3797-9 [12552996.001]
  • [Cites] Biomed Environ Sci. 2002 Dec;15(4):271-6 [12642982.001]
  • [Cites] Environ Health Perspect. 1990 Jul;87:291-300 [2269234.001]
  • [Cites] Carcinogenesis. 1991 Jan;12(1):111-4 [1988169.001]
  • [Cites] Cancer. 1991 Mar 15;67(6):1707-12 [2001562.001]
  • [Cites] Am J Clin Nutr. 1991 Oct;54(4):729-35 [1897480.001]
  • [Cites] Med Oncol Tumor Pharmacother. 1991;8(4):229-33 [1820488.001]
  • [Cites] Cancer. 1993 Jun 15;71(12):3896-907 [8389654.001]
  • [Cites] J Natl Cancer Inst. 1993 Nov 17;85(22):1819-27 [8230262.001]
  • [Cites] Int J Cancer. 1994 Feb 1;56(3):364-9 [8314323.001]
  • [Cites] Int J Cancer. 1994 Feb 1;56(3):379-82 [8314326.001]
  • [Cites] Jpn J Cancer Res. 1994 Jun;85(6):572-7 [8063609.001]
  • [Cites] Br J Cancer. 1995 Jun;71(6):1353-8 [7779738.001]
  • [Cites] J Natl Cancer Inst. 1995 Aug 2;87(15):1154-61 [7674320.001]
  • [Cites] Int J Cancer. 1996 Jan 17;65(2):140-4 [8567108.001]
  • [Cites] Eur J Cancer Prev. 1996 Feb;5(1):19-36 [8664805.001]
  • [Cites] Toxicol Appl Pharmacol. 1996 Aug;139(2):356-64 [8806853.001]
  • [Cites] Am J Epidemiol. 1996 Oct 1;144(7):653-60 [8823061.001]
  • [Cites] Cancer Causes Control. 1996 Jan;7(1):56-68 [8850435.001]
  • [Cites] Am J Clin Nutr. 1982 May;35(5 Suppl):1180-5 [7044096.001]
  • [Cites] J Nutr. 1985 Mar;115(3):369-74 [3973748.001]
  • [Cites] Exp Cell Res. 1996 Nov 25;229(1):60-8 [8940249.001]
  • (PMID = 19444907.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA075332-05; United States / NCI NIH HHS / CA / R01 CA075332; United States / NCI NIH HHS / CA / R01 CA075332-05; United States / NCI NIH HHS / CA / R01-CA75332
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Iron Compounds; 0 / Iron, Dietary; 9007-73-2 / Ferritins
  • [Other-IDs] NLM/ NIHMS163587; NLM/ PMC2798105
  •  go-up   go-down


61. Zuccolo L, Pastore G, Pearce N, Mosso ML, Merletti F, Magnani C: Mortality from cancer and other causes in parents of children with cancer: a population-based study in Piedmont, Italy. Eur J Cancer Prev; 2007 Oct;16(5):390-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mortality from cancer and other causes in parents of children with cancer: a population-based study in Piedmont, Italy.
  • This population-based study (the largest on this issue conducted in Southern Europe) has examined mortality among the parents of 2622 children diagnosed with cancer in Piedmont during 1967-1994.
  • Among mothers, total mortality was similar to that expected [SMR 1.02, 95% confidence interval (CI) 0.85-1.23, 117 cases].
  • A reduced risk of mortality was seen in fathers (SMR 0.91, 95% CI 0.81-1.02, 293 cases); this was largely due to causes other than cancer and the reduction in risk disappeared after the index child's death (SMR 0.98, 95% CI 0.84-1.15, 168 cases).
  • Deaths from cancers of the lymphohaematopoietic system were in excess among mothers (SMR=2.13, 95% CI 1.02-3.92, 10 cases) and breast cancer deaths were in excess specifically among mothers of leukaemic children (SMR 2.32, 95% CI 1.16-4.14, 11 cases).
  • Three mothers dying with breast cancer had index children who had been diagnosed with a bone sarcoma.
  • Parental cancer of the respiratory tract was significantly associated with both tumours of the central nervous system and Hodgkin's lymphoma in the index child.
  • The excess risks identified here may be due to genetic factors or due to parental psychological stress consequent to cancer in a child that may lead to increased mortality either through the direct effects of stress or through consequent changes in lifestyle.

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17923808.001).
  • [ISSN] 0959-8278
  • [Journal-full-title] European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP)
  • [ISO-abbreviation] Eur. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


62. Millikan RC, Newman B, Tse CK, Moorman PG, Conway K, Dressler LG, Smith LV, Labbok MH, Geradts J, Bensen JT, Jackson S, Nyante S, Livasy C, Carey L, Earp HS, Perou CM: Epidemiology of basal-like breast cancer. Breast Cancer Res Treat; 2008 May;109(1):123-39
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidemiology of basal-like breast cancer.
  • Risk factors for the newly identified "intrinsic" breast cancer subtypes (luminal A, luminal B, basal-like and human epidermal growth factor receptor 2-positive/estrogen receptor-negative) were determined in the Carolina Breast Cancer Study, a population-based, case-control study of African-American and white women.
  • Immunohistochemical markers were used to subtype 1,424 cases of invasive and in situ breast cancer, and case subtypes were compared to 2,022 controls.
  • Luminal A, the most common subtype, exhibited risk factors typically reported for breast cancer in previous studies, including inverse associations for increased parity and younger age at first full-term pregnancy.
  • Basal-like cases exhibited several associations that were opposite to those observed for luminal A, including increased risk for parity and younger age at first term full-term pregnancy.
  • Longer duration breastfeeding, increasing number of children breastfed, and increasing number of months breastfeeding per child were each associated with reduced risk of basal-like breast cancer, but not luminal A.
  • Women with multiple live births who did not breastfeed and women who used medications to suppress lactation were at increased risk of basal-like, but not luminal A, breast cancer.
  • Elevated waist-hip ratio was associated with increased risk of luminal A in postmenopausal women, and increased risk of basal-like breast cancer in pre- and postmenopausal women.
  • The prevalence of basal-like breast cancer was highest among premenopausal African-American women, who also showed the highest prevalence of basal-like risk factors.
  • Among younger African-American women, we estimate that up to 68% of basal-like breast cancer could be prevented by promoting breastfeeding and reducing abdominal adiposity.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hum Pathol. 2006 Sep;37(9):1217-26 [16938528.001]
  • [Cites] Environ Health. 2006;5:21 [16859537.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8327-30 [16951137.001]
  • [Cites] CA Cancer J Clin. 2006 Sep-Oct;56(5):254-81; quiz 313-4 [17005596.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1871-7 [17035393.001]
  • [Cites] Arch Intern Med. 2006 Nov 13;166(20):2244-52 [17101943.001]
  • [Cites] Arch Intern Med. 2006 Nov 13;166(20):2253-9 [17101944.001]
  • [Cites] Breast Cancer Res. 2006;8(4):R34 [16846532.001]
  • [Cites] Breast Cancer Res. 2006;8(4):R43 [16859501.001]
  • [Cites] Hum Pathol. 2007 Feb;38(2):197-204 [17234468.001]
  • [Cites] Science. 2007 Feb 2;315(5812):592-4 [17272699.001]
  • [Cites] Obesity (Silver Spring). 2007 Feb;15(2):430-45 [17299117.001]
  • [Cites] Epidemiology. 2007 Mar;18(2):234-9 [17237733.001]
  • [Cites] Epidemiology. 2007 Mar;18(2):280-1 [17301710.001]
  • [Cites] Arch Intern Med. 2007 Feb 26;167(4):408-15 [17325304.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):439-43 [17372238.001]
  • [Cites] Cancer. 2007 May 1;109(9):1721-8 [17387718.001]
  • [Cites] Breast Cancer Res Treat. 2007 Mar;102(1):85-101 [17080310.001]
  • [Cites] Annu Rev Nutr. 2007;27:103-21 [17341160.001]
  • [Cites] Lancet. 2002 Jul 20;360(9328):187-95 [12133652.001]
  • [Cites] Nature. 2002 Aug 22;418(6900):823 [12192390.001]
  • [Cites] Cancer. 2003 Jan 1;97(1 Suppl):211-21 [12491484.001]
  • [Cites] Cancer. 2003 Jan 1;97(1 Suppl):222-9 [12491485.001]
  • [Cites] Cancer. 2003 Jan 1;97(1 Suppl):273-9 [12491491.001]
  • [Cites] J Nutr. 2003 Jan;133(1):305S-309S [12514315.001]
  • [Cites] Obes Res. 1998 Sep;6 Suppl 2:51S-209S [9813653.001]
  • [Cites] Epidemiology. 1999 Jan;10(1):37-48 [9888278.001]
  • [Cites] Ann Epidemiol. 1999 Apr;9(3):188-95 [10192651.001]
  • [Cites] Int J Epidemiol. 1999 Jun;28(3):396-402 [10405840.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Aug 3;96(16):9212-7 [10430922.001]
  • [Cites] Am J Epidemiol. 2005 Jan 1;161(1):40-51 [15615914.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):439-48 [15770008.001]
  • [Cites] Breast Cancer Res Treat. 1999 Nov;58(1):31-9 [10634516.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Jan;9(1):65-71 [10667465.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 16;92(4):302-12 [10675379.001]
  • [Cites] Am J Epidemiol. 2000 Apr 1;151(7):703-14 [10752798.001]
  • [Cites] Cancer Causes Control. 2000 Apr;11(4):345-57 [10843445.001]
  • [Cites] Am J Public Health. 2000 Jun;90(6):966-71 [10846517.001]
  • [Cites] J Appl Physiol (1985). 2000 Aug;89(2):636-43 [10926648.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] J Natl Cancer Inst. 2003 Mar 19;95(6):478-83 [12644541.001]
  • [Cites] Cancer Causes Control. 2003 Mar;14(2):151-60 [12749720.001]
  • [Cites] Breast Cancer Res Treat. 2003 Jun;79(3):355-64 [12846420.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23 [12829800.001]
  • [Cites] Obes Rev. 2003 Aug;4(3):157-73 [12916817.001]
  • [Cites] J Natl Cancer Inst. 2004 Feb 4;96(3):218-28 [14759989.001]
  • [Cites] Cancer. 2004 Apr 15;100(8):1595-604 [15073845.001]
  • [Cites] Nat Rev Immunol. 2004 Jul;4(7):565-72 [15229475.001]
  • [Cites] Cancer. 2004 Jul 15;101(2):353-62 [15241834.001]
  • [Cites] Int J Cancer. 2004 Sep 20;111(5):762-71 [15252848.001]
  • [Cites] J Natl Cancer Inst. 2004 Jul 21;96(14):1094-8 [15265971.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5367-74 [15328174.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Oct;13(10):1558-68 [15466970.001]
  • [Cites] Am J Epidemiol. 1985 Nov;122(5):904-14 [4050778.001]
  • [Cites] Am J Pathol. 1989 Mar;134(3):571-9 [2466404.001]
  • [Cites] Am J Epidemiol. 1991 Aug 15;134(4):421-32 [1877602.001]
  • [Cites] Am J Epidemiol. 1992 Dec 15;136(12):1445-56 [1288274.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1994 Mar;3(2):173-5 [8049640.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1995 Jan-Feb;4(1):11-9 [7894319.001]
  • [Cites] Breast Cancer Res Treat. 1995 Jul;35(1):51-60 [7612904.001]
  • [Cites] Metabolism. 1996 Sep;45(9):1119-24 [8781299.001]
  • [Cites] JAMA. 1998 Mar 25;279(12):915-21 [9544765.001]
  • [Cites] Cell Mol Life Sci. 2007 Dec;64(24):3219-32 [17957336.001]
  • [Cites] Am J Epidemiol. 1998 May 1;147(9):826-33 [9583712.001]
  • [Cites] Am J Public Health. 1998 Jan;88(1):15-9 [9584027.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1998 May;7(5):371-8 [9610785.001]
  • [Cites] Eur J Cancer Prev. 2001 Feb;10(1):15-32 [11263588.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] J Natl Med Assoc. 2001 Sep;93(9):329-34 [11560288.001]
  • [Cites] Int J Cancer. 2002 May 20;99(3):445-52 [11992416.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Jul;11(7):601-7 [12101106.001]
  • [Cites] Br J Surg. 2005 Apr;92(4):429-34 [15736216.001]
  • [Cites] Breast Cancer Res Treat. 2005 Mar;90(2):127-37 [15803359.001]
  • [Cites] Int J Cancer. 2005 Sep 1;116(3):340-50 [15818618.001]
  • [Cites] Am J Epidemiol. 2005 Aug 1;162(3):229-37 [15987723.001]
  • [Cites] Endocr Relat Cancer. 2005 Dec;12(4):1059-69 [16322343.001]
  • [Cites] Oncology. 2005;69(6):478-85 [16410686.001]
  • [Cites] Clin Cancer Res. 2006 Mar 1;12(5):1447-53 [16533767.001]
  • [Cites] J Clin Oncol. 2006 Mar 20;24(9):1342-9 [16549828.001]
  • [Cites] J Clin Oncol. 2006 May 10;24(14):2170-8 [16682736.001]
  • [Cites] Cell Cycle. 2006 May;5(9):963-7 [16687925.001]
  • [Cites] BMC Genomics. 2006;7:96 [16643655.001]
  • [Cites] CA Cancer J Clin. 2006 May-Jun;56(3):168-83 [16737949.001]
  • [Cites] JAMA. 2006 Jun 7;295(21):2492-502 [16757721.001]
  • [Cites] BMC Genomics. 2006;7:127 [16729877.001]
  • [Cites] Eur J Cancer Prev. 2006 Aug;15(4):306-42 [16835503.001]
  • [Cites] N Engl J Med. 2006 Aug 10;355(6):560-9 [16899776.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):8297-308 [16912212.001]
  • [ErratumIn] Breast Cancer Res Treat. 2008 May;109(1):141. Dressler, Lynn G [added]
  • (PMID = 17578664.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA058223-140021; United States / NCI NIH HHS / CA / CA016086-259034; United States / NCI NIH HHS / CA / CA058223-150021; United States / NCI NIH HHS / CA / R01 CA101227; United States / NCI NIH HHS / CA / CA058223-09A10013; United States / NCI NIH HHS / CA / P30 CA016086; United States / NCI NIH HHS / CA / P30 CA016086-259034; United States / NCI NIH HHS / CA / P50 CA058223-150021; United States / NCI NIH HHS / CA / P50 CA058223; United States / NCI NIH HHS / CA / P50-CA58223; United States / NCI NIH HHS / CA / CA058223-100013; United States / NCI NIH HHS / CA / P50 CA058223-140021; United States / NCI NIH HHS / CA / P30-CA16086; United States / NCI NIH HHS / CA / P50 CA058223-100013; United States / NCI NIH HHS / CA / R01-CA101227; United States / NCI NIH HHS / CA / P50 CA058223-09A10013
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Other-IDs] NLM/ NIHMS50834; NLM/ PMC2443103
  •  go-up   go-down


63. Tanasupawat S, Pakdeeto A, Thawai C, Yukphan P, Okada S: Identification of lactic acid bacteria from fermented tea leaves (miang) in Thailand and proposals of Lactobacillus thailandensis sp. nov., Lactobacillus camelliae sp. nov., and Pediococcus siamensis sp. nov. J Gen Appl Microbiol; 2007 Feb;53(1):7-15
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The strains tested in Groups I, II and V had meso-diaminopimelic acid in the cell wall.
  • Five strains in Group III are proposed as Lactobacillus thailandensis sp. nov., and MCH5-2(T) (BCC 21235(T)=JCM 13996(T)=NRIC 0671(T)=PCU 272(T)) is the type strain which has 49 mol% G+C of DNA.
  • Two strains in Group IV are proposed as Lactobacillus camelliae sp. nov., and the type strain is MCH3-1(T) (BCC 21233(T)=JCM 13995(T)=NRIC 0672(T)=PCU 273(T)) which has 51.9 mol% G+C of DNA.
  • One strain in Group VII is proposed as Pediococcus siamensis sp. nov., and MCH3-2(T) (BCC 21234(T)=JCM 13997(T)=NRIC 0675(T)=PCU 274(T)) is the type strain which has 42 mol% G+C of DNA.


64. Chen K, Craig JC, Shumack S: Oral retinoids for the prevention of skin cancers in solid organ transplant recipients: a systematic review of randomized controlled trials. Br J Dermatol; 2005 Mar;152(3):518-23
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oral retinoids for the prevention of skin cancers in solid organ transplant recipients: a systematic review of randomized controlled trials.
  • BACKGROUND: The increased incidence of skin cancers after solid organ transplantation is well recognized.
  • Skin cancers developing in transplant recipients are more aggressive in behaviour.
  • OBJECTIVES: The objective of this review was to summarize the available medical literature from randomized controlled trials on the use of oral retinoids as a preventive agent for skin cancers in the solid organ transplant population.
  • One cross-over trial involving 23 subjects treated with acitretin 25 mg daily for 12 months reported 46 squamous cell carcinomas (SCCs) developing in six subjects during acitretin treatment vs. 65 SCCs developing in 15 subjects during the drug-free period.
  • Another trial involving 44 subjects treated with acitretin 30 mg daily or placebo for 6 months reported two of 19 subjects developing two SCCs in the treatment group vs. nine of 19 subjects developing 18 new skin cancers (15 SCCs, one Bowen's disease, two basal cell carcinomas) in the placebo group.
  • One dose comparison trial involving 26 renal transplant recipients treated with acitretin did not find a significant difference in numbers of skin cancers developing at the doses examined.
  • CONCLUSIONS: The available data from a small number of randomized controlled trials suggest that acitretin may have a role in the management of solid organ transplant recipients with skin cancers.
  • [MeSH-major] Organ Transplantation / adverse effects. Retinoids / therapeutic use. Skin Neoplasms / prevention & control

  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ACITRETIN .
  • PubMed Health. DARE review .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15787821.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Retinoids; LCH760E9T7 / Acitretin
  • [Number-of-references] 11
  •  go-up   go-down


65. Wang BT, Shao JL, Zhang GC, Li WD, Zhang P: Nucleation of hcp and fcc phases in bcc iron under uniform compression: classical molecular dynamics simulations. J Phys Condens Matter; 2010 Nov 3;22(43):435404
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nucleation of hcp and fcc phases in bcc iron under uniform compression: classical molecular dynamics simulations.
  • By classical molecular dynamics simulations employing an embedded atom method potential, we have simulated the bcc to hcp/fcc structural transition in single-crystal iron under uniform compression.
  • The nucleation planes, all belonging to the {110}(bcc) family and parallel to the three compression directions [100], [010], and [001], have been observed.
  • About 20% bcc atoms have transformed to fcc phase under pressure just over the critical point, and under higher pressure the fraction of the fcc phase increases steadily to exceed that of the hcp phase.
  • We have investigated the transition mechanism of iron from initial bcc to hcp/fcc and found that the transition mainly consists of compression, rotation, and shuffle.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21403328.001).
  • [ISSN] 1361-648X
  • [Journal-full-title] Journal of physics. Condensed matter : an Institute of Physics journal
  • [ISO-abbreviation] J Phys Condens Matter
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


66. Herzog Neto G, Sebastiá R, Viana GA, Machado F: [Eyelid reconstruction with Fricke's flap: report of two cases]. Arq Bras Oftalmol; 2006 Jan-Feb;69(1):123-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Eyelid reconstruction with Fricke's flap: report of two cases].
  • [Transliterated title] Reconstrução palpebral com retalho de Fricke: relato de dois casos.
  • Skin cancer is the most common neoplasm in human beings and among them, basal cell carcinoma is the most prevalent.
  • This report shows two cases with this tumor, located in the lateral canthus, affecting both the superior and inferior eyelids.
  • The first case was a female, 72 years old, with amaurosis of the right eye.
  • The histopathological test diagnosed basal cell carcinoma, with clear margins.
  • The histopathological test diagnosed basal cell carcinoma, with clear margins.
  • [MeSH-major] Blepharoplasty / methods. Carcinoma, Basal Cell / surgery. Eyelid Neoplasms / surgery. Skin Neoplasms / surgery. Surgical Flaps

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16491248.001).
  • [ISSN] 0004-2749
  • [Journal-full-title] Arquivos brasileiros de oftalmologia
  • [ISO-abbreviation] Arq Bras Oftalmol
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


67. Kansal A, Brueton L, Lahiri A, Lester R: Hypoplastic thumb in Gorlin's syndrome. J Plast Reconstr Aesthet Surg; 2007;60(4):440-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gorlin's syndrome or naevoid basal cell carcinoma syndrome (NBCCS) is an autosomal dominant disorder that predisposes to basal cell carcinomas of the skin, ovarian fibromas, and medulloblastomas.
  • Gorlin's syndrome is characterized by the development of multiple jaw keratocysts and/or basal carcinomas.
  • We present a case in which the patient presented with bilateral thumb hypoplasia.
  • [MeSH-major] Basal Cell Nevus Syndrome. Thumb / abnormalities
  • [MeSH-minor] Humans. Infant. Male. Polydactyly / diagnosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17349603.001).
  • [ISSN] 1748-6815
  • [Journal-full-title] Journal of plastic, reconstructive & aesthetic surgery : JPRAS
  • [ISO-abbreviation] J Plast Reconstr Aesthet Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


68. Gautam V, Ray P, Puri GD, Sharma K, Vandamme P, Madhup SK, Das A, Malhotra P, Trehan A, Garg RK, Rana S, Koushal V, Kumar A: Investigation of Burkholderia cepacia complex in septicaemic patients in a tertiary care hospital, India. Nepal Med Coll J; 2009 Dec;11(4):222-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Investigation of Burkholderia cepacia complex in septicaemic patients in a tertiary care hospital, India.
  • Burkholderia cepacia complex (BCC) is being increasingly recognized as an important pathogen of humans.
  • During the year 2007-8, 39 putative BCC isolates were obtained from 21 cases and subjected to recA PCR RFLP.
  • Twenty-four isolates were confirmed as Burkholderia cenocepacia IIIA (nineteen isolates, recA PCR RFLP type G and five isolates, recA PCR RFLP type I), six were confirmed as B. cepacia (recA PCR RFLP type E).
  • BCC were isolated from inpatients of different wards of Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh with increased isolation from children admitted to different wards of Advanced Pediatric Centre (11/21 cases).
  • BCC isolates are often resistant to most commonly used antibiotics and an early use of effective antimicrobial therapy can decrease morbidity and mortality.
  • [MeSH-major] Burkholderia cepacia complex / isolation & purification. Sepsis / microbiology

  • MedlinePlus Health Information. consumer health - Sepsis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20635597.001).
  • [Journal-full-title] Nepal Medical College journal : NMCJ
  • [ISO-abbreviation] Nepal Med Coll J
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Nepal
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / DNA, Bacterial
  •  go-up   go-down


69. Mohammadi A, Rosa M, Rhatigan R: Eyelid basal cell carcinoma associated with solitary neurofibroma. J Cutan Pathol; 2010 Jun;37(6):707-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eyelid basal cell carcinoma associated with solitary neurofibroma.
  • [MeSH-major] Carcinoma, Basal Cell / complications. Eyelid Neoplasms / complications. Neurofibroma / complications

  • Genetic Alliance. consumer health - Neurofibroma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19614728.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Denmark
  •  go-up   go-down


70. Pinto Pereira SM, Hipwell JH, McCormack VA, Tanner C, Moss SM, Wilkinson LS, Khoo LA, Pagliari C, Skippage PL, Kliger CJ, Hawkes DJ, Silva IM: Automated registration of diagnostic to prediagnostic x-ray mammograms: evaluation and comparison to radiologists' accuracy. Med Phys; 2010 Sep;37(9):4530-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: X-ray mammograms were simulated from MRIs of 20 women using finite element methods for modeling breast compressions and employing a MRI/x-ray appearance change model.
  • Five mammography film readers independently identified landmarks (tumor, nipple, and usually two other normal features) on pairs of diagnostic and corresponding prediagnostic digitized images from 52 breast cancer cases.
  • Registration accuracy was sensitive to the type of landmark and the amount of breast density.
  • [MeSH-major] Breast Neoplasms / diagnostic imaging. Image Processing, Computer-Assisted / methods. Mammography / methods. Radiology / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Mammography.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20964170.001).
  • [ISSN] 0094-2405
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


71. Woditschka S, Habel LA, Udaltsova N, Friedman GD, Sieh W: Lipophilic statin use and risk of breast cancer subtypes. Cancer Epidemiol Biomarkers Prev; 2010 Oct;19(10):2479-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lipophilic statin use and risk of breast cancer subtypes.
  • BACKGROUND/AIMS: Statins are widely used and of high interest as potential chemopreventive agents for cancer.
  • Preclinical studies suggest that lipophilic statins have anticancer properties targeting hormone receptor (HR)-negative breast cancer.
  • Few epidemiologic studies have investigated the relationship between lipophilic statin use and risk for breast cancer, stratified by HR status.
  • We conducted a large case-control study within Kaiser Permanente of Northern California (KPNC) to determine whether chronic use of lipophilic statins is associated with decreased risk of HR-negative breast cancer or other breast cancer subtypes.
  • METHODS: We identified 22,488 breast cancer cases diagnosed from 1997 to 2007, and 224,860 controls matched to cases based upon birth year and duration of KPNC pharmacy coverage.
  • RESULTS: We found no association between lipophilic statin use (≥2 y versus never) and overall breast cancer risk (odds ratio(adj), 1.02; 95% CI, 0.97-1.08) in conditional logistic regression models adjusted for oral contraceptive and hormone therapy use.
  • Women who used lipophilic statins did not have a decreased risk of HR-negative breast cancer (odds ratio(adj), 0.98; 95% CI, 0.84-1.14) nor altered risk of HR-positive disease (odds ratio(adj), 1.03; 95% CI, 0.97-1.10).
  • CONCLUSIONS: Our results do not support an association of lipophilic statin use with the risk for breast cancer in general or with risks of HR-negative or other breast cancer subtypes specifically.
  • IMPACT: These findings do not confirm previous reports of a possible preventive association.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Statins.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • [Cites] Ann Med. 2000 Apr;32(3):164-76 [10821323.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):416-21 [17372235.001]
  • [Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):18-27 [11134191.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]
  • [Cites] Carcinogenesis. 2003 Mar;24(3):453-9 [12663504.001]
  • [Cites] Menopause. 2003 Jul-Aug;10(4):332-6 [12851516.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23 [12829800.001]
  • [Cites] Carcinogenesis. 2004 Oct;25(10):1887-98 [15180944.001]
  • [Cites] Cancer Lett. 2007 Jun 8;250(2):220-8 [17125918.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2008 Jan;17(1):27-36 [17944002.001]
  • [Cites] Int J Cancer. 2008 Apr 15;122(8):1832-41 [18067133.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1026-7 [18463398.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 May;17(5):1028-33 [18463402.001]
  • [Cites] BMJ. 2008;337:a540 [18621762.001]
  • [Cites] Oncology (Williston Park). 2008 Oct;22(11):1233-9; discussion 1239-40, 1243 [18980022.001]
  • [Cites] Eur J Cancer. 2008 Oct;44(15):2122-32 [18707867.001]
  • [Cites] Int J Cancer. 2009 Feb 1;124(3):698-712 [18988226.001]
  • [Cites] Cancer Prev Res (Phila). 2009 Feb;2(2):161-7 [19196723.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Ann Med. 1991 Dec;23(6):643-8 [1777219.001]
  • [Cites] Am J Public Health. 1992 May;82(5):703-10 [1566949.001]
  • [Cites] Lancet. 1996 Jun 22;347(9017):1713-27 [8656904.001]
  • [Cites] Epidemiology. 1997 May;8(3):275-80 [9115022.001]
  • [Cites] Lancet. 1997 Oct 11;350(9084):1047-59 [10213546.001]
  • [Cites] Lancet. 2005 Jan 1-7;365(9453):82-93 [15639683.001]
  • [Cites] Fundam Clin Pharmacol. 2005 Feb;19(1):117-25 [15660968.001]
  • [Cites] Arch Intern Med. 2005 Oct 24;165(19):2264-71 [16246993.001]
  • [Cites] Nat Rev Cancer. 2005 Dec;5(12):930-42 [16341084.001]
  • [Cites] JAMA. 2006 Jan 4;295(1):74-80 [16391219.001]
  • [Cites] Pharmacoepidemiol Drug Saf. 2006 May;15(5):291-303 [16447304.001]
  • [Cites] J Natl Cancer Inst. 2006 May 17;98(10):700-7 [16705124.001]
  • [Cites] JAMA. 2006 Jun 7;295(21):2492-502 [16757721.001]
  • [Cites] Cancer Res. 2006 Sep 1;66(17):8707-14 [16951186.001]
  • [Cites] J Clin Oncol. 2007 Jan 1;25(1):118-45 [17159189.001]
  • [Cites] Int J Cancer. 2007 Feb 15;120(4):833-43 [17131313.001]
  • [ErratumIn] Cancer Epidemiol Biomarkers Prev. 2013 May;22(5):1001-3
  • (PMID = 20729289.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098838; United States / NCI NIH HHS / CA / R01 CA 098838
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone
  • [Other-IDs] NLM/ NIHMS231480; NLM/ PMC2952055
  •  go-up   go-down


72. Surov A, Holzhausen HJ, Ruschke K, Arnold D, Spielmann RP: Breast plasmacytoma. Acta Radiol; 2010 Jun;51(5):498-504
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast plasmacytoma.
  • BACKGROUND: Breast plasmacytoma (BP) is extremely rare.
  • The published data on this manifestation include predominantly case reports and do not provide any statistical information.
  • RESULTS: The prevalence of BP in our institution was 1.5% of all identified cases with plasmacytoma and 0.2% of the cases with breast cancer.
  • In 8 of 53 patients (15%), primary BP was diagnosed, and in 45 patients (85%) involvement of the breast was a secondary event of the multiple myeloma (MM).
  • Clinically, 83% of the patients presented with breast lumps.
  • In 8% of the cases clinical signs were not reported.
  • They were solitary in 66% of the cases and multiple in 34%.
  • In 9% of the identified cases BP manifested as diffuse infiltration of the breast.
  • Primary BP had a better prognosis than breast involvement as a secondary event in MM.
  • CONCLUSION: In conclusion, BP does not have specific radiological or clinical features and can be misdiagnosed as primary breast carcinoma or even as a benign process.
  • However, BP should be considered in the differential diagnosis of breast disorders, especially in patients with MM.
  • [MeSH-major] Breast Neoplasms / diagnosis. Plasmacytoma / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Breast Neoplasms, Male / diagnosis. Breast Neoplasms, Male / epidemiology. Breast Neoplasms, Male / etiology. Diagnosis, Differential. Female. Germany / epidemiology. Humans. Incidental Findings. Magnetic Resonance Imaging. Male. Mammography. Middle Aged. Multiple Myeloma / complications. Prevalence. Retrospective Studies. Ultrasonography, Mammary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20429767.001).
  • [ISSN] 1600-0455
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


73. Yang H, Zhao JS, Hawari J: Effect of 2,4-dinitrotoluene on the anaerobic bacterial community in marine sediment. J Appl Microbiol; 2009 Dec 1;107(6):1799-808
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of 2,4-dinitrotoluene on the anaerobic bacterial community in marine sediment.
  • AIMS: To study the impact of added 2,4-dinitrotoluene (DNT) on the anaerobic bacterial community in marine sediment collected from an unexploded ordnance dumping site in Halifax Harbour.
  • METHODS AND RESULTS: Marine sediment was spiked with 2,4-DNT and incubated under anaerobic conditions in the presence and absence of lactate.
  • Indigenous bacteria in the sediment removed 2,4-DNT with subsequent formation of its mono- and diamino-derivatives under both conditions.
  • PCR-DGGE and nucleotide sequencing were used to monitor the change in the bacterial population in sediment caused by the presence of 2,4-DNT.
  • The results showed that denaturing gradient gel electrophoresis banding patterns of sediment microcosms treated with 2,4-DNT were different from controls that did not receive 2,4-DNT.
  • Bacteroidetes, Firmicutes and delta-Proteobacteria were present in sediment incubated in the absence of 2,4-DNT.
  • However, several gamma-Proteobacteria became dominant in sediment in the presence of 2,4-DNT, two of which were 99% similar to Shewanella canadensis and Shewanella sediminis.
  • In the presence of both 2,4-DNT and lactate, two additional delta-Proteobacteria were enriched, one closely related (98% similarity) to Desulfofrigus fragile and the other affiliated (96% similarity) to Desulfovibrio sp.
  • In contrast, none of the above four Proteobacteria were enriched in sediment incubated with lactate alone.
  • CONCLUSIONS: Presence of 2,4-DNT led to a significant change in bacterial population of marine sediment with the enrichment of several gamma- and delta-Proteobacteria.
  • SIGNIFICANCE AND IMPACT OF THE STUDY: Our results provided the first evidence on the impact of the pollutant 2,4-DNT on the indigenous bacterial community in marine sediment, and provided an insight into the composition of bacterial community that degrade 2,4-DNT.
  • [MeSH-major] Bacteria, Anaerobic / drug effects. Bacteria, Anaerobic / isolation & purification. Dinitrobenzenes / toxicity. Geologic Sediments / microbiology. Water Pollutants, Chemical / toxicity
  • [MeSH-minor] Canada. DNA, Bacterial / genetics. Electrophoresis, Polyacrylamide Gel. Phylogeny. RNA, Ribosomal, 16S / genetics

  • Hazardous Substances Data Bank. 2,4-DINITROTOLUENE .
  • SILVA. SILVA SSU Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19486208.001).
  • [ISSN] 1365-2672
  • [Journal-full-title] Journal of applied microbiology
  • [ISO-abbreviation] J. Appl. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Bacterial; 0 / Dinitrobenzenes; 0 / RNA, Ribosomal, 16S; 0 / Water Pollutants, Chemical; 6741D310ED / 2,4-dinitrotoluene
  •  go-up   go-down


74. Sanguin H, Remenant B, Dechesne A, Thioulouse J, Vogel TM, Nesme X, Moënne-Loccoz Y, Grundmann GL: Potential of a 16S rRNA-based taxonomic microarray for analyzing the rhizosphere effects of maize on Agrobacterium spp. and bacterial communities. Appl Environ Microbiol; 2006 Jun;72(6):4302-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential of a 16S rRNA-based taxonomic microarray for analyzing the rhizosphere effects of maize on Agrobacterium spp. and bacterial communities.
  • The microarray detection threshold was estimated at 0.03% of a given DNA type based on DNA spiking experiments.

  • COS Scholar Universe. author profiles.
  • SILVA. SILVA SSU Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trends Microbiol. 2004 Aug;12(8):386-93 [15276615.001]
  • [Cites] J Ind Microbiol Biotechnol. 2004 Jul;31(6):278-88 [15221668.001]
  • [Cites] BMC Bioinformatics. 2004 Jul 29;5:103 [15283861.001]
  • [Cites] Appl Environ Microbiol. 2004 Sep;70(9):5094-101 [15345387.001]
  • [Cites] Bioinformatics. 2004 Sep 22;20(14):2317-9 [15073015.001]
  • [Cites] Syst Appl Microbiol. 1999 Sep;22(3):434-44 [10553296.001]
  • [Cites] Nature. 2000 May 11;405(6783):228-33 [10821283.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):9834-9 [10963655.001]
  • [Cites] Environ Microbiol. 2001 Jan;3(1):19-31 [11225720.001]
  • [Cites] Appl Environ Microbiol. 2001 May;67(5):2284-91 [11319113.001]
  • [Cites] Appl Microbiol Biotechnol. 2001 Jul;56(1-2):40-57 [11499947.001]
  • [Cites] Appl Environ Microbiol. 2001 Oct;67(10):4708-16 [11571176.001]
  • [Cites] Appl Environ Microbiol. 2001 Oct;67(10):4742-51 [11571180.001]
  • [Cites] Appl Environ Microbiol. 2001 Dec;67(12):5780-90 [11722935.001]
  • [Cites] Appl Environ Microbiol. 2002 Mar;68(3):1425-30 [11872496.001]
  • [Cites] Appl Environ Microbiol. 2002 May;68(5):2391-6 [11976113.001]
  • [Cites] Appl Environ Microbiol. 2002 May;68(5):2535-41 [11976131.001]
  • [Cites] Appl Environ Microbiol. 1999 Apr;65(4):1662-9 [10103265.001]
  • [Cites] Can J Microbiol. 2004 Jul;50(7):469-74 [15381970.001]
  • [Cites] Microb Ecol. 2004 Apr;47(3):243-51 [14994173.001]
  • [Cites] Appl Environ Microbiol. 1992 Oct;58(10):3413-6 [1444376.001]
  • [Cites] Appl Environ Microbiol. 1995 Jun;61(6):2270-5 [7793948.001]
  • [Cites] Microbiology. 1995 Jul;141 ( Pt 7):1493-506 [7551018.001]
  • [Cites] Gene. 1995 Nov 7;165(1):81-6 [7489921.001]
  • [Cites] J Bacteriol. 1996 Jun;178(12):3496-500 [8655546.001]
  • [Cites] FEMS Microbiol Lett. 1997 Aug 1;153(1):181-90 [9252585.001]
  • [Cites] Appl Environ Microbiol. 1997 Nov;63(11):4516-22 [9361437.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6578-83 [9618454.001]
  • [Cites] J Bacteriol. 1998 Sep;180(18):4765-74 [9733676.001]
  • [Cites] Microbiology. 1998 Dec;144 ( Pt 12):3257-66 [9884217.001]
  • [Cites] Science. 1999 Oct 15;286(5439):542-4 [10521351.001]
  • [Cites] Appl Environ Microbiol. 2004 Dec;70(12):6998-7009 [15574893.001]
  • [Cites] Appl Environ Microbiol. 2004 Dec;70(12):7161-72 [15574913.001]
  • [Cites] Appl Environ Microbiol. 2005 Feb;71(2):826-34 [15691937.001]
  • [Cites] Appl Environ Microbiol. 2005 Mar;71(3):1373-86 [15746340.001]
  • [Cites] J Microbiol Methods. 2005 Jul;62(1):37-56 [15823393.001]
  • [Cites] FEMS Microbiol Lett. 2005 Apr 15;245(2):271-8 [15837382.001]
  • [Cites] Annu Rev Plant Biol. 2005;56:15-39 [15862088.001]
  • [Cites] J Exp Bot. 2005 Jul;56(417):1761-78 [15911555.001]
  • [Cites] BMC Genomics. 2005;6:78 [15918914.001]
  • [Cites] Appl Environ Microbiol. 2005 Nov;71(11):6910-7 [16269725.001]
  • [Cites] FEMS Microbiol Ecol. 2005 Feb 1;51(3):333-40 [16329881.001]
  • [Cites] Environ Microbiol. 2006 Feb;8(2):289-307 [16423016.001]
  • [Cites] Appl Environ Microbiol. 2002 Jul;68(7):3215-25 [12088997.001]
  • [Cites] Annu Rev Phytopathol. 2002;40:309-48 [12147763.001]
  • [Cites] Bioinformatics. 2002;18 Suppl 1:S105-10 [12169537.001]
  • [Cites] Appl Environ Microbiol. 2002 Dec;68(12):6121-8 [12450836.001]
  • [Cites] Mol Ecol. 2003 Jan;12(1):251-62 [12492893.001]
  • [Cites] Nucleic Acids Res. 2003 Jan 1;31(1):514-6 [12520066.001]
  • [Cites] Bioinformatics. 2003 Jan 22;19(2):185-93 [12538238.001]
  • [Cites] Appl Environ Microbiol. 2003 Mar;69(3):1482-7 [12620832.001]
  • [Cites] Appl Environ Microbiol. 2003 May;69(5):2684-91 [12732537.001]
  • [Cites] Environ Microbiol. 2003 Jun;5(6):441-52 [12755711.001]
  • [Cites] Environ Microbiol. 2003 Jul;5(7):566-82 [12823189.001]
  • [Cites] Curr Opin Biotechnol. 2003 Jun;14(3):311-8 [12849785.001]
  • [Cites] Biostatistics. 2003 Apr;4(2):249-64 [12925520.001]
  • [Cites] Environ Microbiol. 2003 Oct;5(10):896-907 [14510843.001]
  • [Cites] Environ Microbiol. 2003 Oct;5(10):933-43 [14510847.001]
  • [Cites] Appl Environ Microbiol. 2003 Oct;69(10):6143-51 [14532074.001]
  • [Cites] Appl Environ Microbiol. 2003 Nov;69(11):6875-87 [14602652.001]
  • [Cites] Appl Environ Microbiol. 2003 Dec;69(12):7354-63 [14660385.001]
  • [Cites] Nucleic Acids Res. 2004;32(4):1363-71 [14985472.001]
  • [Cites] Appl Environ Microbiol. 2004 Mar;70(3):1767-76 [15006803.001]
  • [Cites] Environ Microbiol. 2004 Apr;6(4):347-63 [15008813.001]
  • [Cites] Biotechniques. 2004 Apr;36(4):664-70, 672, 674-5 [15088384.001]
  • [Cites] BMC Biotechnol. 2004 Mar 8;4:3 [15113428.001]
  • [Cites] Environ Microbiol. 2004 Jun;6(6):638-45 [15142252.001]
  • [Cites] Appl Environ Microbiol. 2004 Jun;70(6):3541-51 [15184155.001]
  • [Cites] Curr Opin Microbiol. 2004 Jun;7(3):221-6 [15196488.001]
  • (PMID = 16751545.001).
  • [ISSN] 0099-2240
  • [Journal-full-title] Applied and environmental microbiology
  • [ISO-abbreviation] Appl. Environ. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Bacterial; 0 / RNA, Ribosomal, 16S
  • [Other-IDs] NLM/ PMC1489601
  •  go-up   go-down


75. Tworoger SS, Missmer SA, Eliassen AH, Spiegelman D, Folkerd E, Dowsett M, Barbieri RL, Hankinson SE: The association of plasma DHEA and DHEA sulfate with breast cancer risk in predominantly premenopausal women. Cancer Epidemiol Biomarkers Prev; 2006 May;15(5):967-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The association of plasma DHEA and DHEA sulfate with breast cancer risk in predominantly premenopausal women.
  • Concentrations of adrenal androgens are positively associated with postmenopausal breast cancer risk; however, results in premenopausal women are conflicting.
  • Therefore, we conducted a prospective nested case-control study within the Nurses' Health Study II cohort to examine the relationship of DHEA and DHEA sulfate (DHEAS) with breast cancer risk in predominantly premenopausal women.
  • The analysis included 317 cases of breast cancer diagnosed after blood collection and before June 1, 2003; for each case, two controls were matched on age, fasting status, time of day and month of blood collection, race/ethnicity, and timing of blood draw within the menstrual cycle.
  • No associations were observed between DHEA or DHEAS levels and breast cancer risk overall [in situ and invasive; DHEA relative risk (RR), top versus bottom quartile, 1.2; 95% confidence interval (95% CI), 0.8-1.8, P(trend) = 0.53; DHEAS RR, 1.3; 95% CI, 0.9-2.0; P(trend) = 0.07].
  • However, both DHEA and DHEAS were positively associated with estrogen receptor-positive/progesterone receptor-positive breast cancer (DHEA RR, 1.6; 95% CI, 0.9-2.8, P(trend) = 0.09; DHEAS RR, 1.9; 95% CI, 1.1-3.3, P(trend) = 0.02).
  • Our results suggest that adrenal androgens are positively associated with breast cancer among predominately premenopausal women, especially for estrogen receptor-positive/progesterone receptor-positive tumors and among women over age 45 years.
  • [MeSH-major] Breast Neoplasms / blood. Dehydroepiandrosterone / blood. Dehydroepiandrosterone Sulfate / blood
  • [MeSH-minor] Adult. Case-Control Studies. Female. Humans. Logistic Models. Middle Aged. Premenopause / blood. Prospective Studies. Risk Factors

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16702378.001).
  • [ISSN] 1055-9965
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA50385; United States / NCI NIH HHS / CA / CA67262; United States / NCI NIH HHS / CA / P50 CA089393; United States / NCI NIH HHS / CA / R25 CA 098566-2; United States / NCI NIH HHS / CA / T32 CA090001
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 459AG36T1B / Dehydroepiandrosterone; 57B09Q7FJR / Dehydroepiandrosterone Sulfate
  •  go-up   go-down


76. Limtong S, Srisuk N, Yongmanitchai W, Yurimoto H, Nakase T, Kato N: Pichia thermomethanolica sp. nov., a novel thermotolerant, methylotrophic yeast isolated in Thailand. Int J Syst Evol Microbiol; 2005 Sep;55(Pt 5):2225-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Three strains (N002, N069 and PT31(T)) of a novel thermotolerant methylotrophic yeast species belonging to the genus Pichia were isolated from soil collected in Thailand by three consecutive enrichments in methanol broth at room temperature.
  • The major characteristics of the three strains included the following and placed them in the genus Pichia: the formation of four helmet-/hat-shaped ascospores in a deliquescent ascus that might be unconjugated or produced by conjugation between a cell and its bud or between independent cells; multilateral budding; the presence of ubiquinone Q-7; negative for Diazonium blue B colour and urease reactions; and the absence of arthrospores and ballistospores.
  • The type strain is PT31(T) (=BCC 16875(T)=JCM 12984(T)=CBS 10098(T)).

  • Hazardous Substances Data Bank. METHANOL .
  • SILVA. SILVA LSU Database .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16166737.001).
  • [ISSN] 1466-5026
  • [Journal-full-title] International journal of systematic and evolutionary microbiology
  • [ISO-abbreviation] Int. J. Syst. Evol. Microbiol.
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AB200285
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Fungal; 0 / DNA, Ribosomal; 0 / RNA, Ribosomal; 0 / RNA, ribosomal, 26S; Y4S76JWI15 / Methanol
  •  go-up   go-down


77. Bogner PN, Su LD, Fullen DR: Cluster designation 5 staining of normal and non-lymphoid neoplastic skin. J Cutan Pathol; 2005 Jan;32(1):50-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cluster designation 5 staining of normal and non-lymphoid neoplastic skin.
  • RESULTS: Within normal skin, CD5 labeled lymphocytes, apocrine glands, deep dermal eccrine glands, and smooth muscle (weak).
  • The majority of benign and malignant apocrine lesions demonstrated strong focal (36%, n=11)-to-diffuse (64%, n=16) staining.
  • Microcystic adnexal carcinoma demonstrated focal staining of deeper ductal structures (71%, n=7), whereas desmoplastic trichoepithelioma and basal cell carcinoma showed only rare positive cells.
  • All cases of mammary (n=7) and extramammary (n=8) Paget's disease labeled diffusely for CD5.
  • Pagetoid Bowen's disease (n=6), intraepidermal sebaceous carcinoma (n=3), nor melanoma in situ (n=6) showed any CD5 staining.
  • CONCLUSIONS: Immunohistochemical staining for CD5 is extremely useful in the differential diagnosis of pagetoid epidermal lesions and will mark mammary and extramammary Paget's disease, but not pagetoid Bowen's disease, melanoma in situ, or sebaceous carcinoma.
  • [MeSH-major] Antigens, CD5 / metabolism. Skin / metabolism. Skin Neoplasms / enzymology. Skin Neoplasms / metabolism. Staining and Labeling
  • [MeSH-minor] Cell Count. Diagnosis, Differential. Humans. Immunohistochemistry. Paget Disease, Extramammary / diagnosis. Paget's Disease, Mammary / diagnosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15660655.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD5
  •  go-up   go-down


78. Papalkar D, Sharma S, Francis IC, Downie JA: Red eye and a rodent ulcer. Ophthal Plast Reconstr Surg; 2006 Mar-Apr;22(2):131-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Red eye and a rodent ulcer.
  • The ulcer extended to involve the nose and right upper eyelid.
  • Computed tomography demonstrated widespread erosion of the frontal bone, exposing the dura; histopathology confirmed the lesion to be basal cell carcinoma.
  • The ulcer had slowly progressed for 30 years, but the patient was in denial about her condition.
  • She had kept the ulcer well hidden by combing her hair forward over it.
  • Despite three assessments of her eye by medical staff in the preceding 24 hours, the diagnosis of the extensive basal cell carcinoma had been missed as she had refused to lift her hair for a complete examination.
  • [MeSH-major] Bone Diseases / pathology. Carcinoma, Basal Cell / secondary. Conjunctivitis / pathology. Corneal Ulcer / pathology. Eyelid Neoplasms / secondary. Frontal Bone / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Bone Diseases.
  • MedlinePlus Health Information. consumer health - Pinkeye.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16550059.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Lally A, Bowling J: Contrasting vascular patterns: a helpful dermoscopic feature for identifying basal cell carcinoma within port wine stains. Dermatol Surg; 2010 Jun;36(6):950-1
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contrasting vascular patterns: a helpful dermoscopic feature for identifying basal cell carcinoma within port wine stains.
  • [MeSH-major] Carcinoma, Basal Cell / blood supply. Carcinoma, Basal Cell / pathology. Facial Neoplasms / blood supply. Port-Wine Stain / pathology. Skin Neoplasms / blood supply. Skin Neoplasms / pathology
  • [MeSH-minor] Dermoscopy. Diagnosis, Differential. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20482729.001).
  • [ISSN] 1524-4725
  • [Journal-full-title] Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]
  • [ISO-abbreviation] Dermatol Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Storage SS, Agrawal H, Furst DE: Description of the efficacy and safety of three new biologics in the treatment of rheumatoid arthritis. Korean J Intern Med; 2010 Mar;25(1):1-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the abatacept studies, a few cases of tuberculosis, more cardiovascular events and gastrointestinal bleedings and more basal cell carcinoma were seen.
  • Golimumab was associated with more skin rashes and pneumonia, while tocilizumab was associated with increased lipids, more liver-function abnormalities, and neutropenia.

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Rheumatoid arthritis.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arthritis Rheum. 2002 Jun;46(6):1470-9 [12115176.001]
  • [Cites] Ann Rheum Dis. 2010 Mar;69(3):510-6 [19933744.001]
  • [Cites] Arthritis Rheum. 2005 Aug;52(8):2263-71 [16052582.001]
  • [Cites] N Engl J Med. 2005 Sep 15;353(11):1114-23 [16162882.001]
  • [Cites] J Clin Rheumatol. 2005 Jun;11(3 Suppl):S55-62 [16357751.001]
  • [Cites] Ann Intern Med. 2006 Jun 20;144(12):865-76 [16785475.001]
  • [Cites] Rheumatology (Oxford). 2006 Oct;45(10):1238-46 [16567357.001]
  • [Cites] Arthritis Rheum. 2006 Sep;54(9):2817-29 [16947782.001]
  • [Cites] Expert Opin Pharmacother. 2006 Dec;7(18):2559-70 [17150009.001]
  • [Cites] Ann Rheum Dis. 2007 Sep;66(9):1162-7 [17485422.001]
  • [Cites] Expert Opin Pharmacother. 2007 Sep;8(13):2089-107 [17714062.001]
  • [Cites] Pharmacol Ther. 2008 Feb;117(2):244-79 [18155297.001]
  • [Cites] Lancet. 2008 Mar 22;371(9617):987-97 [18358926.001]
  • [Cites] Arthritis Rheum. 2008 Apr;58(4):953-63 [18383390.001]
  • [Cites] Arthritis Rheum. 2008 Apr;58(4):964-75 [18383539.001]
  • [Cites] Ann Rheum Dis. 2008 Aug;67(8):1096-103 [18055472.001]
  • [Cites] Ann Rheum Dis. 2008 Aug;67(8):1084-9 [18086727.001]
  • [Cites] Arthritis Rheum. 2008 Oct;58(10):2968-80 [18821691.001]
  • [Cites] Ann Rheum Dis. 2008 Nov;67(11):1516-23 [18625622.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2008 Dec;106(6):778-87 [18930662.001]
  • [Cites] Mod Rheumatol. 2009;19(1):12-9 [18979150.001]
  • [Cites] J Rheumatol. 2009 Apr;36(4):736-42 [19273451.001]
  • [Cites] Curr Opin Rheumatol. 2009 May;21(3):224-30 [19365268.001]
  • [Cites] Ann Rheum Dis. 2009 Jun;68(6):789-96 [19066176.001]
  • [Cites] J Rheumatol. 2009 Jun;36(6):1118-25 [19447938.001]
  • [Cites] Lancet. 2009 Jul 18;374(9685):210-21 [19560810.001]
  • [Cites] Arthritis Rheum. 2009 Aug;60(8):2272-83 [19644849.001]
  • [Cites] Ann Rheum Dis. 2009 Nov;68(11):1708-14 [19074911.001]
  • [Cites] Ann Rheum Dis. 2009 Dec;68(12):1870-7 [19124524.001]
  • [Cites] Ann Rheum Dis. 2010 Jan;69(1):88-96 [19297346.001]
  • [Cites] N Engl J Med. 2003 Nov 13;349(20):1907-15 [14614165.001]
  • (PMID = 20195397.001).
  • [ISSN] 1226-3303
  • [Journal-full-title] The Korean journal of internal medicine
  • [ISO-abbreviation] Korean J. Intern. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antirheumatic Agents; 0 / Immunoconjugates; 0 / golimumab; 0 / tocilizumab; 7D0YB67S97 / Abatacept
  • [Number-of-references] 31
  • [Other-IDs] NLM/ PMC2829405
  • [Keywords] NOTNLM ; Abatacept / Arthritis, rheumatoid / Biological products / Golimumab / Tocilizumab
  •  go-up   go-down


81. Okuyama R, Tagami H, Aiba S: Notch signaling: its role in epidermal homeostasis and in the pathogenesis of skin diseases. J Dermatol Sci; 2008 Mar;49(3):187-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Notch signaling: its role in epidermal homeostasis and in the pathogenesis of skin diseases.
  • Skin undergoes self-renewal throughout life.
  • Terminally differentiated keratinocytes, namely the corneocytes, are continually shed from the surface of the skin, whereas immature cells produce progeny that proceed through the differentiation process.
  • Notch signaling controls a number of cellular processes including cell fate decision, proliferation, differentiation and survival/apoptosis.
  • Hence, Notch and its ligands are expressed in multiple tissues including the skin, where they are abundantly expressed in the epidermis.
  • Notch activation results in the promotion of growth arrest and the onset of differentiation, therefore suggesting that specific Notch activation may regulate skin homeostasis by balancing these processes, i.e.
  • Notch signaling functions as a molecular switch that controls the transition of cells between skin layers during the epidermal differentiation process.
  • In addition, Notch counteracts the action of p63 to maintain immature cell characteristics.
  • However, aberrant Notch signaling results in the development of psoriasis and skin cancers such as squamous cell carcinoma, basal cell carcinoma and malignant melanoma.
  • Future efforts to further define how Notch controls cell proliferation and differentiation may lead to the application of Notch in new therapies for various skin diseases.
  • [MeSH-major] Receptors, Notch / physiology. Signal Transduction / physiology. Skin / cytology. Skin Diseases / etiology
  • [MeSH-minor] Animals. Cell Differentiation. Cell Proliferation. Homeostasis. Humans. Langerhans Cells / physiology. Melanocytes / physiology

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17624739.001).
  • [ISSN] 0923-1811
  • [Journal-full-title] Journal of dermatological science
  • [ISO-abbreviation] J. Dermatol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Receptors, Notch
  • [Number-of-references] 67
  •  go-up   go-down


82. Tran KT, Lamb P, Deng JS: Matrikines and matricryptins: Implications for cutaneous cancers and skin repair. J Dermatol Sci; 2005 Oct;40(1):11-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Matrikines and matricryptins: Implications for cutaneous cancers and skin repair.
  • Dermatologists are faced daily with the need to optimize skin repair and excise cutaneous cancers.
  • The extracellular matrix plays a pivotal role in cellular migration, proliferation, and gene regulation during wound healing and progression of melanoma, basal cell carcinoma, and squamous cell carcinoma.
  • Within the last few years, a new class of ligand, the matrikine or matricryptin, has been characterized as subdomains of various ECM proteins capable of signaling to the cell through receptors, such as growth factor receptors.
  • The EGF-like repeats of tenascin-C and laminin-5 signal to EGFR preferentially to upregulate migration during skin repair and tumor progression.
  • Finally, the unique properties of matrikines have been utilized in cancer therapeutics and tissue engineering.
  • Within the next few years, the nature and function of this emerging class of matrikine ligands will have an impact on dermatology, as these proteins are altered in wound repair and skin diseases.
  • [MeSH-major] Extracellular Matrix Proteins / physiology. Skin Neoplasms / etiology
  • [MeSH-minor] Amino Acid Sequence. Animals. Cell Adhesion Molecules / physiology. Collagen / physiology. Humans. Ligands. Molecular Sequence Data. Signal Transduction. Tenascin / physiology. Tissue Engineering. Wound Healing

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15993569.001).
  • [ISSN] 0923-1811
  • [Journal-full-title] Journal of dermatological science
  • [ISO-abbreviation] J. Dermatol. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cell Adhesion Molecules; 0 / Extracellular Matrix Proteins; 0 / Ligands; 0 / Tenascin; 0 / kalinin; 9007-34-5 / Collagen
  • [Number-of-references] 50
  •  go-up   go-down


83. Gerber PA, Schulte KW, Ruzicka T, Bruch-Gerharz D: Eccrine porocarcinoma of the head: an important differential diagnosis in the elderly patient. Dermatology; 2008;216(3):229-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eccrine porocarcinoma of the head: an important differential diagnosis in the elderly patient.
  • BACKGROUND: Eccrine porocarcinoma is a rare malignant tumor of the sweat gland, characterized by a broad spectrum of clinicopathologic presentations.
  • Instead, eccrine porocarcinoma frequently occurs on the lower extremities, trunk and abdomen, but also on the head, resembling various other skin tumors, as illustrated in the patients described herein.
  • OBSERVATIONS: We report 5 cases of eccrine porocarcinoma of the head.
  • All patients were initially diagnosed as having epidermal or melanocytic skin tumors.
  • Porocarcinomas are commonly overlooked, or misinterpreted as squamous or basal cell carcinomas as well as other common malignant and even benign skin tumors.
  • [MeSH-major] Carcinoma, Skin Appendage / diagnosis. Eccrine Glands / pathology. Head and Neck Neoplasms / diagnosis. Sweat Gland Neoplasms / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Diagnosis, Differential. Diagnostic Errors. Female. Humans. Immunohistochemistry. Male. Middle Aged. Prognosis. Skin Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18182815.001).
  • [ISSN] 1421-9832
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


84. Rastogi R, Anand S, Koul V: Flexible polymerosomes--an alternative vehicle for topical delivery. Colloids Surf B Biointerfaces; 2009 Aug 1;72(1):161-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The flexible nature of these nanosystems makes them an efficient alternative to liposomes for targeting melanomas and basal cell carcinomas.
  • [MeSH-minor] Administration, Topical. Epidermis / cytology. Humans. Microscopy, Atomic Force. Microscopy, Confocal. Molecular Weight. Nanoparticles / ultrastructure. Skin Absorption. Unilamellar Liposomes / chemistry

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19403279.001).
  • [ISSN] 1873-4367
  • [Journal-full-title] Colloids and surfaces. B, Biointerfaces
  • [ISO-abbreviation] Colloids Surf B Biointerfaces
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Polymers; 0 / Unilamellar Liposomes
  •  go-up   go-down


85. Inoue S, Inoue M, Takahashi H, Inoue A, Kunitomo K, Fujii H: [Two advanced/recurrent breast cancer cases effectively treated by trastuzumab/capecitabine combination therapy]. Gan To Kagaku Ryoho; 2008 Feb;35(2):319-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two advanced/recurrent breast cancer cases effectively treated by trastuzumab/capecitabine combination therapy].
  • Trastuzumab/capecitabine combination therapy was performed for two advanced/recurrent breast cancer cases with acute deterioration of the disease.
  • The time until partial response in the first case was 7 months and in the second case 12 months.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. Deoxycytidine / analogs & derivatives. Fluorouracil / analogs & derivatives
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Biomarkers, Tumor / blood. Bone Neoplasms / blood. Bone Neoplasms / drug therapy. Bone Neoplasms / radiography. Bone Neoplasms / secondary. Capecitabine. Female. Humans. Immunotherapy. Liver Neoplasms / blood. Liver Neoplasms / drug therapy. Liver Neoplasms / radiography. Liver Neoplasms / secondary. Middle Aged. Neoplasm Staging. Recurrence. Tomography, X-Ray Computed. Trastuzumab

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. Trastuzumab .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18281774.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Biomarkers, Tumor; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; P188ANX8CK / Trastuzumab; U3P01618RT / Fluorouracil
  •  go-up   go-down


86. Yang JH, Spilker T, LiPuma JJ: Simultaneous coinfection by multiple strains during Burkholderia cepacia complex infection in cystic fibrosis. Diagn Microbiol Infect Dis; 2006 Feb;54(2):95-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneous coinfection by multiple strains during Burkholderia cepacia complex infection in cystic fibrosis.
  • Much remains unknown about the natural history of respiratory tract infection by Burkholderia cepacia complex (Bcc) in persons with cystic fibrosis (CF).
  • Specifically, it is not clear whether infected CF patients typically harbor a single Bcc strain or multiple strains that may be phenotypically indistinguishable.
  • We genotyped 912 Bcc isolates recovered from CF sputum culture from in excess of 100 patients to demonstrate that chronic infection generally involves a single strain.
  • Transient coinfection with more than 1 strain occurs infrequently and may be more common early in the course of Bcc infection.
  • [MeSH-major] Burkholderia Infections / microbiology. Burkholderia cepacia complex / isolation & purification. Cystic Fibrosis / complications
  • [MeSH-minor] Chronic Disease. Genotype. Humans. Polymorphism, Restriction Fragment Length. Rec A Recombinases / genetics. Ribotyping. Sputum / microbiology

  • Genetic Alliance. consumer health - BabysFirstTest - Cystic Fibrosis.
  • Genetic Alliance. consumer health - Cystic Fibrosis.
  • MedlinePlus Health Information. consumer health - Cystic Fibrosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16406186.001).
  • [ISSN] 0732-8893
  • [Journal-full-title] Diagnostic microbiology and infectious disease
  • [ISO-abbreviation] Diagn. Microbiol. Infect. Dis.
  • [Language] eng
  • [Grant] United States / NIAID NIH HHS / AI / AI054411-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.7.- / Rec A Recombinases
  •  go-up   go-down


87. Faupel-Badger JM, Sherman ME, Garcia-Closas M, Gaudet MM, Falk RT, Andaya A, Pfeiffer RM, Yang XR, Lissowska J, Brinton LA, Peplonska B, Vonderhaar BK, Figueroa JD: Prolactin serum levels and breast cancer: relationships with risk factors and tumour characteristics among pre- and postmenopausal women in a population-based case-control study from Poland. Br J Cancer; 2010 Sep 28;103(7):1097-102
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolactin serum levels and breast cancer: relationships with risk factors and tumour characteristics among pre- and postmenopausal women in a population-based case-control study from Poland.
  • BACKGROUND: Previous prospective studies have found an association between prolactin (PRL) levels and increased risk of breast cancer.
  • Using data from a population-based breast cancer case-control study conducted in two cities in Poland (2000-2003), we examined the association of PRL levels with breast cancer risk factors among controls and with tumour characteristics among the cases.
  • METHODS: We analysed PRL serum levels among 773 controls without breast cancer matched on age and residence to 776 invasive breast cancer cases with available pretreatment serum.
  • Breast cancer risk factors, assessed by interview, were related to serum PRL levels among controls using analysis of variance.
  • In case-only analyses, higher PRL levels were more strongly associated with lobular compared with ductal carcinoma among postmenopausal women (P=0.02).
  • These results may have value in understanding the mechanisms underlying several breast cancer risk factor associations.
  • [MeSH-major] Breast Neoplasms / blood. Prolactin / blood
  • [MeSH-minor] Adult. Case-Control Studies. Female. Humans. Middle Aged. Parity. Poland / epidemiology. Postmenopause. Pregnancy. Premenopause. Risk Factors

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Causes Control. 2009 Mar;20(2):253-62 [18853263.001]
  • [Cites] Pituitary. 2008;11(2):209-18 [18404390.001]
  • [Cites] Obesity (Silver Spring). 2006 Sep;14(9):1662-77 [17030978.001]
  • [Cites] Endocrinology. 1999 Nov;140(11):5447-50 [10537179.001]
  • [Cites] Clin Endocrinol (Oxf). 1999 Nov;51(5):643-51 [10594527.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 1997 Jan;2(1):29-39 [10887517.001]
  • [Cites] Physiol Rev. 2000 Oct;80(4):1523-631 [11015620.001]
  • [Cites] Proc Nutr Soc. 2001 Feb;60(1):81-9 [11310427.001]
  • [Cites] Br J Cancer. 2002 Oct 7;87(8):876-82 [12373602.001]
  • [Cites] Endocr Rev. 2003 Feb;24(1):1-27 [12588805.001]
  • [Cites] Cancer Res. 2004 Sep 15;64(18):6814-9 [15375001.001]
  • [Cites] Int J Cancer. 1976 Apr 15;17(4):441-7 [945228.001]
  • [Cites] Am J Obstet Gynecol. 1977 May 1;128(1):60-74 [403765.001]
  • [Cites] Fertil Steril. 1978 Aug;30(2):141-5 [98356.001]
  • [Cites] Int J Cancer. 1981 Jul 15;28(1):31-4 [7309279.001]
  • [Cites] N Engl J Med. 1987 Jan 29;316(5):229-34 [3099198.001]
  • [Cites] Eur J Cancer Clin Oncol. 1988 Jul;24(7):1225-31 [3416905.001]
  • [Cites] Med J Aust. 1990 Oct 15;153(8):469-73 [2215338.001]
  • [Cites] Cancer Res. 1995 Jun 15;55(12):2591-5 [7780973.001]
  • [Cites] Cancer Causes Control. 1995 May;6(3):217-24 [7612801.001]
  • [Cites] J Reprod Med. 1995 Aug;40(8):556-60 [7473451.001]
  • [Cites] Gynecol Obstet Invest. 1997;44(2):124-6 [9286727.001]
  • [Cites] J Natl Cancer Inst. 1999 Apr 7;91(7):629-34 [10203283.001]
  • [Cites] Endocr Relat Cancer. 1999 Sep;6(3):389-404 [10516853.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Nov;14(11 Pt 1):2641-7 [16284390.001]
  • [Cites] Cancer Res. 2006 Feb 15;66(4):2476-82 [16489055.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 May;15(5):972-8 [16702379.001]
  • [Cites] Br J Cancer. 2006 Jul 3;95(1):123-9 [16755295.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2005 Oct;10(4):325-35 [16900392.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Dec;15(12):2494-501 [17164375.001]
  • [Cites] Int J Cancer. 2007 Apr 1;120(7):1536-41 [17211859.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Mar;16(3):439-43 [17372238.001]
  • [Cites] J Clin Oncol. 2007 Apr 20;25(12):1482-8 [17372279.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 May;16(5):895-9 [17507612.001]
  • [Cites] Int J Cancer. 2007 Sep 1;121(5):1079-85 [17487843.001]
  • [Cites] Cancer Res. 2007 Nov 1;67(21):10608-17 [17968031.001]
  • [Cites] Mol Cell Endocrinol. 2008 Jan 16;281(1-2):9-18 [18022314.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Jan;17(1):43-50 [18199710.001]
  • [Cites] Breast Cancer Res Treat. 2008 Mar;108(1):57-67 [17468953.001]
  • [Cites] J Mammary Gland Biol Neoplasia. 2008 Mar;13(1):41-53 [18246319.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):1880-3 [18708375.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2010 Apr;19(4):938-46 [20332276.001]
  • (PMID = 20736944.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 CA999999
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] England
  • [Chemical-registry-number] 9002-62-4 / Prolactin
  • [Other-IDs] NLM/ PMC2965860
  •  go-up   go-down


88. Hashimoto K, Yonemori K, Katsumata N, Hotchi M, Kouno T, Shimizu C, Tamura K, Ando M, Takeuchi M, Fujiwara Y: Factors that affect the duration of the interval between the completion of palliative chemotherapy and death. Oncologist; 2009 Jul;14(7):752-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We retrospectively analyzed 255 cases in which patients had received palliative chemotherapy in the medical oncology division and died during the period 2002-2006.
  • RESULTS: There were 133 cases of breast cancer, 77 cases of gynecological cancer, 24 cases of primary unknown cancer, and 21 cases of other cancers.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19596665.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Dünnebier T, Bermejo JL, Haas S, Fischer HP, Pierl CB, Justenhoven C, Brauch H, Baisch C, Gilbert M, Harth V, Spickenheuer A, Rabstein S, Pesch B, Brüning T, Ko YD, Hamann U: Common variants in the UBC9 gene encoding the SUMO-conjugating enzyme are associated with breast tumor grade. Int J Cancer; 2009 Aug 1;125(3):596-602
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Common variants in the UBC9 gene encoding the SUMO-conjugating enzyme are associated with breast tumor grade.
  • Genetic variability may affect expression and activity of UBC9 and may have an impact on breast tumor progression.
  • We investigated associations between UBC9 genotypes and histopathological parameters in 1,021 breast cancer cases of the GENICA collection using a single nucleotide polymorphism (SNP) tagging approach.
  • The present results underline the value of genetic variation in UBC9 for breast cancer prognosis.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / pathology. Polymorphism, Single Nucleotide. SUMO-1 Protein / metabolism. Ubiquitin-Conjugating Enzymes / genetics

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19358266.001).
  • [ISSN] 1097-0215
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Estrogen; 0 / SUMO-1 Protein; EC 6.3.2.19 / Ubiquitin-Conjugating Enzymes; EC 6.3.2.19 / ubiquitin-conjugating enzyme UBC9
  •  go-up   go-down


90. Lavie O, Barnett-Griness O, Narod SA, Rennert G: The risk of developing uterine sarcoma after tamoxifen use. Int J Gynecol Cancer; 2008 Mar-Apr;18(2):352-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The treatment of breast cancer with tamoxifen results in an increased risk of uterine cancer.
  • The objective of this study was to evaluate the association between tamoxifen use and the risk of developing uterine sarcomas and endometrial carcinomas in a historical cohort of women diagnosed with breast cancer in 1987-1988.
  • The medical records of all women diagnosed in Israel with breast cancer in the years 1987-1988 were sought.
  • In 2004, patient identifiers were linked to the Israel Cancer Registry database to identify all uterine cancers that occurred within 15 years of the diagnosis of breast cancer.
  • The records for 1507 breast cancer cases (84%) were retrieved.
  • Among these cases, 32 uterine malignancies were identified; 11 occurred prior to the diagnosis of breast cancer and 21 occurred during the follow-up period.
  • Five of the 875 tamoxifen users (0.6%) died of uterine cancer, compared to no deaths among nonusers (P = 0.08).
  • We conclude that in this national breast cancer cohort, tamoxifen use was associated with elevated risks of uterine cancer incidence and mortality.
  • [MeSH-minor] Adult. Aged. Breast Neoplasms / drug therapy. Endometrial Neoplasms / chemically induced. Female. Humans. Incidence. Middle Aged. Registries. Risk Factors


91. Suzuki T, Matsuo K, Hirose K, Hiraki A, Kawase T, Watanabe M, Yamashita T, Iwata H, Tajima K: One-carbon metabolism-related gene polymorphisms and risk of breast cancer. Carcinogenesis; 2008 Feb;29(2):356-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] One-carbon metabolism-related gene polymorphisms and risk of breast cancer.
  • Environmental exposures and/or genetic background in Japanese population, which might contribute to the relatively low breast cancer incidence rates in Japan, have not been clarified in detail.
  • Folate plays an essential role in DNA methylation and synthesis, and thus may be involved in the development of breast cancer.
  • We therefore conducted a case-control study to clarify their associations with breast cancer risk.
  • A total of 456 breast cancer cases and 912 age-matched and menopausal status-matched non-cancer controls were genotyped for the polymorphisms.
  • We observed an increased risk of postmenopausal breast cancer with the MTHFR 677TT genotype (OR = 1.83, 95% CI: 1.08-3.11) with a menopausal status-based analysis.
  • In addition, interaction between the MTRR A66G polymorphism and folate intake for risk of postmenopausal breast cancer was observed (interaction P = 0.008).
  • Our findings indicated that the MTHFR and MTRR polymorphisms were associated with individual susceptibility to breast cancer among postmenopausal women.
  • [MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / metabolism. Genetic Predisposition to Disease. Polymorphism, Genetic

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. FOLIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18174236.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 935E97BOY8 / Folic Acid; EC 1.18.1.- / methionine synthase reductase; EC 1.18.1.2 / Ferredoxin-NADP Reductase; EC 1.5.1.20 / Methylenetetrahydrofolate Reductase (NADPH2); EC 2.1.1.13 / 5-Methyltetrahydrofolate-Homocysteine S-Methyltransferase; EC 2.1.1.45 / Thymidylate Synthase
  •  go-up   go-down


92. Fair AM, Dai Q, Shu XO, Matthews CE, Yu H, Jin F, Gao YT, Zheng W: Energy balance, insulin resistance biomarkers, and breast cancer risk. Cancer Detect Prev; 2007;31(3):214-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Energy balance, insulin resistance biomarkers, and breast cancer risk.
  • BACKGROUND: American women are five times more likely to be at risk for breast cancer than women from Asian countries.
  • Epidemiologic studies have linked energy balance to an increased risk of breast cancer, yet few studies have investigated potential mediators of this association with Chinese women.
  • We examined the above association by blood levels of insulin-like growth factors (IGFs), binding proteins, and C-peptide in the Shanghai Breast Cancer Study (SBCS), a case-control study conducted among 1,459 breast cancer cases and 1,556 healthy Chinese women from 1996 and 1998.
  • The present analyses consisted of 397 cases and 397 controls whose blood samples were measured for levels of IGFs, insulin growth-factor binding protein 3 (IGFBP-3), C-peptide, and the relationship with physical activity status, total energy intake, and body fat distribution.
  • Additional analyses were performed to evaluate whether the association of energy balance measures with breast cancer risk changed after adjustment for IGFs, IGFBP-3, and C-peptide biomarkers.
  • CONCLUSION: Insulin resistance biomarkers may partially explain the association between positive energy balance and breast cancer risk, but future studies are needed to identify the underlying complex biological mechanisms of action for breast cancer prevention.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1997;76(12):1652-4 [9413957.001]
  • [Cites] Eur J Clin Nutr. 2004 Jan;58(1):17-23 [14679362.001]
  • [Cites] Mech Ageing Dev. 1999 Jun 1;109(1):21-34 [10405986.001]
  • [Cites] Clin Chem. 1999 Aug;45(8 Pt 2):1384-90 [10430822.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1496-501 [15941962.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Dec;14(12):2881-8 [16365005.001]
  • [Cites] J Womens Health Gend Based Med. 1999 Dec;8(10):1265-72 [10643834.001]
  • [Cites] Cancer. 2004 Feb 15;100(4):694-700 [14770423.001]
  • [Cites] Br J Cancer. 1992 Mar;65(3):311-20 [1313689.001]
  • [Cites] Br J Cancer. 1995 Nov;72(5):1065-6 [7577447.001]
  • [Cites] Int J Biochem Cell Biol. 1996 Jun;28(6):619-37 [8673727.001]
  • [Cites] Science. 1997 Jul 25;277(5325):531-2 [9254422.001]
  • [Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1472-89 [10995803.001]
  • [Cites] BMJ. 2000 Oct 7;321(7265):847-8 [11021847.001]
  • [Cites] Br J Cancer. 2001 Apr 6;84(7):994-1001 [11286483.001]
  • [Cites] Endocr Relat Cancer. 2001 Sep;8(3):197-209 [11566611.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Nov;10(11):1207-11 [11700270.001]
  • [Cites] Int J Cancer. 2001 Nov 1;94(3):449-55 [11745429.001]
  • [Cites] Cancer Causes Control. 2001 Dec;12(10):951-8 [11808715.001]
  • [Cites] Lancet Oncol. 2002 May;3(5):298-302 [12067807.001]
  • [Cites] Semin Oncol. 2002 Jun;29(3 Suppl 11):86-95 [12138402.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Aug;11(8):705-12 [12163322.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2002 Sep;11(9):862-7 [12223430.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jan;88(1):337-46 [12519874.001]
  • [Cites] Cancer Causes Control. 2003 Feb;14(1):65-74 [12708727.001]
  • [Cites] Exerc Sport Sci Rev. 2003 Jul;31(3):144-8 [12882481.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Oct;12(10):1067-73 [14578144.001]
  • [Cites] Med Sci Sports Exerc. 2003 Nov;35(11):1834-40 [14600547.001]
  • [Cites] Am J Epidemiol. 2003 Dec 1;158(11):1114-22 [14630608.001]
  • [Cites] Int J Cancer. 1998 Dec 18;79(6):624-8 [9842972.001]
  • (PMID = 17646056.001).
  • [ISSN] 0361-090X
  • [Journal-full-title] Cancer detection and prevention
  • [ISO-abbreviation] Cancer Detect. Prev.
  • [Language] ENG
  • [Grant] United States / NCRR NIH HHS / RR / P20RR011792; United States / NCRR NIH HHS / RR / P20 RR011792; United States / NCI NIH HHS / CA / R01 CA064277; United States / NIMHD NIH HHS / MD / P20 MD000516; United States / NCI NIH HHS / CA / R01-CA64277; United States / NCI NIH HHS / CA / R01 CA064277-04; United States / NCI NIH HHS / CA / CA064277-04; United States / NIMHD NIH HHS / MD / 5 P20 MD000516-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / C-Peptide; 0 / Insulin-Like Growth Factor Binding Protein 3; 67763-96-6 / Insulin-Like Growth Factor I; 67763-97-7 / Insulin-Like Growth Factor II
  • [Other-IDs] NLM/ NIHMS29979; NLM/ PMC1994998
  •  go-up   go-down


93. Justenhoven C, Hamann U, Schubert F, Zapatka M, Pierl CB, Rabstein S, Selinski S, Mueller T, Ickstadt K, Gilbert M, Ko YD, Baisch C, Pesch B, Harth V, Bolt HM, Vollmert C, Illig T, Eils R, Dippon J, Brauch H: Breast cancer: a candidate gene approach across the estrogen metabolic pathway. Breast Cancer Res Treat; 2008 Mar;108(1):137-49
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast cancer: a candidate gene approach across the estrogen metabolic pathway.
  • Polymorphisms within the estrogen metabolic pathway are prime candidates for a possible association with breast cancer risk.
  • We investigated 11 genes encoding key proteins of this pathway for their potential contribution to breast cancer risk.
  • We performed a population-based case-control study with 688 incident breast cancer cases and 724 controls from Germany and genotyped 18 polymorphisms by matrix assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS), PCR based RFLP (restriction fragment length polymorphism), and TaqMan allelic discrimination.
  • Genotype frequencies were compared between cases and controls and odds ratios were calculated by conditional logistic regression.
  • Single factor analyses pointed to CYP1B1_1294_GG as a possible breast cancer risk modulator (OR = 2.57; 95% CI: 1.34-4.93) and two way stratification suggested associations between BMI > or = 30 kg/m(2) and COMT_472_GG (P = 0.0076 and P = 0.0026), BMI < 20 kg/m(2) and HSD17B1_937_GG (P = 0.0082) as well as CYP17A1_-34_CC and HRT use > or =10 years (P = 0.0063).
  • No significant association between breast cancer risk and genetic polymorphisms was observed in multifactor analyses.
  • The tested polymorphisms of the estrogen metabolic pathway may not play a direct role in breast cancer risk.
  • [MeSH-major] Biomarkers, Tumor / genetics. Breast Neoplasms / genetics. Breast Neoplasms / metabolism. Estrogens / metabolism. Genetic Predisposition to Disease
  • [MeSH-minor] Case-Control Studies. Female. Humans. Polymorphism, Restriction Fragment Length. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization


94. Zhu Y, Brown HN, Zhang Y, Holford TR, Zheng T: Genotypes and haplotypes of the methyl-CpG-binding domain 2 modify breast cancer risk dependent upon menopausal status. Breast Cancer Res; 2005;7(5):R745-52
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genotypes and haplotypes of the methyl-CpG-binding domain 2 modify breast cancer risk dependent upon menopausal status.
  • The present case-control study investigated associations between two single nucleotide polymorphisms (SNPs) in the MBD2 gene and breast cancer risk.
  • METHODS: DNA samples from 393 Caucasian patients with breast cancer (cases) and 436 matched control individuals, collected in a recently completed breast cancer case-control study conducted in Connecticut, were included in the study.
  • Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to estimate cancer risk associated with the variant genotypes and the reconstructed haplotypes.
  • Further haplotype analyses showed that the two rare haplotypes (A-C and A-G) were significantly associated with reduced breast cancer risk (OR = 0.40, 95% CI = 0.20-0.83 for A-C; OR = 0.47, 95% CI = 0.26-0.84 for A-G) in premenopausal women.
  • CONCLUSION: Our results demonstrate a role for the MBD2 gene in breast carcinogenesis in premenopausal women.
  • These findings suggest that genetic variations in methylation related genes may potentially serve as a biomarker in risk estimates for breast cancer.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Menopause.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Clin North Am. 2003 Aug;83(4):803-19 [12875597.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Mar 21;302(4):759-66 [12646234.001]
  • [Cites] Cancer Res. 1988 Jan 15;48(2):246-53 [2825969.001]
  • [Cites] Cell. 1990 Aug 10;62(3):503-14 [1974172.001]
  • [Cites] Cancer Causes Control. 1992 Jul;3(4):313-22 [1617118.001]
  • [Cites] EXS. 1993;64:425-51 [8380354.001]
  • [Cites] Cancer Res. 1994 May 15;54(10):2552-5 [8168078.001]
  • [Cites] Cancer Res. 1994 Dec 15;54(24):6374-82 [7987831.001]
  • [Cites] Cancer Res. 1995 Oct 15;55(20):4525-30 [7553621.001]
  • [Cites] Ann N Y Acad Sci. 1995 Sep 30;768:91-100 [8526389.001]
  • [Cites] J Mol Biol. 1997 Mar 28;267(2):276-88 [9096225.001]
  • [Cites] Nat Genet. 1997 Jul;16(3):256-9 [9207790.001]
  • [Cites] Cancer Res. 1997 Aug 15;57(16):3347-50 [9269993.001]
  • [Cites] Cancer Res. 1998 May 15;58(10):2107-10 [9605753.001]
  • [Cites] Nature. 1998 May 28;393(6683):386-9 [9620804.001]
  • [Cites] EMBO J. 1998 Sep 1;17(17):4905-8 [9724627.001]
  • [Cites] Mol Cell Biol. 1998 Nov;18(11):6538-47 [9774669.001]
  • [Cites] Cancer Res. 1998 Oct 15;58(20):4515-8 [9788592.001]
  • [Cites] Br J Cancer. 1999 Jan;79(2):251-6 [9888465.001]
  • [Cites] Nature. 1999 Feb 18;397(6720):579-83 [10050851.001]
  • [Cites] Mamm Genome. 1999 Sep;10(9):906-12 [10441743.001]
  • [Cites] Nat Genet. 1999 Sep;23(1):58-61 [10471499.001]
  • [Cites] Nat Genet. 1999 Sep;23(1):62-6 [10471500.001]
  • [Cites] Ann N Y Acad Sci. 2003 Mar;983:213-9 [12724226.001]
  • [Cites] Biochem Biophys Res Commun. 1999 Nov 2;264(3):962-6 [10544038.001]
  • [Cites] Trends Genet. 2000 Jan;16(1):20 [10647297.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Feb;9(2):167-74 [10698477.001]
  • [Cites] J Natl Cancer Inst. 2000 May 17;92(10):826-32 [10814678.001]
  • [Cites] FASEB J. 2000 Aug;14(11):1585-94 [10928993.001]
  • [Cites] Am J Hum Genet. 2001 Apr;68(4):978-89 [11254454.001]
  • [Cites] Gene. 2001 Oct 3;276(1-2):73-81 [11591473.001]
  • [Cites] Bioessays. 2001 Dec;23(12):1131-7 [11746232.001]
  • [Cites] Oncol Rep. 2002 Mar-Apr;9(2):393-5 [11836615.001]
  • [Cites] Mol Carcinog. 2002 Mar;33(3):163-71 [11870882.001]
  • [Cites] Oncogene. 2002 Apr 18;21(17):2704-12 [11965543.001]
  • [Cites] Oncogene. 2002 Oct 10;21(46):7034-41 [12370825.001]
  • [Cites] Cancer Res. 2003 Jan 15;63(2):498-504 [12543808.001]
  • [Cites] Cancer. 2004 May 1;100(9):1853-8 [15112265.001]
  • (PMID = 16168120.001).
  • [ISSN] 1465-542X
  • [Journal-full-title] Breast cancer research : BCR
  • [ISO-abbreviation] Breast Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA081810; United States / NCI NIH HHS / CA / CA62986; United States / NCI NIH HHS / CA / CA108369; United States / NCI NIH HHS / CA / R03 CA110937; United States / NCI NIH HHS / CA / CA81810; United States / NCI NIH HHS / CA / CA110937; United States / NCI NIH HHS / CA / R03 CA108369
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / DNA-Binding Proteins; 0 / MBD2 protein, human
  • [Other-IDs] NLM/ PMC1242141
  •  go-up   go-down


95. Zanetti-Dällenbach R, Wight E: [Chemotherapy for gynecological malignancies--a contraindication during pregnancy?]. Ther Umsch; 2005 Jan;62(1):53-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Even though a malignant tumor during pregnancy is very rare it occurs in 0.02-0.1%.
  • The coincidence of malignant disease with pregnancy leads to an enormous emotional burden to the patient, the couple and the medical staff.
  • Surgery for malignant tumors during pregnancy seems to be save.
  • The most frequent malignant disorders during pregnancy are cervical cancer, breast cancer, melanoma and Hodgkin lymphoma.
  • We discuss possible treatment options for breast cancer and gynecological tumors during pregnancy.
  • Ovarian Cancer is a rare event during pregnancy.
  • In case of advanced stage of ovarian cancer chemotherapy besides surgery is necessary.
  • To treat breast cancer during pregnancy a mastectomy with axillary lymphonodectomy is necessary to avoid radiotherapy.
  • For invasive cervical cancer surgery or radiotherapy +/- chemotherapy is indicated after induced abortion or cesarean section.
  • Early termination of pregnancy is of no survival benefit to the mother in case of breast cancer and ovarian cancer.
  • In these cases systemic therapy during pregnancy and delivery at 34 weeks is recommended.

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Pregnancy and Medicines.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15702707.001).
  • [ISSN] 0040-5930
  • [Journal-full-title] Therapeutische Umschau. Revue thérapeutique
  • [ISO-abbreviation] Ther Umsch
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 46
  •  go-up   go-down






Advertisement